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ABSTRACT
The human immunodeficiency virus (HIV-1) effectively avoids immunologic 
eradication. Certain characteristics of the virus contribute to this, including the specific 
targeting of the body’s own defense system, the ability to hide in the host cell genome 
and the vast viral variability. Natural killer (NK) cells are important effectors in 
resistance to virus infections and there are indications that NK cells have a role also in 
HIV-1 infection. HIV-1 specific antibodies can cause neutralization of free virions, but 
also contribute to killing of infected cells through interaction with effector cells, such as 
NK cells. In this thesis the involvement of NK cells in acute and chronic HIV-1 
infection has been studied and novel treatment modalities based on NK cells or 
antibodies have been examined. 
In our mouse model for acute HIV-1 infection, we show that NK cells have a role, 
since more infectious virus could be retrieved from NK cell depleted mice than normal 
mice after inoculation of spleen cells infected with a HIV-1/MuLV pseudovirus (paper 
III). In addition, frequency of NK cells at the site of injection of infected cells were 
increased and the NK cells had a more mature phenotype. These studies are interesting 
in relation to previous reports on an enhanced NK cell activity in acute HIV-1 infection 
in humans and highlight the importance of considering activation of NK cells in future 
treatment modalities targeted to HIV-1. 
One possible therapeutic strategy is activation of NK cells by blocking inhibitory NK 
cell receptors. The KIR binding antibody, 1-7F9, induced activation of NK cells from 
HIV-1 infected patients and healthy individuals, and the effect could be associated to 
KIR genotype of the blood donor (paper I). However, we could not detect increased 
NK cell recognition of HIV-1 infected compared uninfected autologous T cells. This 
lack of HIV-1 specific effect may be due to the in vitro system used. 
Phenotypic and functional differences in NK cells from patients that spontaneously 
control their disease were compared to NK cells from patients with viremia or healthy 
individuals, but no striking differences were found (paper I and II). NK cells can 
specifically kill antibody coated infected target cells in a process called antibody 
dependent cellular cytotoxicity (ADCC). The antibodies elicited in patients differed in 
ability to induce Env specific ADCC (paper II). Qualitative differences in HIV-
specific ADCC antibody responses may thus contribute to control of disease.  
For induction of efficient antibody mediated killing, monoclonal antibodies may be 
chemically coupled to cytotoxic drugs. This treatment modality was examined in our 
model for acute HIV-1 infection and was found to contribute to eradication of HIV-
1/MuLV infected cells in the mouse (paper IV).  
We conclude, based on our studies in the HIV-1/MuLV mouse model, that NK cell 
activity in acute HIV-1 infection may contribute to early control of infected cells and 
that HIV-1 envelope specific antibodies conjugated to drugs may efficiently resolve 
virus infected cells. In addition the possible differences in ADCC inducing antibodies 
in controller patients deserve further investigation, as do KIR blockade for the 
treatment of HIV-1 infection. 
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Humant immunbrist virus (HIV) orsakar en av de största epidemierna i världen idag. 
Viruset attackerar främst de celler i vår kropp som skyddar oss mot infektioner och 
detta tillsammans med HIVs förmåga att snabbt förändra sig gör att vårt immunsystem 
inte klarar av att utplåna viruset. Den behandling som finns idag hindrar HIV från att 
föröka sig, men eftersom viruset kan gömma sig i kroppens celler i latent form kan 
behandlingen inte helt utplåna det. Det saknas därför ett botemedel mot HIV och detta 
är en av de större utmaningarna inom den biomedicinska forskningen idag.  
I den här avhandlingen har vi studerat en typ av immuncell som tillhör det medfödda 
immunförsvaret och som kallas natural killer (NK) cell. Det är känt sedan tidigare att 
denna cell snabbt och effektivt kan döda virusinfekterade celler. Vi har använt en 
musmodell för att undersöka om NK-celler är viktiga för att skydda mot infektion med 
HIV och funnit att möss som saknar NK-celler har ett sämre skydd. Det visade sig 
också att frekvensen mogna NK-celler ökade där de HIV infekterade cellerna fanns, 
vilket är intressant eftersom det är troligt att en mer mogen NK-cell är bättre på att döda 
infekterade celler. 
Vi har även studerat NK-celler från HIV-infekterade patienter. Vissa patienter klarar av 
att kontrollera sina virusnivåer utan behandling och är därmed intressanta att studera för 
att ta reda på vilka faktorer som bidrar till detta skydd. Vi undersökte om dessa 
patienter har NK-celler som skiljer sig från NK-cellerna hos patienter med höga 
virusnivåer och friska individer, men vi fann inga stora skillnader som skulle kunna 
förklara det fördelaktiga sjukdomsförloppet. NK-celler kan också känna igen 
infekterade celler specifikt genom att binda till antikroppar, det vill säga kroppsegna 
proteiner som kan angripa HIV infekterade celler. Detta antikropps-orsakade dödande 
av infekterade celler kallas för ADCC (antibody dependent cellular cytotoxicity). Vi 
fann att patienter som kan kontrollera sina virusnivåer har antikroppar med något 
annorlunda ADCC förmåga än patienter med höga virusnivåer och vi spekulerar därför 
i om detta kan vara en bidragande orsak till ett långsammare sjukdomsförlopp. 
Antikroppar kan även användas experimentellt för att påverka NK-cellernas funktion, 
genom att blockera vissa proteiner som uttrycks på NK-cellytan. Vi har studerat 
blockering av NK-cell hämmande proteiner och undersökt om det på så vis är möjligt 
att öka NK-cellernas förmåga att reagera mot HIV-infekterade celler. Vi fann att NK-
cellerna reagerade starkare när den blockerande antikroppen tillsattes till cellkulturerna, 
men denna aktivitet var lika stor mot oinfekterade celler som mot HIV-infekterade 
celler. 
Vi har också studerat effekten av att kemiskt koppla ett cellgift till en antikropp som 
specifikt binder till HIV-infekterade celler. Detta ökade antikroppens förmåga att döda 
HIV-infekterade celler i cellkultur och även i vår musmodell för HIV.  
Sammanfattningsvis har vi funnit att NK-celler utövar ett skydd i den tidiga fasen av 
HIV-infektion i möss och att patienter som kontrollerar sina virusnivåer kan ha 
antikroppar med en bättre förmåga att orsaka NK-cells dödande av infekterade celler. 
Vi har även visat att antikroppar kopplade till toxiska läkemedel är en effektiv strategi 
för att utplåna HIV-infekterade celler. 
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21 AIMS OF THE THESIS 
The overall aim with my studies has been to investigate different aspects of NK cells 
and antibodies in HIV-1 infection. The specific aims were the following: 
x To investigate if HIV-1 controller patients differ from patients with viremia 
regarding their NK cell phenotype and function (paper I and II).  
x To investigate if ADCC-inducing antibodies from HIV-1 controller patients 
differ from antibodies from patients with viremia (paper II).  
x To delineate the role of NK cells in a mouse model for acute HIV-1 infection 
(paper III)
x To evaluate if an antibody blocking inhibitory KIR receptors could increase the 
NK cell activity in response to HIV-1 infected cells (paper I)
x To evaluate the therapeutic effect of a HIV-1 envelope specific antibody 
conjugated to a cytotoxic drug in a mouse model for HIV-1 infection (paper 
IV)
  3 
2 THE IMMUNE SYSTEM 
The immune system is our defense against intruding organisms, like viruses and 
bacteria. For simplicity, the immune system can be divided into two parts, the innate 
and the adaptive. The innate immune system contributes to the activation of the 
adaptive immune system and controls the infection during the first days to weeks it 
takes for the adaptive immune system to become active and effective. Cells belonging 
to either part of the system have specific functions but they interact through soluble 
molecules and cell-to-cell contacts in a complex manner. 
2.1 INNATE IMMUNE RESPONSES 
The innate immune system is the rapid first defense against intruders. Physical barriers, 
like skin, mucosa and tears prevent pathogens from entering the body. If the pathogen 
passes through these barriers it will come across various cells and molecules with 
ability to eliminate the intruder. The cells of the innate immune system have germline 
encoded receptors that recognize certain pathogen structures, not found on self 
molecules. These pattern recognition receptors (PRR), including for example Toll-like 
receptors (TLR), recognize the pathogen-associated molecular patterns (PAMPs) found 
on for example bacteria, fungi, protozoa and viruses [1]. PAMPs found on viruses 
include for example double and single stranded RNA bound by TLR3 and TLR7/8 
respectively and CpG motifs in viral DNA recognized by TLR9 [2]. Signaling through 
TLRs trigger immediate inflammatory and antiviral responses, and influences 
subsequent activation of the adaptive immune response. DCs can capture pathogens 
and transport the foreign material to lymphoid organs where it is presented to cells of 
the adaptive immune system. DCs are induced to express co-stimulatory molecules by 
activation through TLRs and this increases their ability to induce better activation of the 
T cells of the adaptive immune system. Cells presenting antigens to the adaptive 
immune cells in presence of co-stimulatory molecules are called professional antigen 
presenting cells (APCs) and include B cells and macrophages in addition to DCs. 
Plasma proteins belonging to the complement system circulate in the blood and bind to 
pathogens or tumor cells and induce killing either directly or by recruiting phagocytic 
cells. Phagocytes like macrophages, monocytes and neutrophils can engulf pathogens 
and kill them. These cells also secrete molecules, like cytokines and chemokines. 
Cytokines induce responses and affect the behavior of cells with the cytokine receptor, 
while chemokines are a class of cytokines that activates cells and stimulates migration 
towards the chemokine source. An inflammatory response is induced by the release of 
these factors and this will attract more cells and effector molecules and also prevent the 
pathogen from spreading. Natural killer (NK) cells are lymphocytes, which can 
recognize and kill infected cells but also secrete cytokines and chemokines with ability 
to influence the overall immune response to a pathogen [3]. They are regulated by a 
fine balance between stimulation of activating and inhibitory receptors [4]. NK cells 
will be introduced in more detail in section 3. 
2.2 ADAPTIVE IMMUNE RESPONSES 
The adaptive immune system provides a specific response to individual pathogens. It 
can develop memory, leading to a fast and specific response to reappearing antigens. 
The adaptive immune system consists of two kinds of lymphocytes, B cells and T cells. 
4T cells are responsible for the cellular response and also aid in the humoral response 
produced by B cells. Both of these cell types have antigen receptors that are produced 
by site-specific somatic DNA recombination, which leads to an almost unlimited 
repertoire of receptors and thus recognition of most antigens.  
2.2.1 Major histocompatibility complex molecules 
The proteins encoded by the major histocompatibility gene complex have a central role 
in the adaptive, but also in the innate immune response. There are two kinds of major 
histocompatibility complex (MHC) molecules on the cells in our body, MHC class I 
and MHC class II. MHC class I consists of a class I Į chain and a non-covalently 
linked, non-polymorphic E chain called ȕ2-microglobulin. MHC class II consists of two 
chains, the class II Į chain and the class II ȕ chain. MHC class I molecules are 
expressed on all nucleated cells in the body and present cytoplasmic peptides, which 
are 8 to 10 amino acids long and derived from for example virus proteins. MHC class II 
molecules are highly expressed on professional APCs and present longer peptide 
fragments of exogenous antigens that have been taken up from the extracellular 
environment. 
In humans, the MHC molecules are termed human leukocyte antigens (HLA). There 
are three different genetic loci encoding the MHC class I Į chain, HLA-A, HLA-B and 
HLA-C. These genes are highly polymorphic, leading to a wide variety of alleles. Both 
alleles at each locus of an individual are transcribed and translated. Hence each 
individual can express up to six different MHC class I molecules. In mice the MHC 
class I molecules are H-2K, H-2D and H-2L. The human MHC class II molecules are 
named HLA-DP, HLA-DQ and HLA-DR. They can exist in even more variants than 
the MHC class I molecules, since the class II Į and ȕ chains are both polymorphic. 
Humans also express the non-classical MHC class Ib molecules HLA-E, HLA-G and 
HLA-F, which display a rather limited polymorphism [5]. Qa-1b is a MHC class Ib 
molecule present in mice. 
2.2.2 T cells 
T cells are produced in the bone marrow but mature in the thymus. They circulate 
between the blood and peripheral lymphoid organs, searching their specific antigen. On 
encountering it in a lymph node or in the spleen, they are induced to proliferate and 
differentiate into effector cells and memory cells. The T cell receptor (TCR) on T cells 
specifically recognizes peptides bound to MHC molecules. Activation of a naïve T cell 
requires that co-stimulatory molecules are present at the same time as the TCR 
recognizes its antigen. Co-stimulatory molecules are expressed on professional APCs 
and include B7 molecules that bind to the activating receptor CD28 on T cells [6].  
Cytotoxic T lymphocytes (CTLs), which are CD8+, can recognize antigenic peptides 
bound to MHC class I and this leads to killing of the target cell. CTLs kill cells by 
release of cytotoxic effector molecules, like perforin and granzymes [7], and/or the 
expression of the death receptors, such as Fas ligand (FasL), which can induce 
apoptosis in the target cell. CTLs also release cytokines like interferon-J (IFN-J) and 
tumor necrosis factor (TNF) that for example enhance antigen presentation and mediate 
anti-viral effects [8]. 
T helper lymphocytes, which are CD4+, recognize antigens bound by MHC class II 
molecules. Upon activation, these cells secrete cytokines, which help to activate other 
parts of the immune system, like macrophages, CTLs and B cells [8]. There are several 
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different subsets of CD4+ T cells, including T helper 1 (Th1), Th2, Th17 and regulatory 
T cells. Th1 cells help controlling intracellular pathogens by secreting, for example 
IFN-J and interleukin-2 (IL-2) that activate CTLs and macrophages. They can also 
activate B-cells and induce their switch towards production of opsonizing antibody 
isotypes which is important in clearing of extracellular pathogens. Th2 cells produce 
cytokines like IL-4 and IL-10 and activate B cells, inducing switching to neutralizing 
antibody isotypes. The IL-17 producing Th17 cells have a role in the host defense 
against certain extracellular pathogens [9]. Regulatory T cells are able to suppress 
effector T cell proliferation and cytokine production either through secretion of anti-
inflammatory cytokines such as IL-10 and tumor growth factor ȕ (TGF-ȕ) or direct 
cell-to-cell contact [10]. 
NKT cells are a subset of T cells with both T and NK markers. Most express an 
invariant TCR molecule and NK-receptors such as CD161. These cells become 
activated upon TCR mediated recognition of glycolipids presented by the non-classical 
MHC class I molecule CD1d, which is nonpolymorphic. A key feature for this subset 
of T cells is the immediate production of large quantities of cytokines like IFN-Ȗ and 
IL-4 after antigen stimulation [11]. 
2.2.3 B cells 
B cells develop in the bone marrow and mature in secondary lymphoid organs like the 
spleen, lymph nodes and mucosa-associated tissue. B cells express a B cell receptor 
(BCR) that specifically recognizes antigens, which can for example be viral or bacterial 
proteins. Each B cell expresses BCRs of one specificity. Different variable gene 
segments are combined by a somatic recombination process, which results in the high 
number of variable BCRs expressed by the B cells in one individual. The BCRs have 
antigen binding parts, called complementarity determining regions (CDRs) that are the 
most variable parts of the molecule, in addition to a constant fragment crystalline (Fc) 
part. When a B cell recognizes its antigen and receive co-stimulatory signals from T-
cells, it will proliferate undergo “switching” and differentiate into plasma cells or 
memory cells (see further below). Plasma cells produce large amounts of secreted 
BCRs, called antibodies. Memory cells stay in the body for a long time and quickly 
respond if the antigen reappears. During stimulation by antigen and repeated rounds of 
proliferation, B-cells may go through a process called somatic hypermutation. This is 
based on stochastic mutations in the CDRs [12], followed by selection through 
competition for antigen If this process is successful it may result in BCRs with a higher 
affinity for the antigen – a process named affinity maturation. These B cells will then 
proliferate and can differentiate into plasma cells or memory cells.  
During B cell maturation and proliferation the Fc part expressed by the B cell may be 
exchanged for another Fc part at the gene level, the so called “switch” [12]. The 
cytokine milieu affects this process, called class switching, and the Fc part of the 
immunoglobulin determines the characteristics of the antibody. There are five classes 
of antibodies or immunoglobulins (Ig) with different functions. These are called IgM, 
IgG, IgA, IgE and IgD. IgG is the most abundant antibody in the blood and can be 
divided into four subclasses: IgG1 to IgG4. IgAs are the main antibodies at mucosal 
surfaces. Upon binding of an antibody to a pathogen or a cell, different immunological 
pathways are induced, depending on the antibody class. Antibodies of the IgG and IgA 
class can neutralize pathogens by preventing them from binding to their receptor on 
host cells [13]. Antibodies may also induce activation of the complement cascade, a 
property of mainly IgM, IgG3 and IgG1. By binding of the antibody Fc part to Fc 
6receptors the antibody-coated antigen can be opsonized, i.e. antibodies can promote 
phagocytosis of for example pathogens [14]. Antibody binding to Fc receptors can also 
result in killing of infected cells by NK-cells, macrophages or eosinophils through a 
mechanism called antibody-dependent cellular cytotoxicity (ADCC). IgG1 and IgG3 
are the main antibody subclasses involved in ADCC mediated by NK cells. The type of 
effector mechanism induced by a certain antibody may also be affected by the 
glycosylation profile of the antibody, which affects the binding to Fc-receptors [15]. 
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3 NATURAL KILLER CELLS 
3.1 EARLY CHARACTERIZATION OF NK CELLS AND “MISSING SELF” 
RECOGNITION 
Natural killer (NK) cells were defined more than 30 years ago as non T , non B- large 
granular lymphocytes capable of killing tumor cells in vitro without prior 
sensitization [16, 17]. This “natural” killing contrasted to the priming required for T 
cell responses. In vivo evidence for NK cell resistance to tumor growth in mice was 
soon to follow, as was evidence on a role for NK cells in rejection of bone marrow 
transplants [18]. NK cells also seemed to be involved in response to infections [19]. 
This concept was later strengthened in humans lacking NK cells or with defective NK 
cell activity, who are more susceptible to certain infections and may be at increased 
risk of malignancies [20, 21]. 
The molecular basis for NK cell recognition of these various target cells was however 
poorly understood. A first clue to the complex specificity of NK cells came when 
Klas Kärre proposed the “missing self” hypothesis [22-24], based on inhibition of NK 
cell activity by self MHC class I molecules on a potential target cell. This was later 
shown to be due to interaction between inhibitory receptors on NK cells and self 
MHC class I molecules on the target cell. Down-regulation of MHC class I molecules 
on tumor cells [22, 24] or infected cells [25, 26] can result in increased NK cell 
sensitivity (Figure 1b). Lack of one recipient self MHC molecule on bone marrow 
transplants is another area where “missing self” recognition is important [27]. 
However NK cells do not attack all cells lacking MHC class I molecules equally 
efficiently [28], which is explained by the presence of various ligands on target cells 
binding to activating receptors on NK cells [4]. Interaction between activating 
receptors and their ligands on target cells is necessary for an NK cell to be able to kill 
a target cell. These activating ligands can be upregulated upon transformation or 
infection of cells or by other stress stimuli acting on cells [29-31] (Figure 1c).
Additionally, viral proteins expressed on infected cell surfaces also bind activating 
receptors [32-35]. Thus, a potential target cell can avoid NK cell killing either 
through active inhibition, via MHC class I molecules, or through absence of 
activating ligands [4]. “Natural” killing by NK cells is thus not “non-specific” as 
previously thought, rather is it influenced by complex interactions with a multitude of 
receptors, as well as various cytokines present upon infection [36].  
3.2 NK CELL DEVELOPMENT AND EDUCATION 
Human NK cells derive from CD34+ hematopoietic progenitor cells present in the bone 
marrow. Interestingly, recent data indicate that further maturation to NK cells can take 
place not only in the bone marrow but also in secondary lymphoid organs [37, 38], 
possibly in close contact with DCs and APCs expressing membrane-bound IL-15, 
needed for NK cell development [3]. In mice, bone marrow has been considered the 
primary site of NK cell maturation, although emerging data indicate, similarly as in 
humans, that NK cell precursors and immature NK cells that give rise to mature NK 
cells are present in other organs as well, including lymph nodes, liver, spleen and 
thymus [39]. Thus it is possible that multiple sites support NK cell differentiation.  
8Figure 1: NK cell recognition of target cells. a) NK cell interaction with normal cell 
expressing MHC class I molecules does not result in lysis. b) An NK cell recognising for 
example an infected cell, which has downregulated the expression of MHC class I molecules, 
kills the target cell due to ”missing-self” recognition. c) An infected target cell expressing many 
activating ligands in addition to normal levels of MHC class I molecules will also be killed by 
the NK cell. 
To prevent NK cells from killing autologous cells, NK cells are educated to become 
unresponsive or tolerant to the “self” phenotype. This process is believed to be 
dependent on recognition of MHC class I molecules by the inhibitory NK cell 
receptors. Usually each NK cell expresses a selection of the inhibitory receptor genes 
present in an individual [40]. The acquisition of these receptors is believed to be a 
stochastic event and it results in an NK cell population with diverse MHC class I 
specificities [41]. MHC class I expression in the host influence the NK cell repertoire to 
some extent. NK cells lacking inhibitory receptors for self MHC class I molecules are 
functionally impaired [42-44]. This finding has led to the proposal of two opposing 
models to explain how NK cell activity is influenced by the interaction of MHC class I 
molecules and inhibitory receptors for self MHC during development. The “disarming 
model” states that persistent activation of an initially responsive NK cell in the absence 
of inhibitory signals leads to an unresponsive state [43]. This is similar to activation 
induced anergy in T and B cells. The “licensing model” on the other hand suggests that 
NK cells become activated or “licensed” when they receive signals through their 
inhibitory receptors [44]. Irrespective of model it seems that the number and type of 
MHC class I alleles recognized by an NK cell during education can influence the 
responsiveness of that particular cell in a quantitative manner. Thus, according to the 
recently proposed “rheostat model” education is a quantitative tuning of NK cell 
activity along a continuous scale [45]. 
+- + +++-
Target cell
NK cell
a) No lysis b) Lysis c) Lysis
Inhibitory
receptor
Activating
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3.3 NK CELL PHENOTYPE 
Human NK cells are defined phenotypically as cells expressing an isoform of the neural 
cell-adhesion molecule (NCAM), CD56, but lacking expression of CD3, to distinguish 
them from T cells expressing CD56 [46] (Figure 2). Mice lack CD56 and instead NK 
cells are defined depending on expression of NK1.1 (NKR-P1C) in C57BL/6 mice, and 
CD49b (bound by the DX5 mAb), expressed in a wide range of mouse strains [47], 
together with lack of CD3 expression (Figure 2). Recently, a new phenotypic definition 
of NK cells as NKp46+CD3- cells was proposed, since this population includes the vast 
majority of NK cells in humans and mice, permitting comparisons between species 
[48]. 
Figure 2: Gating strategies used to define NK cells in humans and mice. Human 
CD56+CD3- NK cells from blood and C57BL/6 mouse NK1.1+CD3- NK cells from spleen. 
FACS plots show events within the lymphocyte gate. 
3.3.1 Human NK cell subsets 
In human peripheral blood from healthy individuals about 5-20% of all lymphocytes 
are NK cells. Based on the level of expression of CD56, human NK cells can be 
divided into two subsets with distinct functional capabilities [49]. CD56bright NK cells 
have a high density of CD56 on the surface and these cells primarily produce cytokines 
in response to stimulation. CD56dim NK cells, on the other hand, have low levels of 
CD56 and are naturally more cytotoxic than the CD56bright  NK cells [36, 50]. This is 
also reflected by expression of the Fc-receptor, CD16, involved in ADCC, on CD56dim
cells [49]. The majority of NK cells (approximately 90%) in blood of healthy 
individuals belong to the CD56dim subset, while the minority is CD56bright (Figure 2).
The ratio between the subsets differs in various diseases [51, 52]. In human 
immunodeficiency virus (HIV) infected patients a hyporesponsive CD56-CD16+ NK 
cell subset has also been identified [53, 54]. In secondary lymphoid organs, such as 
lymph nodes and tonsils CD56bright NK cells are the dominant subset [55]. Recent data 
suggest that CD56bright NK cells mature into CD56dim NK cells and that the later have 
shorter telomere length [56, 57]. In addition to differences in CD56 and CD16 
expression, there are other major phenotypic differences between the NK cell subsets 
for example in expression of inhibitory receptors, where most CD56dim NK cells 
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preferentially express killer immunoglobulin-like receptors (KIRs) whereas CD56bright
NK cells mainly express CD94/NKG2A heterodimer [36, 58]. Chemokine receptors are 
also differently expressed on the NK cell subsets, since CD56bright cells express CCR7, 
important in homing to secondary lymph nodes and CXCR3, while CD56dim cells 
express CXCR1 and CX3CR1 [59]. Further, CD56bright NK cells express higher levels 
of certain cytokine receptors, including preferential expression of the high-affinity IL-
2RĮȕȖ, explaining the strong activation induced by IL-2 on this subset [36]. 
The possibility that NK cells develop under various influences in different tissues in 
can be one explanation for the different NK cell subsets found in certain organs. One 
distinct NK cell subset is found in the uterus during pregnancy, where NK cells 
dominate among the decidual lymphocytes. These have mainly a CD56bright phenotype, 
but in contrast to other NK cells of this subset they express KIRs. These NK cells are 
not cytotoxic despite the expression of several activating receptors, although they 
secrete high amounts of cytokines and angiogenic factors important in vascular 
remodeling during pregnancy [60]. Another recently described NK cell subset is the IL-
22 producing NK cells that are present at mucosal sites and may help constrain 
inflammation and protect mucosal sites [61]. 
3.3.2 Mouse NK cell subsets 
Recently it was realized that mouse NK cells similarly to human NK cells can be 
divided into subsets [62, 63]. Based on the expression of the TNF receptor CD27 and 
the integrin Mac-1 (CD11b), four differently mature subsets with distinct functions 
have been identified [62, 64]. Starting from the most immature Mac-1lowCD27low
(double negative, DN) and going through Mac-1lowCD27high (Mac-1low) and Mac-
1highCD27high (double positive, DP) and ending with the most mature subset, Mac-
1highCD27low (CD27low). The tissue distribution of these NK cell subsets is quite 
distinct, with mainly Mac-1low and DP NK cells in lymphoid organs, such as bone 
marrow and lymph nodes and mostly DP and CD27low NK cells in spleen, blood and 
liver [62]. The most immature subsets (DN and Mac-1low) have the highest capacity for 
homeostatic expansion [62-64]. DP cells produce high amounts of IFN-Ȗ upon 
stimulation, an ability which is less pronounced in the CD27low subset [62]. However, 
the CD27low subset has the highest expression of genes involved in NK cell mediated 
cytotoxicity and secretory pathways [64]. A higher frequency of NK cells of the 
CD27low subset also expresses inhibitory Ly49 receptors, indicating a possible need for 
inhibition of cytotoxic activities [62, 64]. Thus, although expression of CD27 and 
CD56 in humans does not completely overlap [65, 66], there are similarities in function 
and distribution between mouse subsets based on Mac-1 and CD27 and human CD56 
subsets. Chemokine receptors expressed on mouse NK cells further reflect this 
similarity since Mac-1low and DP NK cells express CXCR3 and CD27low express 
CX3CR1 similarly to CD56bright and CD56dim human NK cells respectively [67]. In 
human and mouse, L-selectin, CD62L, is used by the more immature NK cell subsets 
for homing and recruitment to lymph nodes, [62, 68], whereas egress from lymph 
nodes involves the sphingosine 1-phosphate (S1P) receptor, S1P5, expressed on the 
most mature NK cell subsets [69]. 
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3.4 NK CELL EFFECTOR FUNCTIONS 
3.4.1 Cytotoxicity 
NK cells can kill target cells by a variety of mechanisms, with the directed release of 
cytotoxic granules (also known as secretory lysosomes) considered to be the most 
important. The release of cytotoxic granules induce apoptosis in the target cell, since 
the granules contain the membrane-disrupting proteins perforin and granulysin as well 
as granzymes, belonging to the serine protease family [70]. The exact mechanism 
whereby perforin contributes to granzyme delivery is debated. One model suggests that 
perforin is needed for release of granzymes from endosomal compartments, into the 
cytoplasm of the target cell, while another model proposes that it allows entrance of 
granzymes through the plasma membrane [7]. The granzymes induce apoptosis of the 
target cell through distinct pathways. Granzyme B can for example induce direct 
activation of cellular caspases or promote mitochondrial permeabilization [7]. Granules 
also contain cell membrane bound proteins, such as lysosomal-membrane-associated 
glycoprotein 1 (LAMP-1, also known as CD107a) that are exposed on the cell-surface 
upon degranulation [70, 71]. Proteins belonging to this family are highly glycosylated 
and have been proposed to protect the effector cell membrane from the lytic enzymes 
released upon degranulation [72]. Thus, CD107a can be used as a marker for activated 
NK cells that have degranulated [71, 73, 74]. Death-receptor-mediated apoptosis is 
another mechanism by which NK cells can kill target cells. NK cells express Fas ligand 
(FasL) and TNF-related apoptosis inducing ligand (TRAIL) upon activation [75, 76]. 
When these are bound by their receptors, death domain containing Fas and TRAIL 
receptor, expressed on target cells, apoptosis is induced  
3.4.2 Release of cytokines and chemokines 
NK cells are not only “killers”, they are also potent producers of cytokines, such as 
IFN-J, TNF, granulocyte macrophage-colony stimulating factor (GM-CSF), IL-5, IL-
10 and IL-13 [50, 77]. Immature NK cells can produce IL-13 and IL-5, whereas mature 
NK cells mainly produce IFN-J [78]. NK cell-produced IFN-J contributes to antiviral 
responses, stimulates macrophages and other antigen presenting cells and contributes to 
differentiation of T cells [77, 79, 80]. NK cells secrete CC-chemokines like 
macrophage inflammatory protein (MIP)-1Į, MIP-1ȕ and RANTES, which have 
chemoattractant and pro-inflammatory functions [77, 81]. The CC-chemokines are 
important in HIV-1 infection, since they are natural ligands for the co-receptors 
commonly used by the HIV-1 virus [82].  
3.5 REGULATION OF NK CELL ACTIVITY 
The type of effector function generated by an NK cell depends on the activation or 
inhibitory signals received. These signals can either be transmitted through soluble 
factors that bind cytokine and chemokine receptors on the NK cell or through direct 
interaction between the NK cell and the potential target cell.  
3.5.1 Soluble factors 
NK cells develop in the bone marrow in the presence of the crucial cytokine IL-15 [83, 
84]. Several cytokines regulate NK cell activity, such as IL-2, IL-12, IL-15, IL-18, IL-
21, IL-10, TGF-ȕ and IFN-D and-E [77, 85]. These cytokines can have multiple effects 
on NK cells, including induction of proliferation, maturation, cytotoxicity and cytokine 
12
production as well as inhibition of the same. Certain combinations of these cytokines 
induce distinct effects. During viral infections type I interferons IFN-D and -E are 
produced by infected cells and TLR stimulated plasmacytoid DCs [86]. IFN-D and -E
stimulate NK cell cytotoxic activity and induce expression of TRAIL on NK cells [77, 
86-88]. Type I interferons also activate DCs, monocytes and macrophages to produce 
IL-15, which in addition to its role in NK cell development and differentiation seems to 
promote NK cell survival, proliferation and cytotoxicity [87, 89]. IL-2 shares the 
medium-affinity IL-2RȕȖ with IL-15 and promotes similar effects on NK cells. In 
addition this cytokine induces expression of KIRs and CD16 on CD56bright NK cells 
[89]. TLR stimulated or IFN-Ȗ stimulated monocytes produce IL-12, which in turn 
induces IFN-Ȗ production by NK cells [87, 90, 91]. There is also evidence that NK cells 
express TLRs that directly sense the presence of viral particles and activates the cell 
[92, 93]. Various chemokines affect NK cell migration and whether a specific NK cell 
will be affected depends on the chemokine receptors expressed which varies depending 
on the NK cell subset, as discussed previously (section3.3). 
3.5.2 NK cell receptors 
At the site of interaction between the NK cell and its potential target cell a local and 
transient immunological synapse is formed to which inhibitory and activating receptors 
are recruited. The net outcome of inhibitory versus activating signals transduced at the 
site determines the fate of the target cell [94]. Inhibitory receptors have a cytoplasmic 
tail with immunoreceptor tyrosine-based inhibitory motifs (ITIM), which are 
phosphorylated upon ligand binding. This results in recruitment of phosphatases like 
the tyrosine phosphatases SHP-1 and SHP-2 and the lipid phosphatase SHIP-1, which 
suppress NK cell responses by dephosphorylating molecules of importance in signal 
transduction from activating NK cell receptors [95]. Several activating receptors 
interact through charged transmembrane amino acids with transmembrane-anchored 
adaptor proteins that contain immunoreceptor tyrosine-based activation motifs (ITAM). 
These are constitutively expressed by NK cells and include FcİRI-Ȗ, CD3-ȗ and 
DAP12, which forms dimers linked by disulfide bonds. Upon crosslinking of an 
activating receptor ITAMs are phosphorylated by protein tyrosine kinases, which in 
turn recruit the tyrosine kinases Syk and ZAP70. This initiates a cascade of events, 
which in the absence of inhibitory signals results in cytoskeleton reorganizations 
needed for release of cytotoxic granules and transcription of cytokine and chemokine 
genes [96]. Other activating receptors signal through other adaptor proteins or signaling 
motifs in their own cytoplasmic tails, inducing diverse signaling cascades. There are a 
multitude of activating and inhibitory receptors expressed by NK cells and the receptors 
most relevant to the thesis are described below. Other important receptors not 
mentioned in the text can be found in table 1.
3.5.2.1 Killer immunoglobulin-like receptors (KIR) 
Two structurally different NK receptor systems with analogous function are the KIR 
and the Ly49 receptors, in humans and mice, respectively. These highly variable 
receptors recognise the polymorphic MHC class I molecules and have evolved 
independently. The human genome possesses several KIR genes but only one non-
functional Ly49 pseudogene. Mice on the other hand lack KIR genes but have a 
varying number of Ly49 receptors depending on the mouse strain [4]. Also other 
species have diversified KIR or Ly49 genes. Primates and cattle use KIR genes, 
whereas rodents and horses use Ly49 genes. 
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KIR genes and proteins 
KIR proteins are expressed on NK cells and subsets of T cells and belong to the Ig 
superfamily. The nomenclature is based on structure and KIR proteins can either have 
two (KIR2D) or three (KIR3D) extracellular Ig-like domains [97, 98] (Figure 3). The 
cytoplasmic tail varies in length, a property connected to functional activity, since 
inhibitory KIRs have long (L) cytoplasmic tails with ITIM motifs and activating KIRs 
have short (S) cytoplasmic tails which can associate with the ITAM-containing DAP12 
adaptor protein. To date about 14 KIR genes and 2 pseudogenes have been described in 
the KIR gene cluster on chromosome 19 in humans. The number of genes varies 
greatly between individuals and there are only three commonly shared framework 
genes present in all individuals (KIR2DL4, KIR3DL2 and KIR3DL3). Since the KIR 
genes are highly homologous it is likely that the variability is due to gene duplications 
or non-allelic homologous recombinations during evolution [99]. Based on the gene 
content two kinds of haplotypes have been defined, where B haplotypes have more 
activating KIRs compared to A haplotypes. Individuals with a KIR haplotype B have 
one or more of the KIR genes; 2DS1, 2DS2, 2DS3, 2DS5, 3DS1 and 2DL5 and 
individuals with haplotype A lack all of these and can instead possess inhibitory KIRs 
including 2DL1, 2DL3 and 3DL1 as well as the activating 2DS4 [100] 
(http://www.ebi.ac.uk/ipd/kir/). An extensive allelic variation in several genes adds to 
the diversity and influences the amount of KIR protein expressed on each NK cell 
[101-103]. In addition, some allelic variants do not generate functional proteins 
expressed at the cell surface [102]. It is believed that at the population level, this highly 
diverse expression would be important for giving a broad NK cell response against 
different pathogens. The KIR proteins are also expressed in a variegated manner on NK 
cells, i.e. a certain KIR is expressed on some NK cell clones but not on others [40, 97, 
98]. However, once an NK cell clone has started to express a certain KIR gene during 
development the expression is stable and does not appear to be affected by cytokines 
[103, 104]. Recently it was realized that KIR gene transcription is controlled by 
epigenetic mechanisms, like methylation, and by the presence of a bidirectional 
promoter able to stochastically switch direction of transcription during development of 
the NK cell, thus determining whether the NK cell will express the KIR gene or not 
[105, 106]. This results in a diverse repertoire of KIR expressing NK cell clones that 
can recognize almost every MHC class I molecule [40].  
KIR ligands 
The inhibitory KIRs are known to bind MHC class I molecules (Figure 3). KIR2DL1 
and the alleles KIR2DL2/3 recognize HLA-C molecules that can be divided into two 
groups called C1 and C2 that are distinguished by the amino acids at positions 77 and 
80 in the Į1 domain. All alleles fall into either of these two groups, where KIR2DL1 
binds HLA-C2 and KIR2DL2/3 bind HLA-C1. This specificity in binding appears to be 
determined by amino acid 44 in the D1 domain of the KIR molecules [107]. However 
the binding specificity might not be as strict as previously thought since recent data 
suggest that KIR2DL2/3 bind to some HLA-C2 alleles as well, a property mainly found 
in KIR2DL2 which has a higher affinity for HLA-C [108, 109]. KIR3DL1 interacts 
mainly with HLA-A and HLA-B allotypes with the Bw4 epitope [110, 111], differing 
from the Bw6 epitope at position 79-83 in the Į1 helix [112]. HLA-Bw4 allotypes with 
isoleucin at position 80 (Bw4Ile80) have been suggested to bind better to KIR3DL1 
than those with threonine at the same position (Bw4Thr80), although this is not true for 
all KIR3DL1 alleles [110, 113]. Peptides bound to HLA has in some instances been 
shown to affect the interaction with KIR molecules [114, 115]. Although KIR 
molecules do not seem to distinguish self from non-self peptides, KIR3DL2 was shown 
to bind certain HLA-A molecules only in presence of specific Epstein-Barr virus 
14
(EBV) peptides [116]. The unique framework gene KIR2DL4 with features typical of 
both inhibitory and activating receptors binds the non-classical MHC class I molecule 
HLA-G expressed on fetal trophoblasts, possibly indicating a role for KIR2DL4 during 
pregnancy [117]. 
Figure 3: Schematic representation of killer immunoglobulin-like receptors (KIR) and 
their ligands. Inhibitory and activating KIR receptors with known ligands are included in the 
figure, in addition to KIR2DS2 and KIR3DS1 for which the ligands are still unknown. 
Extracellular immunoglobulin-like domains D0, D1 and D2 are depicted in gray, blue and green 
respectively. Inhibitory KIRs and 2DL4 have ITIMs in their cytoplasmic tail. Activating KIRs 
possess a basic amino acid in the transmembrane domain that can interact with the ITAM-
containing DAP12 adaptor protein. Figure modified from Bashirova et.al. Annu Rev Genomics 
Hum Genet. 2006, 7, 277-300 
Less is known about the ligands for activating KIRs, but since they are similar in the 
extracellular sequence to inhibitory KIRs, it is believed that they bind to the same 
ligand as their corresponding inhibitory receptor (Figure 3). Although KIR2DS1 binds 
weakly to HLA-C2 no conclusive evidence for binding of KIR2DS2 to HLA-C1 or 
KIR3DS1 to HLA-Bw4 has been established [109, 118-120]. It is possible that 
activating KIR receptors recognize MHC class I molecules loaded with disease-specific 
or stress-induced peptides or bind non-class I MHC ligands. The later seems to be the 
case for KIR2DS4 that upon recognition of a ligand on melanoma cells induces killing 
of the tumor cells [121]. However since a substantial proportion of humans lack most 
activating KIR genes (individuals homozygous for haplotype A) these genes are 
probably not absolutely required for NK cell function. Disease association studies have 
on the other hand indicated a role for both inhibitory and activating KIR receptors and 
there respective ligands in infectious diseases, autoimmunity, cancer and reproduction 
[122]. This will be discussed in more detail in section 5.1.3.3 regarding KIR 
associations to HIV-1 progression. 
3.5.2.2 Ly49 receptors 
Ly49 receptors belong to the C-type lectin-like family and are expressed on NK cells 
and subsets of T cells. Ly49 receptors are either inhibitory or activating. The inhibitory 
Inhibitory Activating
Ligand HLA-Bw4 HLA-A HLA-C2 HLA-C1 HLA-G HLA-C2 ? Non-MHC on 
melanoma
cells
?
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Ly49s encode an intracellular ITIM and interact with certain MHC class I molecules, 
resulting in inhibition of NK cell cytotoxicity [4]. Activating Ly49 receptors associate 
with the ITAM-containing DAP12 and in C57BL/6 mice two such receptors exist, 
Ly49D and Ly49H [4]. Ly49D recognize the MHC class I molecule H-2Dd. Ly49H on 
the other hand binds the “MHC-like” murine Cytomegalovirus (MCMV) encoded 
protein m157, which activates NK cell functions and contributes to control of MCMV 
infection [32, 35].  
3.5.2.3 NKG2A/NKG2C 
Another MHC class I binding receptor family are the heterodimers CD94/NKG2, 
expressed in mice and humans and belonging to the C-type lectin-like receptor family 
[123]. As for KIR and Ly49 these are either inhibitory or activating receptors. The 
inhibitory NKG2A contains intracellular ITIMs and the CD94/NKG2A complex is 
expressed on most normal NK cells. The ligands for the CD94/NKG2 receptors are the 
non-classical MHC class Ib molecules, HLA-E in humans [124, 125] and Qa-1b in mice 
[126]. The most abundant peptides bound to the peptide groove of HLA-E are leader 
sequence peptides from other MHC class I molecules. It was demonstrated that the 
inhibitory receptor binds with a higher affinity than the activating receptor and that 
peptides bound to HLA-E can affect the binding [127]. As an example, HLA-E 
molecules that have bound stress induced peptides derived from heat shock protein 60 
(hsp60) do not bind to the inhibitory CD94/NKG2A, and this loss of inhibition could 
lead to NK cell elimination of these stressed cells in a peptide-dependent manner [128]. 
An activating counterpart for the inhibitory CD94/NKG2A heterodimer is the 
CD94/NKG2C complex. NKG2C associates with the adaptor protein DAP12, which 
induces activation signals in the cell [129]. As stated above, activating and inhibitory 
CD94/NKG2 bind the same MHC class I ligands albeit with different affinity. Few 
resting blood NK cells express CD94/NKG2C, although the expression can be 
regulated by the cytokine environment and might be affected by ongoing infections [4, 
130]. 
3.5.2.4 NKR-P1 
The NK1.1 protein, bound by the PK136 antibody [131] is used to define NK cells in 
C57BL/6 mice. This protein belongs to the NKR-P1 gene family, which encode 
proteins of the C-type lectin-like family. The ligand for NK1.1 (NKR-P1C) is not 
known but upon antibody cross-linking NK1.1 associates with an ITAM-containing 
adapter protein, resulting in NK cell activation [132]. In humans only one receptor of 
this family is present, CD161 (NKR-P1A), expressed by most NK cells since immature 
NK cells express it before they acquire CD56 and CD16 [133]. It is also present on 
subsets of T cells. CD161 has been suggested to be inhibitory upon binding of its 
ligand, lectin-like transcript 1 (LLT1), which leads to inhibited cytotoxicity and IFN-Ȗ
production by NK cells [134, 135]. However, in certain instances it seems to have an 
activating function as seen in T cells when CD3 and CD161 are ligated simultaneously 
[134].  
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Table 1: Some NK cell receptors expressed by human and mouse NK cells and their 
respective ligands. *More information regarding inhibitory and activating KIRs, see figure 3 
3.5.2.5 LIR-1
Leukocyte Ig-like receptor (LIR) -1 (ILT2, CD85j) belongs to the Ig superfamily and 
has four extracellular Ig-like domains and four intracellular ITIM motifs [136]. LIR-1 
is expressed on a varying number of NK cells in different human individuals, on some 
T cells and all B cells and monocytes. Ligands for LIR-1 are all HLA class I molecules, 
including HLA-A, -B, -C, -E, -F, and -G [137]. Interestingly, LIR-1 expression has 
been implicated in human CMV (HCMV) disease [138]. LIR-1 binds an HCMV 
encoded MHC class I-like molecule, UL18, with a much higher affinity than for MHC 
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class I molecules [136, 137]. This probably contributes to inhibition of LIR-1+ NK cell 
activity in response to HCMV infected cells, despite downregulation of MHC class I on 
the infected cells [139]. 
3.5.2.6 KLRG1 
Inhibitory NK cell receptors also bind non-MHC class I ligands. The inhibitory killer 
cell lectin-like receptor G1 (KLRG1) possesses an ITIM and binds to members of the 
cadherin family [140, 141]. KLRG1 is present on subsets of NK cells and T cells in 
both man and mice. The most mature subset of NK cells in naïve mice express KLRG1 
and upon MCMV infection a transient expansion of this NK cell subset was detected 
[142, 143]. 
3.5.2.7 CD16
The first activating NK cell receptor to be characterized was the Fc-receptor, FcJRIIIa 
(CD16), which binds the Fc part of IgG antibodies [144, 145]. When IgG molecules 
have recognized a specific antigen on for example an infected cell or tumor cell, the 
NK cell is able to bind the target cells, which results in the lethal hit called antibody 
dependent cellular cytotoxicity (ADCC). CD16 associates with homo- and 
heterodimers of ITAM-containing CD3-ȗ and FcİRI-Ȗ in humans and with FcİRI-Ȗ
homodimers in mice [146-148]. Upon CD16 stimulation these adaptor proteins 
transduce signals that in addition to ADCC result in cytokine production and release, 
proliferation and apoptosis of activated NK cells [149, 150]. In contrast to most 
activating receptors that need co-activation via other activating receptors in order to 
induce NK cell activation, CD16 stimulation is sufficient for NK cell degranulation 
[151]. However, a more effective target cell killing was induced when another 
activating receptor and CD16 were engaged simultaneously by their respective ligands 
[151]. CD16 have different affinities for IgG subclasses, with the highest affinity for 
IgG1 and IgG3 in humans and IgG1, IgG2a and IgG2b in mice [14, 152, 153]. 
Polymorphisms in the human CD16 gene have been reported [152]. A polymorphism at 
amino acid 158 influences binding efficacy of IgG, since NK cells from individuals 
homozygous for Valine (V) at this position bind IgG better than NK cells from 
individuals with at least one allele with Phenyalanin (F) [153, 154]. Patients with 
lymphomas treated with the monoclonal antibody Rituximab (IgG1 anti-CD20) had a 
better prognosis if they were homozygous for V at position 158, indicating an ADCC 
mechanism in killing of cancer cells in vivo [155, 156]. Another polymorphism in 
CD16 has been associated with severe herpes virus infections, although in vitro ADCC 
function in these patients was normal [21].
3.5.2.8 NCRs 
The natural cytotoxicity receptors (NCRs), including NKp30, NKp44 and NKp46 
belong to the immunoglobulin superfamily and are selectively expressed by NK cells 
[157-159]. NKp30 and NK46 are expressed by all NK cells, while NKp44 is only 
expressed by activated NK cells, as seen after culture in presence of IL-2. The NCRs do 
not share structural homology but they all associate with membrane-anchored adaptor 
proteins with ITAM motifs. The ligands for the NCRs are not well characterized but 
seem to exist on tumor cells and virally infected cells. NKp46 and NKp44 bind to 
hemagglutinin of Influenza and Parainfluenza virus [34, 160] and mice lacking NKp46 
(Ncr1) were more susceptible to influenza induced death [33]. NKp46, NKp30 and 
NKp44 bind heparan sulfate proteoglycans expressed on tumor cells [161, 162]. 
NKp30 mediates NK cell killing of immature DCs [163] and binds the nuclear factor 
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HLA-B-associated transcript 3 (BAT3) released by tumor cells and DCs [164]. NKp30 
can also be bound by a HCMV tegument protein called pp65, which leads to decreased 
surface expression of NKp30 [165]. An unknown ligand for NKp44 is suggested to be 
induced on CD4+ T cells in HIV-1 infected patients [166]. 
3.5.2.9 NKG2D 
NKG2D is an activating receptor expressed on all human and mouse NK cells and a 
fraction of T cells. The expression can be manipulated by different cytokines [4]. 
NKG2D forms homodimers and is not structurally related to the other NKG2 receptors. 
Ligands for NKG2D are structurally related to MHC class I and human ligands include 
MHC class I chain related protein A (MICA), MICB and UL16-binding protein 1-4 
(ULBP1-4) [167-169] and mouse ligands are Rae1, H60 and MULT1 [170-172]. These 
ligands are often upregulated on stressed cells, i.e. during infection or transformation 
[173]. NKG2D signals via its associated adaptor protein DAP10 [174], which instead 
of an ITAM contain a phosphatidylinositol-3 kinase (PI3K) binding motif, resulting in 
activation of other signaling pathways. Mouse NKG2D exists in two isoforms, differing 
in length of the cytoplasmic domain. The short isoform (NKG2D-S), not present in 
humans, interacts with either DAP10 or DAP12, whereas the long isoform (NKG2D-L) 
only interacts with DAP10 [4]. The importance of NKG2D ligands in infections can be 
exemplified by presence of several viral proteins in human and mouse CMV that 
interfere with these ligands and inhibit cell surface expression, protecting the cells from 
killing through NKG2D activated NK cells [168, 175]. A similar mechanism seem to 
be present also in HIV-1 infection [176]. 
3.5.2.10 DNAM-1 
The leukocyte adhesion molecule CD226 (DNAX accessory molecule 1 (DNAM-1)) is 
an activating receptor expressed on most NK cells, T cells and monocytes [177]. It 
belongs to the Ig superfamily and the ligands for this receptor are Poliovirus receptor 
(PVR, CD155) and Nectin-2 (CD112) [178]. These are highly expressed in many tumor 
cell lines and DNAM-1 mediated NK cell activation is involved in killing of tumor 
cells as well as DCs [179, 180]. DNAM-1 association with the adhesion molecule 
leukocyte functional antigen 1 (LFA-1) in the NK cell might be required for activation 
of cytotoxicity [181]. The expression of the ligand PVR was shown to be 
downregulated by a viral gene product in cells infected with HCMV, probably 
contributing to a decreased killing of CMV-infected cells by NK cells [182]. 
3.5.2.11 Integrins 
NK cells express integrins such as leukocyte functional antigen LFA-1 (CD11a/CD18) 
and Mac-1 (CD11b/CD18), which bind intercellular adhesion molecule (ICAM) -1 on 
target cells. LFA-1 and ICAM-1 interaction contributes to the initial contact and 
adhesion to the target cell as well as to granule polarization in the NK cell [151]. This 
interaction is important for efficient ADCC through the CD16 receptor and also in 
induction of natural cytotoxicity. LFA-1 is also involved in NK cell extravasation [67]. 
3.6 NK CELL INTERACTION WITH OTHER IMMUNE CELLS 
Immune cells interact in complex networks with each other and this is an area where 
new knowledge is constantly unraveled. Here I will only touch on this briefly. 
Interestingly, DCs which are required for activation of NK cells are also affected by the 
NK cells in many ways [183, 184]. Immature DCs can be killed by NK cells, while 
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mature DCs are protected and this has been shown to be due to upregulation of MHC 
class I molecules on the surface of mature DCs [185, 186]. Killing of immature DC 
may involve interaction with NKp30 and DNAM-1 and killing through TRAIL [163, 
179, 180, 187]. NK cells activate immature DCs by releasing the cytokines IFN-Ȗ and 
TNF in addition to cell-contact dependent signals [188]. This leads to production of IL-
12 by DCs, further stimulating NK cells, but the cytokines also indirectly activate T cell 
responses. Another indirect contribution to the adaptive immunity is the antigens from 
NK cell lysed target cells provided to DCs, which are presented to T cells. NK cells are 
also involved in direct priming of Th1 T cells, by contributing with the initial source of 
IFN-Ȗ [80]. Induction of isotype class switching in B cells is another area where NK 
cells might be involved .[183]. In addition, NK cells do not only activate immune 
responses they can also terminate them, which could be of importance in preventing 
immunopathology [183]. 
3.7 NK CELLS IN VIRAL INFECTIONS 
NK cells contribute to control of certain viral infections, as has been mentioned 
previously. The majority of data concerns Herpesvirus infections and mainly CMV 
infection, both in humans and mice. However, NK cells play a role also in other viral 
infections, for example in infections with Poxviruses, Influenza virus, Hepatitis viruses 
and HIV-1 [189, 190]. From this research an understanding on how NK cells are 
activated through virally induced cytokines [86-88, 90, 91] or upregulation of ligands 
for activating NK cell receptors on infected cell surfaces [32-35] has been gained. NK 
cells have also been shown to be recruited [191, 192] and to proliferate [193, 194] at 
the site of infection. This virally induced NK cell activation results in release of 
cytokines and direct killing of infected cells [88, 90, 195]. Recently, in an adoptive 
transfer model, specific NK cells expanded during MCMV infection, were shown to 
respond more vigorously to stimulation than naïve NK cells. This capacity remained up 
to two months after the infection [196], which indicates that NK cells might have a 
memory-like function, similarly to the adaptive T and B cells. In two other 
corroborating reports NK cells stimulated with cytokines or haptens have also had a 
prolonged memory-like response [197, 198].  
In humans, in vivo data on the role of NK cells in infection comes from rare 
immunodeficiencies affecting NK cell numbers or function [21, 199]. The importance 
of NK cells in vivo in infected mice has often been studied by depletion of NK cells 
with antibodies specific for NK cell markers, such as NK1.1, or by using transgenic 
mice lacking certain genes important in NK cell function. A problem however has been 
the lack of specific NK cell depletion since some T cells share most NK cell markers 
and have similar effector functions as NK cells do. Mice depleted of NKp46 are 
increasingly used for studies on NK cell functions [48]. In addition, it was recently 
reported that deletion of a transcription factor acting downstream of the IL-15 receptor 
results in a specific lack of NK cells [200]. These transgenic mice could be an 
important tool in future research on many areas concerning NK cell function and 
development.  
Despite the sometimes vigorous NK cell response to infections it is often not enough 
for complete control of a viral infection. One reason for this could be the immune 
evasion mechanisms evolved by many viruses [190]. To avoid NK cell activation due 
to recognition by inhibitory NK cell receptors MHC class I molecules important for NK 
cell recognition are kept on the cell surface, while others are selectively downregulated 
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to avoid T cell recognition [201]. Some viruses also express viral homologues of MHC 
class I which bind inhibitory receptors, as exemplified by the HCMV UL18 protein, 
which bind LIR-1 [136, 137]. To avoid recognition by activating receptors cell surface 
expression of activating ligands [168, 175, 182] or receptors [165] are inhibited by 
certain viral proteins. In HCMV infection certain NKG2D and DNAM-1 ligands are 
affected by the UL16 and UL141 proteins respectively and NK cell expression of 
NKp30 is as previously mentioned decreased by binding of the HCMV pp65. Several 
of these escape mechanisms are used by HIV-1 to avoid NK cell recognition and this is 
an exciting field of research which will be covered in detail in section 5.2. 
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4 HUMAN IMMUNODEFICIENCY VIRUS INFECTION 
In 1981 USA clinicians identified an immunodeficiency syndrome that was affecting 
previously healthy individuals that now succumbed to rare infections [202, 203]. The 
main risk groups were men who had sex with men, intravenous drug users and 
hemophiliacs. Early on it was suspected that a virus would be the causative agent and in 
1983 the French scientists Luc Montagnier and Francoise Barré-Sinoussi with co-
workers managed to isolate a previously unknown retrovirus from a patient with 
symptoms of acquired immunodeficiency syndrome (AIDS) [204]. Knowledge on how 
to grow the virus in cell culture and how to easily detect it in human specimens was 
soon to follow [205]. Although the virus was named differently from the beginning the 
name human immunodeficiency virus (HIV) was subsequently agreed on. Since then 
the HIV epidemic has escalated to a pandemic with over 60 million people infected of 
whom 33 million are currently living with the infection. Globally there are about 2.7 
million newly infected each year and 2 million people dying from AIDS-related 
illnesses [206]. Despite this a pleasant news is that the spread of the disease is 
decreasing, a trend seen over the last ten years [206]. The leading cause of death among 
HIV-infected world-wide is co-infection with Mycobacterium tuberculosis, which 
approximately on third of the world’s population is infected with. The problem with 
HIV-1 infections is greatest in Sub-Saharan Africa and Asia, where the health problem 
is compounded by economic and infrastructural effects.  
4.1 THE ORIGIN OF HIV 
HIV is a Lentivirus belonging to the Retroviridae family. Like its relatives within the 
retrovirus family, the viruses causes a slow chronic disease targeted to hematopoietic 
cells [207]. There are two different human immunodeficiency viruses: HIV-1, which is 
the main cause of the AIDS epidemic in the world, and HIV-2, which is a less 
pathogenic virus spread mostly in West African countries. The HIV viruses resemble 
viruses present in African non-human primates. It is likely that HIV-1 originates from 
the chimpanzee (Pan troglodytes troglodytes) simian immunodeficiency virus (SIVCPZ)
[208] and that HIV-2 originates from the sooty mangabey SIV (SIVSM) [209]. It is 
believed that humans acquired these viruses through cross-species transmission and it is 
estimated that the first infection with HIV-1 took place in the early 20th century [210]. 
The oldest evidence for HIV-1 infection was identified in a retrospective study on 
stored plasma samples and dates back to 1959 [211]. There are three different groups of 
HIV-1: M (major), O (outlier) and N (non-M, non-O). Approximately 95% of all HIV-
1 isolates belongs to group M, which can be further divided into eleven clades or 
subtypes (A-K) [207]. Circulating recombinant forms of these subtypes are also present 
to varying extents in the world. 
4.2 HIV-1 INFECTION AND PATHOGENESIS 
HIV-1 is spread by sexual contacts, contaminated blood, or from mother to child during 
pregnancy, birth or breastfeeding. The majority of infections in the world occur through 
heterosexual contacts, this despite that the risk of infection per sexual act is estimated to 
be below 1% [212]. Factors that are known to influence the risk of transmission are 
genital infections and lesions, type of sexual activity and viral load in the infected 
partner. 
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HIV-1 infection through the genital mucosa results in binding to DCs or direct infection 
of DCs or Langerhans cells, which is another APC present in the epithelium [213]. DCs 
express a molecule called DC-SIGN which traps the HIV-1 virus in the genital mucosa 
and allows it to be transported to lymphoid tissues [214]. Infected APCs also 
disseminates to draining lymph nodes where active CD4+ T cells, the prime target for 
HIV-1, are infected. In the case of presence of other genital infections or inflammation 
the risk of viral transmission increases. Co-infections can cause ulcerations, which 
leads to breaching of the epithelium and influx of CD4+ T cells to the site of viral entry 
[213]. 
In the acute phase, occurring within a few weeks of HIV-1 transmission, the viral load 
is high (Figure 4) and flu-like symptoms appear in most individuals due to immune 
hyperactivation. During this phase the majority of the gastrointestinal tract CD4+ T 
cells are lost [215] and the gastrointestinal tract mucosal barrier is injured. After the 
acute phase, the level of virus in plasma decreases to a stable level, called the viral set 
point. The viral set point is predictive of the disease course, since a high viral set point 
correlates with a more rapid disease progression [216]. Following the acute phase of the 
infection, comes the latent phase that may last for years. During this phase the CD4+ T 
cell count decline slowly, probably due to viral replication and the chronic systemic 
immune activation. Chronically infected patients have elevated levels of LPS in the 
blood, which might contribute to the chronic immune activation. The elevated LPS 
levels is thought to result from microbial translocation over the injured mucosal barrier 
of the gastrointestinal tract [217].  
When the CD4+ T cell count falls below 200 cells/ȝl of blood, opportunistic infections 
usually appear and this defines the AIDS stage of the infection. Examples of 
opportunistic infections that are common for AIDS patients include Pneumocystis 
carinii, Mycobacterium avium and viral infections that cause AIDS defining 
malignancies like Kaposi’s sarcoma and various lymphomas. In the late stage of the 
disease, the viral load increases sharply and the CD4+ T cell counts decrease rapidly 
resulting ultimately in immune incompetence and death due to opportunistic infections. 
Figure 4: The clinical course of HIV-1 infection
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4.3 VIRAL STRUCTURE AND REPLICATION 
4.3.1 The replication cycle of HIV-1 
HIV-1 is an enveloped virus with a protein core that encloses two single-stranded 
genomic RNAs and various regulatory proteins important for the replication cycle 
(Figure 5a). The infection starts when the HIV-1 envelope protein gp120 binds to a 
CD4 molecule on a target cell (Figure 5b). CD4 is mainly expressed on T helper 
cells, macrophages, monocytes, DCs and brain microglia. When gp120 binds its 
receptor conformational changes are induced that result in exposure of the co-receptor 
binding-site on gp120. The most important co-receptors for HIV-1 are the chemokine 
receptors CCR5 and CXCR4 [218]. The interaction with the co-receptor leads to an 
additional conformational change in the viral transmembrane envelope protein gp41, 
which is linked non-covalently to the gp120 protein. The gp41 protein then mediates 
fusion between the viral and cellular membranes [219].  
After fusion the viral capsid is released into the cytoplasm of the cell. The viral RNA 
genome is then reversibly transcribed by the viral reverse transcriptase (RT) into 
double-stranded DNA. During this process, mutations are frequently introduced since 
the reverse transcriptase lacks proof-reading mechanisms. These mutations are 
important for the viral diversity and can result in escape from the immune system and 
from antiretroviral drugs. The preintegration complex, consisting of viral DNA and 
integrase, is directed to the nucleus by the accessory protein viral protein r (Vpr) [220]. 
Linear double-stranded DNA is then integrated into the host genome, catalyzed by the 
viral enzyme integrase. The site of integration is not chosen randomly, rather it targets 
specifically transcriptionally active genes [221]. 
The virus can establish a latent infection if the infected cell returns to a resting state 
when viral DNA has been integrated in the genome. This transition from an active to a 
resting state can be exemplified by activated CD4+ T cells that develop into memory 
cells. Virus is produced by transcriptionally active cells, as cellular transcription factors 
are necessary for transcription to be initiated from the HIV-1 long terminal repeat 
(LTR) flanking the HIV-1 DNA genome. In resting cells, these transcription factors are 
not expressed and this together with the formation of a heterochromatin structure at the 
site of integration is believed to contribute to lack of proviral transcription [222]. The 
heterochromatin structure results in reduced capacity of binding of transcriptional 
factors due to sterical hindrance [222]. The latent phase can persist for years, 
throughout the life-span of the infected cell, but is reverted upon activation of the cell. 
In activated cells, the viral DNA is transcribed into RNA and this step is greatly 
enhanced by the transactivating viral protein Tat. RNA is then transported to the 
cytoplasm, aided by the viral regulator of RNA transport (Rev) protein [220], where 
translation into polyproteins takes place. The polyproteins are formed from the 
structural genes: group-specific antigen (Gag), polymerase (Pol) and envelope (Env). 
Three different polyproteins are formed: Gag, Gag-Pol and Env [223]. Gag directs the 
assembly of viral proteins and RNA beneath the cell membrane. These proteins include 
Gag and Gag-Pol polyproteins and accessory proteins like Vpr, viral infectivity factor 
(Vif) and negative factor (Nef). The Env gene is translated into the fusion protein 
gp160 in the ER. Cleavage into the envelope proteins gp120 and gp41 takes place in 
the Golgi apparatus before the proteins are transported to the cell surface. The envelope 
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proteins form trimers consisting of three transmembrane gp41 molecules in complex 
with three gp120 molecules [219]. These are incorporated in the budding virion by 
binding to the matrix proteins, which line the inner surface of the virion membrane.  
Figure 5: a) The viral structure and genome. b) The viral replication cycle of HIV-1.
Courtesy: a) Annika Wiklund b) National Institute of Allergy and Infectious Diseases
a)
b)
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The Vpu and Nef proteins are involved in degradation of CD4 molecules, in order to 
avoid interaction between the newly synthesized Env proteins, enabling the viral 
surface proteins to be transported to the surface and new virions to be released from the 
cell [223]. During assembly and during budding from the cell surface the Gag and Gag-
Pol polyproteins are cleaved by protease. Cleavage of Gag results in formation of p17 
matrix, p24 capsid, nucleocapsid (NC or p7) and p6 proteins. Pol encodes the enzymes 
viral protease, reverse transcriptase and integrase. This cleavage leads to structural 
reorganizations essential for viral infectivity [207, 220, 223]. HIV-1 can also infect 
neighboring cells through directed release at cell to cell contacts where a virological 
synapse is formed with a preferential accumulation of Gag and Env proteins [224]. 
4.3.2 The envelope protein structure 
The gp120 molecule is divided into five conserved (C1-C5) and five variable (V1-V5) 
segments. The inner domain of the gp120 protein in its trimeric conformation is mainly 
formed by the C1 and C5 regions [225]. This part of gp120 is in contact with the 
transmembrane gp41 molecule. The gp120 molecule also has a heavily glycosylated 
outer domain and in between the inner and outer domain lies a bridging sheet. The 
interface between the inner domain, bridging sheet and outer domain forms the binding 
site for CD4. As mentioned, when CD4 is bound conformational changes in gp120 
results in exposure of regions with co-receptor binding properties. One of these regions 
is the V3 loop, which is partly shielded by the variable loops V1 and V2. V3 is likely to 
protrude from the core and interact with the co-receptor upon CD4 binding [226]. This 
extended form of the V3 loop could be an explanation to the immune dominant 
responses to this region. CCR5 is the primary co-receptor during mucosal transmission 
but later in the course of infection, when the immune pressure is lower, the virus often 
changes the co-receptor usage to CXCR4. This change in co-receptor usage is believed 
to be due to mutations in the V3 loop [227]. 
4.4 PREVENTION AND TREATMENT 
4.4.1 Antiretroviral treatment 
Since the introduction of antiretroviral treatment (ART) in the mid 1990´s, the death 
rate in AIDS has declined sharply in the Western world. Antiretroviral treatment now 
consists of a combination of drugs targeting different parts of the viral life cycle. The 
most commonly used drugs target the reverse transcriptase and the protease. Drugs that 
inhibit the fusion of HIV-1 with the target cell, by binding to gp41 and preventing the 
conformational change needed for fusion, are also used. Novel drugs include integrase 
inhibitors that block integration of HIV-1 DNA into the host genome and CCR5 
antagonists that interfere with the binding of HIV-1 to the target cell [228]. Efficient 
ART treatment leads to a rapid decrease in the plasma virus levels down below the 
limit of detection (<50 copies per ml), because infection of new susceptible cells is 
almost completely stopped. ART treatment also results in increased CD4+ T cell counts. 
Despite the positive effects of ART, the virus is not eradicated and HIV-1 is still a life-
long disease without any cure as of today. This is due to latently infected resting 
memory CD4+ cells that persist despite long-lasting ART treatment [229]. The virus 
also hides in compartments like the central nervous system with poor antiretroviral drug 
penetration. Upon therapy interruption there is a rapid onset of virus replication and 
production of new viruses. An interesting field of research is the development of 
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interventions to specifically antagonize the mechanisms of latency [230]. This is meant 
to induce proviral replication in latently infected cells in presence of effective ART, 
something that might result in a reduction of the pool of latent virus.  
A major drawback of the antiretroviral drugs is that they are toxic to a varying degree 
and can cause numerous side effects, such as gastrointestinal disturbances and 
metabolic rearrangements, and this can lead to problems with medical compliance since 
the treatment needs to be continued indefinitely. Although the availability of ART in 
low and middle income countries has increased substantially in the last five years [231], 
the high costs and difficulties in distribution of ART are problematic for combating the 
HIV-1 epidemic. Due to the high mutation rate in HIV-1 combined with the problems 
of adherence, resistance to drugs is also becoming a problem in HIV-1 treatment [228]. 
New ways of treating HIV-1 are therefore needed and much attention has been given to 
different ways of activating the immune response against HIV-infected cells. 
4.4.2 Preventive measures 
The most effective strategy for preventing sexual HIV-1 transmission as of today is 
education on HIV infection and transmission, and promotion of condom use. Male 
condoms, if consistently and correctly used, decreases the risk of infection with 95%, 
although problems with non-coherent usage decreases the estimated protective effect 
substantially [232]. Another preventive measure is male circumcision, which in three 
large randomized trials performed in Africa reduced the risk of male infection with 
about 60% [233]. The high concentration of cells susceptible for HIV-1 in the foreskin 
might explain this beneficial effect [234]. A major problem is that condom use and 
circumcision both are controlled by males and as females globally account for 60% of 
all HIV-1 infections there is a need for female-targeted preventive measures. 
Intravaginal application of microbicides, which are substances that reduce the 
infectivity of a microbe, could serve such a purpose. The action of a microbicide can be 
to disrupt the pathogen membrane, mainly through the use of detergents, or to lower the 
pH of the intravaginal tract to reduce infectivity. Microbicides can also be specifically 
targeted to the HIV-1 virus or host cell proteins bound by the virus [235]. New types of 
microbicides are constantly developed and tested in the search for a successful agent. A 
good preventive measure is lowering of the viral load in infected patients by ART 
treatment, which reduces the risk of transmitting the virus. Importantly, ART treatment 
of HIV-1 infected mothers is an effective countermeasure for mother-to-child 
transmission which together with terminated breastfeeding have decreased the risk of 
transmission to only 1% in high income countries [236]. The best preventive strategy 
would be a protective HIV-1 vaccine. It is believed that such a vaccine should induce 
specific neutralizing antibodies and/or T cell responses, and different vaccine 
modalities inducing this kind of responses are constantly being explored (see section 
6.2.3) 
4.5 ANIMAL MODELS IN HIV RESEARCH 
There is no proper animal model for HIV-induced AIDS; and the closest model has 
been the chimpanzee, which can be infected with HIV-1, but rarely develop AIDS 
[237]. Rhesus and cynomolgus macaques can be infected with SIV or a genetically 
engineered variant of the virus, called SHIV, which is carrying some of the genes from 
HIV-1. Depending on which virus is used SIV and SHIV can cause AIDS in macaques 
within a couple of months from infection [238, 239]. Macaques are used for studying 
HIV pathogenesis and evaluation of potential vaccines and immunotherapeutics. Sooty 
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mangabey monkeys are naturally infected with SIV but do not develop AIDS and are 
therefore an interesting model for studying natural resistance to disease [240].  
For ethical and economic reasons, primates cannot be used as a first line model for 
testing new immunotherapeutics. Instead, small animal models, such as mice, are 
preferable. HIV-1 replication in rodent cells is restricted due to species differences in 
cellular host factors like Cyclin T1 [241] and APOBEC3G (apolipoprotein B mRNA-
editing enzyme, catalytic polypeptide-like 3G) [242]. Mouse cells also lack the 
receptors for HIV-1 entry. To overcome these species barriers models of various kinds 
have been developed for HIV-1 infection in mice. These include sever combined 
immunodeficiency (SCID) mice with human xenografts, mice irradiated and 
repopulated with human cells and transgenic mice [243]. In the SCID mouse models 
human peripheral blood mononuclear cells (PBMCs) or tissues from thymus and liver, 
permissive for HIV replication, are engrafted into the mice. In some models such as the 
SCID-hu (Thy/Liv) mice CD4+ T cells are depleted resembling the infection in humans 
[244]. In newer SCID-models, where human hematopoietic stem cells are transplanted, 
functional human immune systems with primary humoral and cellular responses to 
HIV-1 have been achieved, although for a limited period of time [245, 246].  
Instead of modulating the mice, it is possible to instead construct pseudoviruses that 
express HIV-1 antigens and have the ability to infect murine cells. This can be done by 
constructing HIV-1 particles that bind other receptors than CD4 and CCR5/CXCR4. 
The sodium phosphate channel receptor Ram-1 is expressed on cells of many species 
and is used by amphotropic retroviruses for entry [247-249]. By exchanging the HIV-1 
envelope with the envelope protein from a virus with tropism for this receptor HIV-1 
can enter murine cells [250]. Exchange of viral envelopes can be achieved naturally by 
infecting a cell with two viruses, a process referred to as pseudotyping. One model for 
this is the HIV-1/MuLV challenge model where pseudovirions of HIV-1 and murine 
leukemia virus (MuLV) are produced (described below) [251, 252]. Another model 
based on the same principle and recently developed by Potash et.al. takes the advantage 
of genetical engineering to exchange the coding region for the HIV-1 gp120 envelope 
with the MuLV envelope gp80 in a plasmid encoding the virus [253]. This virus is able 
to spread to multiple organs in infected mice and induce immune responses to HIV-1. 
4.5.1 The HIV-1/MuLV mouse challenge model 
We have chosen to use the HIV-1/MuLV challenge model as a model system for HIV-1 
infection. Pseudoviruses are produced by in vitro HIV-1 infection of a cell line that 
carries an integrated murine leukemia virus (MuLV) genome (Figure 6). The cell line 
will theoretically produce four different viral variants, with HIV-1 or MuLV genomes 
each contained in virions surrounded by HIV-1 or MuLV envelopes. These 
pseudoviruses are harvested and subsequently used for infecting activated murine 
splenocytes, which can be infected with the viral particles with a MuLV envelope 
(MuLV/MuLV or HIV-1/MuLV). The syngeneic HIV-1/MuLV infected splenocytes 
are then injected intraperitoneally (i.p.) into mice. After ten days, cells from the 
peritoneal cavity are harvested from the mice and the peritoneal cells are co-cultured in 
vitro with HIV-1 susceptible cells, such as Jurkat T cells or activated human PBMCs. 
The amount of viral replication is measured by production of HIV-1 p24. This is used 
as an indirect measurement of amount of infected cells present in the peritoneal cavity 
of the mice [252].  
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It is unclear if HIV-1 actively replicates in the transplanted murine cells and the virus is 
thereby unlikely to spread to new cells in vivo, unless helper MuLV is present. The 
model thus mostly resembles the antigen exposure during the acute phase of HIV-1 
infection in humans. Injection of infected cells induces HIV-1 specific cellular and 
humoral immune responses probably contributing to the complete clearance of the 
infected cells 4-6 weeks after challenge [252]. Unspecific stimulation with Toll-like 
receptor adjuvants, like CpG-oligonucleotides (ODNs), seem to induce a level of 
protection against the HIV-infected cell challenge [243]. This indicates that also innate 
immune mechanisms can contribute to clearing of the infected cells. The role for NK 
cells in the HIV-1/MuLV challenge model was investigated in paper III. Several 
vaccine evaluation studies have been performed with this model and have shown that 
vaccinated mice can be protected against challenge with infected cells [243, 252, 254]. 
The model is also suitable for investigating effects of other immunotherapeutic 
strategies as discussed in relation to a drug-conjugated anti HIV-1 envelope antibody in 
paper IV.
Figure 6: The HIV-1/MuLV challenge model. (1) A human T cell line with a proviral MuLV 
is infected with a HIV-1 isolate. (2) Four types of particles are produced with HIV-1 and/or 
MuLV genome/envelope. (3) These are used to infect primary murine splenocytes in vitro. (4)
The infected cells are injected intraperitoneally into syngeneic mice. (5) One to ten days later 
peritoneal cells are harvested and (6) co-cultivated with a human T cell line or activated 
PBMCs. (7) Supernatant is retrieved and HIV-1 p24 is quantified. 
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5 THE HOST RESPONSE AGAINST HIV-1 INFECTION 
5.1 CORRELATES OF PROTECTION 
There are no definite correlates of protection against HIV-1 infection or control of viral 
replication, but there are many factors identified that are suggested to be important. 
Some HIV-1 infected patients are able to control their infection without treatment. 
These individuals have been grouped into three different categories. Long-term non-
progressors (LTNPs) are patients that have been infected for a long time with stable 
CD4 counts and often low viral loads [255]. Controller patients are patients that are 
able to suppress the viral load for an extended period of time and elite controller 
patients are patients that maintain a viral load of below 50 HIV-1 RNA copies/ml for 
long periods (at least one year) [256]. In paper I and II we use the designation 
controller patients, although some of these patients might also fit into the LTNP or elite 
controller groups. Another interesting group of individuals is the exposed uninfected 
(EU) that seem to have some kind of protection against infection, as they remain 
uninfected despite repeated exposures to the virus [257]. These individuals have been 
found among commercial sex workers, discordant couples and intravenous drug users 
[258-260].  
Extensive studies have been performed on these groups of patients and the exposed 
individuals to try to identify parameters that correlate with a slower disease progression 
or protection from infection. Although there are some studies suggesting that patients 
that control their infection are infected with a defective virus, the majority of results 
indicate that most controller patients are infected with replication-competent viruses, 
indicating that there is some protective mechanism in these patients acting to control 
the virus [261]. It is plausible to believe that genetic differences and host immune 
responses may contribute to the outcome of the infection. 
5.1.1 Innate immune responses to HIV-1 infection 
The innate immune response is a possible contributor to protection from HIV-1 
infection. Early events in the acute HIV-1 infection appear to have an effect on disease 
progression, and it is therefore likely that features of the innate immune response play a 
role in the establishment of a state of control of the virus. HIV-1 can activate the pDCs 
to produce type I interferons by binding of single stranded RNA or CpG DNA motifs to 
TLR7/8 and TLR9 respectively. Certain polymorphisms in the TLR9 gene have been 
associated with rapid disease progression [262]. In addition, pDCs are present in 
increased numbers in controller patients compared to uninfected individuals and 
patients with a progressive disease [263]. NK cells and NKT cells from EUs have an 
increased activity as compared to uninfected individuals, indicating a role in protection 
from infection [260, 264]. Other innate immune mechanisms include intracellular 
antiviral proteins such as APOBEC3G, which hypermutate the viral RNA leading to 
lethal mutations in the viral genome [242]. HIV-1 counteracts APOBEC3G via the viral 
protein Vif, which targets APOBEC3G for degradation. However, the protein may be 
upregulated in EUs and an increased APOBEC3G mRNA level has been shown to 
correlate with lower viral load [265]. 
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5.1.1.1 NK cell responses to HIV-1 infection 
The potential importance of NK cell activity in protection from primary infection was 
first shown in a study of exposed uninfected Vietnamese intravenous drug users. 
PBMCs from these EUs had a significantly increased cytotoxic activity against the NK 
cell sensitive cell line K562 and an increased proportion of NK cells from these patients 
produced the cytokines IFN-Ȗ and TNF-Į and the CC-chemokines MIP-1Į, MIP-1ȕ
and RANTES than both intravascular drug users who became HIV-1 infected, or 
uninfected controls [260]. They also had increased frequency of CD69+ NK cells ex 
vivo and an increased frequency NK cells degranulating ex vivo without in vitro
addition of stimulants [266]. The correlation between a high cytokine production by 
NK cells and protection from infection has also been shown in a cohort of sexually 
exposed EUs [264].  
In acute HIV-1 infection, before onset of the adaptive immune response, the frequency 
and absolute number of NK cells in the blood are increased [267, 268]. There is a 
preferential expansion of CD56dimCD16+ NK cells [268, 269] and NK cell activity is 
elevated and parallels the decrease of viral load from peak viremia to the viral set point 
[267]. This indicates that NK cells may contribute to the early immune response to 
HIV-1 infection. Similarly, in SIV infected rhesus macaques NK cell cytotoxicity and 
CD69 expression on NK cells is elevated early after infection [270]. When 
investigating the effects of NK cells in control during infection, SIV infected macaques 
that control their viral load for an extended time were shown to have increased 
production of IFN-Ȗ as compared to viremic macaques [271]. NK cell cytotoxicity and 
chemokine production is elevated in humans infected with the less pathogenic HIV-2 
virus as compared to HIV-1 infected patients with similar CD4 counts [272]. This 
suggests that an enhanced NK cell activity may be involved in control of HIV-2 
infections. Studies on human HIV-1 controller patients have not given any clear 
correlates of control regarding NK cells. Controller and viremic patients have similar 
frequencies of NK cells and this frequency is often lower than for healthy individuals 
(Figure 11) (paper I and [268, 273, 274]). In addition, controller patients do not seem 
to have a stronger NK cell activity as compared to viremic patients and healthy controls 
(paper I and [274]).  
NK cells can mediate control of infection in vitro through several mechanisms (Figure 
7). Direct cytotoxic killing of HIV-1 infected tumor cell lines have been reported [275], 
while presence of NK cell cytotoxicity against autologous HIV-1 infected CD4+ T cells 
have been less clear. Bonaparte et.al showed that NK cells from healthy individuals are 
unable to kill autologous CD4+ T cells infected with HIV-1 [25, 276], whereas 
Tomescu et.al reported an increased NK cell cytotoxicity against autologus CD4+ T 
cells infected with a primary HIV-1 strain [277]. NK cells from viremic patients also 
had an increased NK cell cytotoxicity against autologous CD4+ T cells stimulated to 
express endogenous virus [278]. NK cells can inhibit viral replication in autologous 
CD4+ T cells in a cell-contact dependent manner in vitro [279]. However they can also 
suppress viral infection in vitro by production of CC-chemokines, which bind to the 
CCR5 co-receptor and prevent the virus from entering the cell, by competing for or 
down-regulating CCR5 [82, 235, 280]. Another potent NK cell mediated mechanism 
for killing of HIV-1 infected cells is ADCC in presence of HIV-1 specific antibodies 
(paper II and [281]).  
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Figure 7: Possible effects exerted by NK cells on HIV-1 infection. a) NK cells that recognise 
activating ligands on the infected cell in the absence of MHC class I molecules may kill the 
infected cell. b) NK cell secreted chemokines and cytokines block viral entry or activate other 
immune effector cells to respond to the virus infection.CCL3 = MIP-1Į, CCL4 = MIP-1ȕ,
CCL5 = RANTES. Reprinted by permission from Macmillan Publishers Ltd: Nature reviews 
immunology, Fauci et.al. 2005 Nov;5 (11):835-43, copyright 2005.
5.1.2 Adaptive immune responses to HIV-1 infection 
The adaptive immune response reacts specifically to the HIV-1 antigens and it is well 
established that the mounted response is able to suppress the viral replication. However, 
ultimately in the vast majority of cases, the virus will win this struggle. 
5.1.2.1 Anti-HIV-1 antibodies 
In non-human primate experiments it has been shown that antibodies are important for 
protection from HIV-1 and SHIV infections [282-285]. This was proven by passive 
immunizations of non-human primates with neutralizing monoclonal antibodies in 
different infection models [282-285]. Although in most of these trials the passive 
immunizations did not induce complete protection, antibody treatment before challenge 
was able to prolong the time until infection. Interestingly, antibodies delivered after 
SIV challenge of macaques also led to control of disease [286], indicating that 
antibodies may exert effects during the acute infection. This was corroborated by a 
study where B cells were depleted in macaques before SIV challenge, resulting in 
lower antibody responses, higher viral loads and a more rapid progression [287]. In 
addition to neutralization, antibodies can also exert protective effects via other 
mechanisms including ADCC or complement mediated lysis. Recently Hessell et.al. 
investigated the importance of the Fc-part of the antibody molecule in SHIV challenged 
macaques and their results indicate that it is not merely the neutralizing ability of 
antibodies that is important but also the ability to bind to Fc-receptors [288, 289]. The 
potential effect of the antibody Fc-part was further confirmed in neonatal macaques that 
was protected from oral SIV challenge by infusion of sera without neutralizing ability 
but with known antibody-dependent cell-mediated virus inhibition activity [290, 291]. 
Passive immunization has also been carried out in HIV-1 infected patients and the 
results show that neutralizing antibodies can transiently affect the viral load, but that the 
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rapid development of virus with resistance against the transferred antibodies limits the 
therapeutic use of such a treatment [292]. 
In infected humans, HIV-1 triggers production of high levels of antibodies against the 
envelope proteins gp120 and gp41, but most of these antibodies either cannot bind the 
virion or binds to epitopes that are not important for neutralization of the virus. The 
reason for this may be that the majority of antibodies produced have been triggered by 
shedded free envelope proteins and viral debris from lysed cells [293]. The HIV-1 virus 
can escape antibody recognition, indicating that antibody-mediated mechanisms can 
contribute to immunologic control of viral replication [225, 294]. Both high antigenic 
variation at immunogenic regions and structural features of the envelope protein 
contribute to the resistance against antibody binding. The highly variable loops of 
gp120 can cover and sterically hinder antibodies from reaching parts that are essential 
for entry of virus. The trimeric envelope complex also makes it possible for potential 
epitopes to hide inside the trimer and only become exposed when gp120 binds to CD4 
and changes conformation. Another mechanism for masking of essential epitopes is the 
extensive glycosylation of the envelope protein, with glycans making up 50% of the 
protein mass [295]. It is also possible that HIV-1 specific antibodies enhance infection 
of cells by mediating binding of antibody-bound virus particles to Fc-receptors or 
complement receptors on cells. This may result in uptake of HIV-1 via phagocytosis 
and subsequent infection of the phagocyting cell or dissemination to other cells [13]. 
However, none of the human or animal studies where high amounts of antibodies have 
been injected in vivo have given any evidence of antibody-driven enhancement [292]. 
Figure 8: Antibody mediated mechanisms for combating HIV-1. a) Neutralization of free 
virus by antibodies, b) complement-mediated lysis of free virus and infected cells triggered by 
antibodies, (c) opsonization of virus particles by antibodies and phagocytosis of virus particles 
via Fc- or complement-receptors, (d) ADCC against infected cells. Reprinted by permission 
from Wiley InterScience: Journal of Internal Medicine, Huber and Trkola, 2007 Jul 262, (1), 5-
12, copyright 2007. 
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Neutralizing antibodies 
Neutralizing antibodies against HIV-1 (Figure 8a) have been suggested to appear 
after the viral load has declined in the acute phase of HIV-1 infection, which would 
indicate that they are not important for this first control of viral replication after 
infection [296-298]. However neutralizing antibodies to autologous virus can develop 
within weeks of seroconversion and drive the evolution of viral escape mutations in 
the envelope protein [299], indicating that neutralizing antibodies exert a certain level 
of selective pressure. Most neutralizing antibodies appearing early during infection 
are highly specific for the autologous virus, while cross-reactive antibodies that can 
neutralize heterologous viral isolates may develop later over time as the infection 
progresses [296, 297, 299]. Strong broadly neutralizing antibodies have been 
described in some LTNPs [297, 300], however most elite controller patients have low 
levels of neutralizing antibodies suggesting that an effective control of the virus can 
be achieved without these antibodies [301-303]. An effective neutralizing antibody 
can inhibit infection by preventing receptor or co-receptor interactions or preventing 
virus-membrane fusion [13, 225, 304]. Thus, most neutralizing antibodies are directed 
to the CD4-bindig site, to the CD4-induced binding epitopes involved in binding to 
co-receptors and to the V3 loop in gp120. They can also be directed to the membrane 
proximal external region of gp41. HIV-1 specific mucosal IgA antibodies have been 
correlated with possible immune protection. These antibodies are present in many 
EUs and some may neutralize HIV-1 [257, 258, 305]. 
ADCC inducing antibodies 
HIV-1 specific ADCC responses are readily detected in most HIV-1 infected patients 
(Figure 8d). ADCC inducing antibodies can hinder cell to cell spread of the HIV-1 
virus, since infected cells are targeted by the effector cells [306]. ADCC inducing 
antibodies are present early in infection before the initial drop in viral load, implying an 
important function in the acute infection [307-309]. These antibodies also have a broad 
cross-reactivity against the envelope protein, evident already in the acute infection 
[308, 310]. ADCC-mediating antibodies have been described to influence disease 
progression in HIV-1 infected patients; strong ADCC responses associate with slower 
disease progression and lower viral loads (paper II and [302, 311-313]). In addition to 
antibodies in plasma, HIV-1 specific ADCC mediating antibodies are also present in 
vaginal fluid where antibody titers correlate negatively with genital viral load [314]. 
However, contradicting reports exist where no correlation between disease progression 
and ADCC antibodies were observed [315, 316].  
Other antibody mediated effector mechanisms 
Another critical effector mechanism exerted by HIV-1 specific antibodies is activation 
of the complement system which results in lysis of virions and infected cells (Figure 
8b). Complement lysis activity correlates inversely with viral load in the acute phase of 
the infection and could thus be involved in the early immune-mediated control of the 
virus [317]. Phagocytosis and opsonization of antibody coated virions are also 
important mechanisms in clearing virus particles [13] (Figure 8c).
5.1.2.2 T cell responses to HIV-1 infection 
HIV-1 infected patients develop strong virus-specific CTL responses against HIV-1 
proteins [318]. In primary infection, HIV-1 specific CTL responses correlate to the 
decrease in viral load after the acute phase of the disease [298, 319]. Depletion of CD8+
cells in monkeys points to the importance of these cells in control of SIV viremia [320]. 
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The appearance of mutations in CTL epitopes of viral proteins, which probably is due 
to a selective pressure by the CTLs on the virus to change its amino acid sequence, 
strengthens the importance of the cytotoxic cellular responses [321]. Recently the 
quality of the CTL response has been appreciated and shown to correlate with disease 
progression. A polyfunctional response has been defined as CTLs producing several 
cytokines, often including IFN-Ȗ, MIP-1ȕ, IL-2, TNF-Į and being positive for the 
degranulation marker CD107a. HIV-1 controller patients have a more polyfunctional 
CTL response [322], in addition to a response preferentially directed to the more 
conserved Gag protein as compared to the Env protein [303, 323, 324]. Some HIV-1 
infected controller patients have CD8+ T cells that can control HIV-1 infection in 
autologous CD4+ T cells ex vivo and this activity is correlated with HIV-1 Gag specific 
CTL responses [325, 326]. A high percentage of EUs have HIV-1 specific CTL 
responses, although this response decline over time after the last exposure and does 
only seem to be protective during the period of time when the person is frequently 
exposed to antigen [257, 259, 327].  
The lymphoproliferative response to HIV-1 antigens is inversely correlated to HIV-1 
viral load [328, 329]. Also in CD4+ T cells is co-production of IL-2 and IFN-Ȗ
beneficial since it correlates to control of viremia [303, 324, 330]. HIV-1 specific CD4+
T cell responses occur in EUs [257, 331] and these CD4+ T cells proliferate and 
produce high amounts of IL-2 in addition to CC-chemokines [332].  
5.1.3 Genetic factors associated with disease progression and 
protection.
There are several gene polymorphisms that have been associated to slower disease 
progression [265], however only co-receptors, HLA and KIR, which are the most 
relevant to the thesis, will be described here. 
5.1.3.1 CCR5 
One factor that can contribute to protection from infection and control of disease is the 
genotype of the chemokine receptor CCR5 [333]. Strikingly, it has been shown that 
individuals homozygous for a mutation (CCR5¨32) resulting in a defective form of 
CCR5, are almost completely protected from infection of CCR5-tropic HIV-1. 
Heterozygotes have lower expression of functional CCR5 on cell surfaces and have 
often a delayed disease progression. The presence of this genotype is highest in the 
Caucasian population, especially in people in northern Europe, and it is almost absent 
in black Africans [265, 334]. Several other genetic variants of CCR5 and other co-
receptors for HIV-1 that may influence disease progression have been described [265]. 
There are also genetic variants of the co-receptor ligands, most importantly the CC-
chemokines RANTES and MIP-1Į that may contribute to protection from infection or a 
slower rate of disease progression [265]. 
5.1.3.2 HLA 
Several HLA types associate with different outcomes of HIV-1 infection. Homozygosis 
for HLA alleles in general and presence of certain HLA alleles, such as HLA-B35 and 
Cw4, have been shown to associate with a more rapid disease progression [335]. 
Presence of the HLA-B57 allele, on the other hand, is associated with slower 
progression to AIDS and is more prevalent in controller patients, as is the HLA-B27 
allele and homozygosis for the HLA class I Bw4 epitope [336, 337]. Recent studies 
estimate that the frequency of protective HLA alleles is about 60% in patients that can 
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control their viremia [303, 324]. It is possible that the HLA associated effects on 
disease progression are linked to differences in presentation of antigen for T cells [338] 
and this strengthens the fact that cytotoxic T cell responses are important for control of 
the infection. Another explanation can be that different HLA alleles are recognized 
differently by KIR molecules expressed on NK cells as will be discussed in the next 
section [339]. A single nucleotide polymorphism in the HLA-C promoter was 
associated with lower viral loads in a whole genome association study [340]. This 
polymorphism results in a higher expression of the HLA-C protein per cell which might 
have an effect on NK cell recognition, but also on T cell recognition since HIV-1 
infected cells preferentially downregulate HLA-A and -B, but keep the expression of 
HLA-C [201]. However, a subsequent study in another cohort of patients pointed out 
that a linkage disequilibrium between the HLA-C promoter polymorphism and 
presence of the protective HLA-B57 allele may explain the positive effect on viral load 
[341].  
5.1.3.3 KIR
The importance of KIR recognition in HIV-1 progression is supported by studies which 
show that KIR genes alone, as well as interactions between different KIRs and HLA 
ligands, can influence the outcome of HIV-1 infection [339]. Not all studies agree on 
which KIRs or KIR/HLA combinations that associate with a better outcome in HIV-1 
infection, but KIR3DL1/DS1 and HLA-Bw4 alone or in combination have received 
particular attention. In the first study by Martin et.al., the combination of genes for the 
activating KIR3DS1 and HLA-Bw4Ile80 associated with delayed progression to AIDS 
[342], subsequently suggested to be due to both a modest lowering of viral load and 
protection against opportunistic infections [343]. In early HIV-1 infection presence of 
KIR3DS1 has been associated with higher CD4 counts, and presence of HLA-
Bw4Ile80 with lower viral load, when investigated separately [344]. However, Gaudieri 
et.al. found that possession of both KIR3DS1 and HLA-Bw4Ile80 associated with 
faster disease progression, but also a slower decline in CD4+ T cells [345]. This report 
also suggested a detrimental effect of possessing KIR2DL2/DS2, which was associated 
with a faster CD4+ T cell decline [345].  
When possible immune mediated mechanisms behind the protective effects of 
possessing both KIR3DS1 and HLA-Bw4Ile80 were investigated, NK cells from 
individuals with this genetic combination were found to inhibit viral replication in vitro
to a greater extent [279]. In addition, in presence of HIV-1 infected autologous CD4+ T 
cells, KIR3DS1+ NK cells from HLA-Bw4+ individuals degranulated more than NK 
cells from HLA-Bw6+ individuals [279]. This indicates that these molecules might 
interact, although no such interaction have been found despite attempts to show binding 
of KIR3DS1 with Bw4Ile80 tetramers in complex with HIV-1 derived epitopes [118]. 
In acute HIV-1 infection KIR3DS1+ NK cells expand in presence of HLA-Bw4Ile80 
[346], indicating that a potential interaction between KIR3DS1 and HLA-Bw4Ile80 
results in a proliferation signal to the NK cell. Interestingly, patients with an early HIV-
1 infection that possess KIR3DS1 also have more active NK cells ex vivo [347]. 
The inhibitory counterpart of KIR3DS1, KIR3DL1, has also been implicated in 
lowering the rate of progression to AIDS. Different KIR3DL1 alleles are expressed to 
different levels and some, like KIR3DL1*004, are not expressed on the cell surface 
[102]. Patients possessing the HLA-Bw4 epitope and KIR3DL1*004 have a slower 
disease progression, as do patients with HLA-Bw4Ile80 and KIR3DL1 alleles 
expressed to a high degree [348]. The later association may be explained by stronger 
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education signals during NK cell development when the highly expressed inhibitory 
receptor and its ligand are simultaneously present [45]. These NK cells would be 
expected to have a higher activation potential and be more responsive to the lack of 
inhibition when interacting with HIV-1 infected cells that have down-regulated HLA-
B.
Exposed uninfected individuals have also been investigated with regards to their KIR 
genes. KIR3DS1 homozygotes were more prevalent in the EU group as compared to 
primary HIV-1 infected patients [349] and the KIR3DS1 transcript levels are reported 
to be increased in some EUs [266]. In addition, the frequency of EUs with high 
expressing KIR3DL1 alleles plus the HLA-B57 allele is increased as compared to the 
frequency in infected patients [350]. An earlier study indicated that lack of cognate 
HLA ligand for KIRs were more prevalent among EUs, which was suggested to 
contribute to a lower threshold for NK cell activation in these individuals [351]. 
5.2 PATHOGENIC INFLUENCE BY THE HIV-1 VIRUS 
The pathogenesis in HIV-1 infection can be due both to the destruction of immune cells 
and to the chronic immune activation induced. The selective destruction of CD4+ T 
helper cells, important for activation of other immune cells, may for example result in 
functionally impaired HIV-1 specific CD8+ T cells [328]. The memory CD4+ T cells in 
the gut are preferentially targeted by the virus and this is devastating for the hosts’ 
immune system since the majority of memory CD4+ T cells are found in the lymphoid 
tissues of the gut. The chronic immune activation correlates with disease in HIV-1 
infected patients. Interestingly, a group of HIV-1 infected patients with high viral loads 
but no disease progression were shown to have low immune activation [352]. The 
importance of immune activation is further stressed when comparing HIV-1 infected 
patients and patients infected with the HIV-2 virus. HIV-2 infected patients have 
reduced levels of immune activation and a less pathogenic disease process [353]. Also 
different primate species infected with SIV have either non-pathogenic or pathogenic 
infections, which may be due to the differences in immune activation [240]. The 
immune activation may affect the cells of the immune system in several ways and it 
causes many of the defects found in NK cells [354], NKT cells [355], DCs [356], B 
cells [357] and T cells [358] in HIV-1 infected patients. Since this thesis is focused on 
NK cells I will discuss phenotypic and functional defects found in these cells in more 
detail below. 
5.2.1 Effects of HIV-1 on the infected cell 
The HIV-1 virus can induce changes in the infected cells, which make them escape 
killing by NK cells and CTLs. One such mechanism is the downregulation of cell 
surface expressed MHC class I molecules on HIV-1 infected cells via regulatory HIV-1 
proteins like Nef and Vpu [359, 360]. The Nef dependent downregulation is specific for 
HLA-A and HLA-B, which are recognized by CTLs, but the expression of HLA-C and 
HLA-E, which are mainly recognized by inhibitory receptors on NK cells, is spared 
[201]. The end result is that HIV-1 infected cells can avoid killing by both CTLs and 
NK cells. This is reflected by studies showing that NK cell cytotoxicity of autologous 
CD4+ cells infected with HIV-1 depends on the ability of the virus to modulate MHC 
class I expression [25, 277]. Furthermore blocking the interaction between MHC class I 
molecules and inhibitory NK cell receptors increases NK cell killing of HIV-1 infected 
target cells [25, 277, 278, 281]. Another potential benefit of keeping HLA-C on the 
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infected cell surface is the selective incorporation of HLA-C into the HIV-1 envelope 
which increases the infectivity of HIV-1 [361].  
HIV-1 infection also affects ligands for activating NK cell receptors. NKG2D may be 
involved in control of HIV-1 infection since recent reports show that blocking of 
NKG2D on NK cells decreases the killing of HIV-1 infected autologous T cells [278, 
362]. NKG2D interacts with the ULBP-1, -2 and -3 ligands that are upregulated on in 
vitro infected T cells [176, 278, 362]. It has been suggested that the HIV-1 protein Vpr 
induces expression of the NKG2D ligands [363], while the viral protein Nef might 
downregulate their expression [176]. It is thus possible that while infection per se 
induces the expression of NKG2D ligands, which are of importance in NK cell 
recognition of HIV-1 infected cells, the virus has evolved a strategy to dampen this 
effect. In addition, the expression of ligands for the co-receptors NTB-A and 2B4 on 
NK cells are also downregulated on HIV-1 infected cells [362]. 
Expression of ligands for the activating NCRs (NKp30, NKp44 and NKp46) are not 
induced on HIV-1 infected cells [278, 362], but a ligand for NKp44 is expressed on 
uninfected CD4+ T cells from HIV-1 infected patients and on uninfected cells in 
infected in vitro cultures [166, 362, 364]. A peptide from HIV-1 gp41 induces the 
expression of the unknown NKp44 ligand, which results in increased sensitivity of 
uninfected CD4+ T cells to NK cell lysis [166, 364]. Nef mediates intracellular 
retention of the NKp44 ligand in infected cells, thereby avoiding NK cell recognition of 
these cells [364]. When macaques were immunized with the gp41 peptide and 
challenged with SHIV, a decreased frequency of NKp44 ligand expressing CD4+ T 
cells and increased CD4 counts were found [365]. This indicates that NK cells may be 
involved in the pathogenic destruction of uninfected CD4+ T cells. 
5.2.2 Effects of HIV-1 disease on NK cells 
HIV-1 infection can affect NK cells directly or indirectly. A direct effect is the possible 
infection of NK cells. NK cells express the HIV-1 co-receptors CCR5 and CXCR4 and 
a subset of NK cells also express the CD4 receptor, which is needed for HIV-1 
infection. These NK cells were shown to be infected even in patients on ART, 
indicating that NK cells could be a latent reservoir for HIV-1 production [366]. Direct 
infection of NK cells may lead to some of the dysfunctions seen in the NK cell 
repertoire (Figure 9). The general chronic immune activation seen in HIV-1 infection 
also affects the NK cells, partly due to a decrease in the release of cytokines of 
importance for NK cell activation and proliferation, like IL-2, IL-12, IL-15 and IL-21 
[354]. The increased concentrations of the immunosuppressive cytokines IL-10 and 
TGF-ȕ in the blood of HIV-1 infected patients may also contribute. 
5.2.2.1 Phenotypic differences in the NK cell compartment 
Although it is hard to determine whether the effects on NK cells are direct or indirect, 
many studies have reported defects detected in the NK cell repertoire after HIV-1 
infection (Figure 9). The number of NK cells in blood decreases in HIV-1 infected 
patients (paper I and [54]), but this may be restored after ART treatment [367, 368]. 
Similarly, frequency of NK cells in colonic lamina propria is decreased in viremic 
patients [369]. NK cell subset proportions are different in HIV-1 infected patients 
compared to healthy individuals. They have a decreased proportion of cytolytic 
CD56dimCD3- NK cells [53, 54, 370] and an increased frequency of CD56-CD16+ NK 
cells [53, 54, 370, 371]. The later subset is functionally defective in cytotoxicity and 
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production of cytokines [372], but may have a different functional profile as compared 
to “normal” NK cells since they produce increased levels of MIP-1ȕ [53].  
Figure 9: HIV-1 viremia effects on NK cell phenotype and function. This has consequences 
for the antiviral immune response elicited. Reprinted by permission from Macmillan Publishers 
Ltd: Nature reviews immunology, Fauci et.al. 2005 Nov;5 (11):835-43, copyright 2005.
Several reports have investigated the expression of receptors on NK cells from viremic 
HIV-1 infected patients. Generally, the expression of the inhibitory receptors, KIR and 
LIR-1, increases (paper I and [274, 371, 373]) and the expression of the activating 
receptors, NKp30 and NKp46, decreases on NK cells from patients (paper I and [53, 
371, 374]). This could probably make the NK cells unresponsive to infected cells and 
might be a reason for the decreased function seen in NK cells from HIV-1 positive 
patients. However, the C-type lectin like receptors NKG2A (inhibitory) and NKG2C 
(activating) behave just the other way around (paper I and [375, 376]). This has been 
suggested to be due to a concomitant CMV infection in HIV-1 infected patients since 
HIV-1 negative individuals with CMV infection have a similar pattern of NKG2A and 
NKG2C expression [130, 377]. The CD161 receptor which may have an inhibitory 
function [134, 135] is also downregulated on NK cells from HIV-1 infected patients 
(paper I and [53, 367, 368, 370]). These abnormalities in the NK receptor repertoire is 
in most cases restored in patients with a low viral load due to ART treatment (paper I
and [371]). 
5.2.2.2 Differences in NK cell function 
Cytotoxicity against tumor target cell lines is decreased in HIV-1 infected patients with 
a high viral load [278, 368, 371], but can be restored in patients with an undetectable 
viral load receiving ART, who have a cytotoxic capacity similar to healthy individuals 
[368, 371]. This decrease in cytolytic function may be due to presence of the non-
cytotoxic CD56-CD16+ cells in the NK cell pool. NK cell degranulation ability on the 
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other hand is not compromised in HIV-1 infected patients, their NK cells either 
degranulate more vigorously or to the same degree as NK cells from healthy 
individuals (paper I and [53, 266, 268, 367]). The NK cell ability to mediate ADCC 
may be decreased in HIV-1 infected patients [378, 379]. Possible factors that might 
contribute are defects in expression of the ȗ chain associated with CD16 [380] and the 
recently reported increased expression of matrix metalloproteases (MMPs) that 
removes CD16 from the cell surface following NK cell activation [379]. 
The production of cytokines like IFN-Ȗ and TNF by NK cells is affected by the 
infection (Figure 9). When NK cells from patients with a high viral load and from ART 
treated patients with a low viral load are stimulated with different combinations of IL-2, 
IL-12, IL-15 and IL-18, a decreased production of IFN-Ȗ has been observed compared 
to healthy controls [368, 381, 382]. In other studies, however, where NK cells were 
stimulated with the NK cell sensitive K562 cell line, which lacks MHC class I 
expression, an increased production of IFN-Ȗ was seen in patients with a high viral load 
compared to successfully treated patients and healthy controls [268, 367]. It is possible 
that the increased expression of inhibitory MHC class I specific receptors on NK cells 
from viremic HIV-1 infected patients make these cells more responsive to target cells 
lacking MHC class I. Secretion of CC-chemokines from NK cells has been shown to 
suppress HIV-1 infection in vitro and both the amount of suppression and the levels of 
MIP-1Į and RANTES correlate to HIV-1 viral load [82, 383]. Thus, in patients with a 
high viral load, the secretion of CC-chemokines and the suppression of HIV-1 infection 
by these soluble factors, are defective [383]. 
NK cell interaction with other immune cells is also affected by the HIV-1 infection 
(Figure 9). Killing of immature DCs by NK cells is defective in chronic HIV-1 
infection [384] and this is mainly due to the presence of the dysfunctional CD56-CD16+
NK cell subset and their impaired NKp30 and TRAIL expression/secretion and 
function [179]. Interestingly, a recent study showed that NK cells can inhibit HIV-1 
replication in monocyte-derived DCs by interaction between LIR-1 and an unknown 
non-MHC class I ligand expressed during HIV-1 infection [385]. This interaction 
seems to be inhibited by the downmodulation of NK cell expression of LIR-1 upon 
interaction with the infected cells. 
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6 IMMUNOTHERAPIES BASED ON NK CELLS AND 
ANTIBODIES
6.1 NK CELL BASED IMMUNOTHERAPIES 
6.1.1 Stimulation of NK cell activity 
The cytokine IL-2 can be used to stimulate lymphocytes in vitro to obtain lymphokine-
activated killer (LAK) cells, which include NK cells. Infusion of LAK cells into cancer 
patients have been performed in several clinical trials but the clinical response rate have 
only been about 20% [386]. Cytokines involved in NK cell differentiation and 
activation have also been infused into cancer patients, including IL-2, IL-12, IL-18, IL-
21 and IFN-Į with varying effects on NK cell activity and clinical response [386]. NK 
cells may also be stimulated by different vaccine modalities, which have mainly been 
studied in relation to DC-based vaccines [386, 387]. The role for NK cells in these 
vaccine-mediated immune responses is believed to be due to the immunomodulatory 
function of NK cells [387].  
6.1.2 “Missing self” reactivity of NK cells in hematopoietic stem cell 
transplantations 
NK cells may be important effector cells in hematopoietic stem cell transplantations to 
patients with leukemia. In a retrospective study Ruggeri et.al. found that relapses in 
stem cell transplanted acute myeloid leukemia (AML) patients were eliminated when 
there was a KIR-ligand mismatch between the transplanted cells in the graft and host 
cells in the recipient [388]. This was interpreted as a “missing self” reaction mediated 
by donor-derived NK cells expressing KIR molecules that did not recognize MHC class 
I molecules in the host. Interestingly, it seems as tumor cells are specifically targeted by 
these alloreactive NK cells, since only graft-versus-leukemia (GVL) effects and not 
increased graft versus host disease (GVHD) was seen. The preferential killing of 
leukemic cells is probably due to an increased expression of activating ligands on the 
tumor cells making them sensitive to NK cell killing. NK cell killing of host DCs [185, 
186] may contribute to the lack of GVHD since it prevents DCs of the recipient from 
presenting antigens to donor T cells [388, 389]. The protective effect of KIR-ligand 
mismatch was reported in transplantations between related donors and recipients 
(haploidentical transplantation), but has not been as clearly documented in 
transplantations from unrelated donors [390]. The reason for controversies in this field 
may be the many discrepancies between the studies regarding for example T cell 
depletion of the graft, stem cell source and dose, preconditioning treatment and GVHD 
prophylaxis as well as type of malignancy and disease stage of the patient [391]. 
Adoptive transfer of haploidentical NK cells have also been performed in the clinical 
setting. Miller et.al. injected pure NK cells along with IL-2 in AML patients that had 
been treated with immunosuppressive medication, which resulted in production of 
endogenous IL-15 and subsequent expansion of donor NK cells [392]. Complete 
remission was achieved in five of nineteen AML patients with poor prognosis. Three of 
the four patients that had received cells from a KIR-ligand mismatched donor were 
among the five that responded to the therapy. 
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6.1.3 Blocking of inhibitory receptors to induce “missing self” 
reactions 
“Missing self” reactivity can also be achieved by blocking the interaction between 
inhibitory NK cell receptors and MHC class I molecules. This enhanced the anti-tumor 
response in a mouse system when inhibitory Ly49 receptors were blocked using 
monoclonal antibodies [393]. A similar approach for blocking of KIR receptors is 
presently evaluated by the company Innate Pharma in a phase I clinical trial in patients 
with relapsed AML and multiple myeloma. The antibody used is called 1-7F9 and is a 
fully-human IgG4 antibody [394]. It induces NK cell mediated lysis of primary AML 
cells in vitro and protects immunodeficient mice injected with human NK cells and 
autologous primary AML blasts from disease [394]. This antibody has been used by us 
in paper I to delineate its potential as an immunotherapeutic for use in HIV-1 infected 
patients, with the aim to increase NK cell recognition of virus infected cells. Antibodies 
can also be used to specifically target the infected cells as is further discussed in the 
next section. 
6.2 IMMUNOTHERAPIES BASED ON HIV-1 SPECIFIC ANTIBODIES 
6.2.1 Passive immunization 
Passive immunization with antibodies is a well-known treatment modality. Treatment 
with sera from humans or animals that have previously encountered a specific antigen 
has long been used as prophylaxis and treatment after potential exposure to, for 
example, Hepatitis and Rabies [395]. In recent decades the ability to produce 
monoclonal antibodies (mAb), specific for particular antigens [396], have resulted in 
new group of drugs emerging. These have many possible applications including 
treatment of various tumors and infectious diseases [395, 397]. The first to be used for 
human treatment were mouse mAbs, but many of them had a low efficacy in vivo,
mainly because they were immunogenic in humans, had a short half-life and did not kill 
target cells efficiently since they did not bind well to human complement or Fc-
receptors inducing ADCC. This has now been circumvented by production of human or 
humanized mAbs [397]. Several mAbs are approved for clinical use against cancer 
including for example Rituximab in Non-Hodgkin lymphoma targeting CD20 on B 
cells [398]. The main mechanism behind the effect of unconjugated mAbs in cancer 
therapy has been proposed to be ADCC, although other mechanisms are also plausible 
[397]. The importance of the Fc-receptor CD16 expressed on NK cells has been 
substantiated by the associations between clinical effect of mAb treatment and presence 
of polymorphisms in CD16 affecting binding of the antibody [153, 155, 156]. 
Despite the potential for antibody induced protection against HIV-1 infection, which 
has been shown in non-human primate models [282-286] human trials have so far been 
disappointing [292]. Due to the high mutation rate in HIV-1, a cocktail of several 
antibodies binding to different parts of the envelope may be preferable to antibodies to 
a single epitope, similar to the strategy used during highly active antiretroviral therapy. 
Neonatal rhesus macaques orally challenged with SHIV and then treated with three 
different unconjugated neutralizing antibodies were protected from infection [284]. 
When the same antibodies were used in HIV-1 infected patients undergoing ART 
interruption, two out of eight chronically infected patients were able to retain the 
viremia for a longer time than during previous treatment interruptions. The study 
concluded that neutralizing antibodies can have an effect on persistent HIV-1 infection, 
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but that a high concentration of antibodies to multiple conserved epitopes is required. 
Unfortunately, the immune pressure elicited by the antibodies induced a rapid escape in 
most patients [292]. 
6.2.2 Conjugated antibodies 
One plausible way to specifically and effectively kill HIV-1 infected cells is by using 
immunoconjugates. This is successfully used in cancer therapies and several 
immunoconjugates are approved for clinical use [399]. Antibodies or soluble proteins 
targeted to HIV-1 infected cells and conjugated to toxins [400-403], radioisotopes 
[404] or cytotoxic drugs (paper IV) have been investigated both in vitro and in vivo 
for their potential use against HIV-1 infection. Despite promising preclinical results, 
the failure of the first clinical trial with an immunotoxin consisting of a soluble CD4 
protein conjugated to a variant of the toxin Pseudomonas exotoxin (PE) [400, 401], 
hampered the field. This toxin was immunogenic and the short half life of the CD4 
fusion protein probably contributed to the lack of efficacy. The treatment was also 
hepatotoxic which may be due to binding of the immunotoxin to free gp120 and 
subsequent clearance of immune complexes in the liver. The highly glycosylated 
gp120 protein can likely pose as a substrate for hepatic receptors, leading to killing of 
hepatocytes when levels of free gp120 are high [405]. Lessons learnt from this study 
were that a non-immunogenic conjugate with a longer half life should be tested in 
patients with low viral loads, i.e. in combination with ART treatment. 
Another goal with immunotoxins could be to target latently infected cells in ART 
treated patients in order to eradicate these reservoirs [406]. Specific targeting of the 
CD45RO+ memory CD4+ T cells, one of the main reservoirs for latent viruses, with a 
CD45RO specific antibody conjugated to a ricin A chain is one approach with 
promising preclinical results [402]. The in vitro  treatment of PBMCs from 
successfully ART treated patients with this immunotoxin resulted in decreased 
numbers of viral copies and infected cells [402]. Another approach for reducing the 
number of latently infected cells is to reactivate latently infected cells in the presence 
of ART. This can be achieved by immune activation therapy [407, 408] or by a more 
selective induction of viral expression [230, 409]. Reagents tested with partial success 
include IL-2, IL-7, prostratin and histone deacetylase inhibitors [407-409]. This type 
of therapy could be combined with immunoconjugates that specifically kill the 
reactivated and HIV-1 antigen expressing cells [407] and ART that inhibit reinfection 
of new cells. The problem with this kind of treatment is the difficulty in getting a 
complete eradication of the latent reservoir which will be crucial for cure of the 
disease [406]. 
6.2.3 Active immunization 
Instead of passive immunization, antibody production can be induced by immunizing 
with antigen from the pathogen of interest. Vaccines based on the HIV-1 envelope 
protein have been tested in humans, but the first phase III efficacy trial with a 
recombinant gp120 protein did not protect immunized persons from infection, despite 
induction of specific antibodies [410]. It is widely believed that for an antibody 
response to be protective the antibodies need to be broadly neutralizing, i.e. able to 
neutralize a wide range of subtypes and strains of HIV-1 [225]. So far, immunization 
with monomeric gp120 has not been able to evoke this kind of response [410]. A proof-
of-concept trial, called the STEP trial, investigated the protective effect of a 
recombinant adenovirus vaccine encoding the HIV-1 genes Gag, Pol and Nef [411]. 
This trial was terminated due to futility and, disturbingly, a higher frequency of 
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individuals in the vaccine group became infected as compared to the placebo group. 
The primary goal with this vaccine was to induce specific T cell responses able to blunt 
the initial viremia and lower the viral set point [411]. Since the vaccine did not include 
gene sequences encoding the HIV-1 envelope protein no neutralizing antibodies were 
induced. 
Results from the third HIV-1 vaccine efficacy trial, performed in Thailand, were 
recently released [412]. This prime boost vaccine regimen contains two vaccine 
modalities. A recombinant canarypox virus encoding HIV-1 Env, Gag and protease 
was used to prime the immune response, which was then boosted with a gp120 protein. 
An increased protection from infection in individuals receiving the vaccine was 
reported [412]. Over 16 000 participants were enrolled, half of them receiving the 
vaccine, and 51 in the vaccine group got infected with HIV-1 as compared to 74 in the 
placebo group [412]. Despite the total low number of infections and the marginal 
statistical significance, this study is the first to show that protective immunity can be 
achieved by vaccination and that has increased the hopes for the development of a 
future protective vaccine. The type of immune response that might have contributed to 
this possible protective effect is now being investigated. The vaccine has previously 
been reported to induce binding, but not broadly neutralizing, antibodies [412, 413]. 
Since only a few percent elicited potent T cell responses [412] it is believed that the 
binding antibodies might have contributed to protection [413]. In the absence of 
directly neutralizing antibodies, ADCC is one potential effector mechanism that might 
be responsible for the protective effects of the antibodies. 
Many new types of HIV-1 vaccines that elicit either strong T cell responses or 
neutralizing antibodies are in the pipeline and the potential for both prophylactic and 
therapeutic vaccination is investigated. One strategy for induction of T cell responses, 
with promising clinical results, is to prime with a DNA vector encoding viral genes and 
then boost with a viral vector [414]. To achieve better antibody responses, oligomeric 
HIV-1 envelope proteins, more closely mimicking the native form of the protein, are 
being developed. In contrast to the earlier monomeric envelope proteins these 
oligomers are expected to elicit more broadly neutralizing antibodies as the aim is to 
target epitopes present in the functional viral envelop spike [225]. 
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7 RESULTS & DISCUSSION 
In this thesis I have investigated different aspects of the immune system that may 
contribute to the control of HIV-1 infection (Figure 10). The discussion is divided into 
three parts starting with possible roles for NK cells and ADCC in natural control of 
HIV-1 disease progression, i.e. in the rare HIV-1 infected patients that spontaneously 
control their viremia. In the second part different factors affecting NK cell reactivity, 
including HIV-1 virus infection of target cells, a KIR blocking antibody and the KIR 
genotype are discussed. In the last part, results on the effect of NK cells and a drug-
conjugated antibody in our in vivo HIV-1/MuLV mouse model are presented. 
Figure 10: Schematic representation of the NK cell and antibody effector mechanisms 
investigated in the thesis. a) Antibody-mediated blocking of inhibitory KIRs (paper I) b) 
ADCC of HIV-1 infected cells (paper II) c) NK cell effect on HIV-1 (paper I) and HIV-
1/MuLV infected cells (paper III) d) Effect of doxorubicin-conjugated anti-gp120 mAb on 
HIV-1 or HIV-1/MuLV infected cells (paper IV).
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7.1 CHARACTERISTICS OF HIV-1 CONTROLLER PATIENTS 
7.1.1 NK cell phenotype in controller patients does not seem to 
influence the disease (paper I). 
To investigate whether NK cell phenotype and function differ in HIV-1 infected 
controller patients as compared to viremic patients and healthy individuals we recruited 
six HIV-1 controller patients, fourteen viremics and a number of healthy individuals. 
The controller patients had a viral load below 500 HIV-1 RNA copies/ml blood, and 
had been infected for at least eight years without receiving treatment (table 1in paper 
I). For the phenotypic investigations a group of ten patients on ART was also included. 
Controller patients, ART treated patients and viremic patients had a similar frequency 
of CD56+CD3- NK cells, which was lower than the frequency in healthy individuals 
(Figure 11a) (paper I and II) and this corroborates previous studies [268, 273, 274]. 
There were no differences in NK cell subsets between any of the groups, in line with 
some [274] but not other reports [268, 273].  
Figure 11: Frequency of NK cells in blood and degranulation in response to target cells. a) 
Frequency of CD56+CD3- NK cells in blood and b) frequency of NK cells degranulating in 
response to the MHC class I deficient K562 tumor cell line. The horizontal line represents the 
median in each group. P-values in the figure are derived by the Kruskal-Wallis post-hoc test. 
Expression of a panel of NK cell receptors was investigated and we found a similar 
effect in viremic and ART treated patients as previously reported (Table 1, Figure 1 and 
2 in paper I) [354, 371, 376]. Regarding controller patients they had an NK cell 
receptor phenotype most similar to the phenotype in viremic patients [274]. Possible 
exceptions include frequency of KIR+ and NKG2A+ NK cells, where the controller 
patients NK cells were more similar to NK cells from healthy individuals as compared 
to viremic patients (Figure 1 and 2A in paper I). Since frequency of NK cells 
expressing KIR2DL2/L3/S2 (positive correlation) and KIR2DL1/S1 (negative 
correlation) correlated with viral load it is likely that the deviant KIR expression in 
viremic patients is due to the viremia [267]. Interestingly when comparing the two 
patient groups with low viremia, there was a trend towards a higher frequency of 
NKG2A+ NK cells in controller patients as compared to ART treated patients. Since it 
is known that CMV infection results in decreased NK cell expression of NKG2A [130, 
375] one possible explanation is that differences in CMV infection contribute to the 
NKG2A expression. Although the frequencies of CMV seropositive individuals were 
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similar in all groups, the lower CMV antibody titers in controller patients as compared 
to ART treated patients (5000 (910-25000) and 21000 (4500-28000) respectively, 
p=0,06 when using the Mann-Whitney U-test) may reflect a lower CMV viral load or 
more infrequent periods of reactivation in controller patients, possibly affecting 
NKG2A expression. Thus the controller status is probably not affected by the NK cell 
phenotype. A more likely explanation is that the NK cell phenotype abnormalities in 
active HIV-1 infection are due to viremia or constant immune activation. 
7.1.2 NK cell activity in controller and viremic patients is similar to the 
activity in healthy individuals (paper I and II). 
The activity of NK cells from the controller patients was investigated by staining NK 
cells with an antibody to CD107a, which is a membrane-bound protein present in 
secretory lysosomes and which is exposed upon degranulation of NK cells. PBMC 
effector cells were purified from blood and then incubated in IL-2 over night, before 
the effector cells were mixed with various target cells. NK cells, defined as CD56+CD3-
from controller patients, viremic patients and healthy individuals degranulated to 
similar levels in response to the tumor cell lines lacking MHC class I (K562 and 
721.221) (Figure 11b), tumor cell lines expressing HLA-C (721.Cw3 and 721.Cw4), 
uninfected and HIV-1IIIB infected Jurkat T cells or autologous T cells (paper I).
Infected Jurkat T cells coated with HIV-1 specific antibodies also induced similar NK 
cell degranulation in the various groups (Figure 4 in paper II). Thus, NK cells from 
our patient cohorts have similar degranulation abilities as NK cells from healthy 
individuals regardless of the target cell lines used. When staining for intracellular IFN-
Ȗ, only low frequencies of positive NK cells were detected (Figure 4 in paper II) and 
no differences between the controller patients viremic patients and healthy individuals 
were detected for this marker either. Since the activity of NK cells from controller 
patients did not differ from viremic patients or healthy individuals, our controller 
patients do not seem to have NK cells with a generally increased activity that could 
explain the control of the disease. 
Similarly to us Alter et.al. previously showed that HIV-1 infected patients with a non-
progressive disease had similar degranulation ability as healthy individuals [268, 379]. 
Viremic patients have been reported to have an increased [53, 268, 367] or similar 
[266] frequency of NK cells degranulating in response to K562 cells as compared to 
healthy individuals, although a decreased response to antibody coated target cells was 
also reported [379]. The higher CD4 counts in our viremic patients compared to 
previous studies where degranulation has been investigated probably reflects a better 
clinical status, which may contribute to the more normal NK cell function in our 
viremic patients.  
7.1.3 ADCC mediating antibodies in controller patients may differ from 
antibodies in viremic patients (paper II). 
HIV-specific antibodies may induce killing of infected cells through ADCC involving 
NK cells or other Fc-receptor bearing cells. This is a potent mechanism for induction of 
NK cell responses and antibody ADCC activity has been correlated to a better disease 
progression [302, 311-313]. We therefore compared the ability of controller patients’ 
and viremic patients’ antibodies ability to induce an ADCC response. Plasma from the 
HIV-1 infected patients contained antibodies that induced killing of target cells coated 
with HIV-1 gp140, a soluble oligomeric envelope protein [415]. Increased plasma 
mediated killing correlated with lower viral loads in the viremic patients (Figure 2 in 
  47 
paper II) substantiating previous findings [308, 416]. The ability of plasma antibodies 
to induce NK cell degranulation and IFN-Ȗ secretion was also investigated [415, 417]. 
Interestingly, antibodies from controller patients induced higher NK cell secretion of 
IFN-Ȗ compared to antibodies from viremic patients (Figure 1 in paper II) which is in 
line with the recently reported increase in killing of target cells via ADCC in elite 
controller patients compared to viremic patients [302]. It is thus possible that ADCC 
inducing antibodies are involved in control of disease or viremia. Another possible 
interpretation is that a lower viral load and less progressive disease could contribute to 
the ability to produce antibodies with better ADCC function. The detrimental immune 
activation in HIV-1 viremic patients contributes to polyclonal activation and functional 
exhaustion of the B cell pool and may result in antibodies with lower specificity [357]. 
To further delineate this, investigations of the ADCC mediating ability of antibodies 
from controller and HAART treated patients with similar low viral loads are desirable. 
Further, the antibody specificity for the V3 loop in the HIV-1 gp140 protein was 
investigated in our cohort by incubating plasma with either wt gp140 or a V3 truncated 
version of gp140 (gp140ǻV3) [415]. Whereas plasma from all viremic patients and 
some of the controller patients lost their ability to induce NK cell degranulation in 
presence of gp140ǻV3, two of the controller patients induced a similar response to the 
wt and ǻV3 gp140 protein (Figure 1 in paper II). This indicates that these two 
controller patients may have ADCC inducing antibodies to other parts of the gp140 
protein than the V3 loop. However, one should keep in mind that only one viral isolate 
(AD8) has been investigated and since some antibodies to the V3 loop may be strain 
specific it is possible that using an envelope protein from another viral isolate might 
have given different results. The two controller patients that mediated V3-independent 
ADCC participated in a vaccination study with gp160 protein more than seven years 
ago [418] and it may be that this vaccine has induced antibodies directed to other parts 
of the envelope protein than the naturally induced antibody epitope specificities present 
in HIV-1 infected patients. Nevertheless, it is possible that antibodies to other parts of 
gp140 than to the immunodominant V3 loop may be more beneficial and contribute to 
control of disease. As an example an immunogenic epitope in the C5 region of gp120 
that induced functional ADCC antibodies was earlier identified in a long-term non-
progressive patient [419]. 
Antibody IgG1 titers to the ǻV3 gp140 protein correlated positively to the antibody 
induced NK cell degranulation (Figure 1 in paper II). Interestingly this was not seen 
for IgG1 antibody titers to wt gp140 protein. This may be interpreted as antibodies 
binding to V3-independent regions of the envelope protein being more important for 
mediating ADCC. Further studies are warranted to delineate the epitopes in the HIV-1 
envelope protein that may contribute to ADCC responses and possibly to control of the 
disease. This is important for future developments of HIV-1 specific vaccines and other 
immunotherapies based on ADCC. 
7.1.4 What makes a controller patient control HIV-1? 
(paper I and II) 
The reasons why certain HIV-1 infected patients control viremia without ART 
treatment may be several and although it is not possible to know the exact reason why 
some patients can control their viremia, I will here summarize the possible correlates to 
control that we found in our six controller patients. Mutations in the CCR5 gene is 
known to influence disease progression [333] and one of our controller patients was 
heterozygous for the CCR5ǻ32 mutation. Interestingly, five of the viremic patients 
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with similar viremia and CD4 counts as the other viremic patients were also 
heterozygous for the CCR5ǻ32 mutation, indicating that this might not be sufficient for 
control over the virus. The relatively high frequency of CCR5ǻ32 heterozygous 
individuals in our cohort (7/31) may be due to the high prevalence of this 
polymorphism in Scandinavia [334]. Other genetic factors that correlate with disease 
progression are polymorphisms in the HLA and KIR genes [335, 337, 339]. Presence of 
the KIR3DS1 gene together with a HLA-Bw4Ile80 allele correlates with slower disease 
progression [342] and this combination was found in two of our controller patients, but 
only one of the viremic patients. Certain immune responses also seem to confer control 
over the disease, as discussed in section 5.1 [261]. Two of our controller patients had 
ADCC mediating antibodies directed to V3-independent parts of the gp140 protein 
whereas viremic patients had a more V3 specific ADCC activity. Thus from our 
investigations of patients that control their viremia a potential explanation to this 
control has been found for five out of the six patients. However, there may be many 
other factors that have contributed to their controller status as well, which were not 
investigated by us, including for example viral fitness, specific HLA alleles and T cell 
responses [261, 322, 326, 336, 337]. 
Figure 12: Ligands for NK cell receptors expressed on PHA and IL-2 stimulated
uninfected CD3+ cells and HIV-1IIIB infected p24+CD3+ cells seven days after infection.
Frequency of cells positive for a) ULBP-1, b) ULBP-2, c) PVR and d) Nectin-2. Frequency of 
cells positive for control IgG have been subtracted from ULBP-1, -2, PVR and Nectin 2 values. 
Lines connect results from one experiment. 
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7.2 FACTORS AFFECTING NK CELL ACTIVITY 
 
7.2.1 Similar NK cell activity to autologous HIV-1 infected cells and 
uninfected cells (paper I). 
There are conflicting data regarding the ability of NK cells to recognize and kill 
autologous HIV-1 infected T cells in vitro. While some reports state that there is no 
difference in the level of NK cell mediated killing of HIV-1 infected versus uninfected 
cells [25, 276], others have found such a difference [277, 278]. We aimed at comparing 
the ability of NK cells from patients and healthy individuals to recognize HIV-1 
infected autologous T cells, as opposed to allogeneic T cells or immortalized cell lines 
studied in some of the previous reports [420, 421]. CD4+ T cells were purified from 
blood and stimulated with IL-2 and PHA before infection with the viral isolate HIV-
1IIIB. These infected cells or uninfected control cells were incubated for four hours with 
IL-2 stimulated PBMCs derived from the same individual and NK cell degranulation 
was analyzed. We did not detect any difference in NK cell degranulation in response to 
uninfected and HIV-1IIIB infected autologous T cells, neither were there any difference 
in activity of NK cells from HIV-1+ patients and healthy individuals (Figure 3 in paper 
I). Similar results were obtained with uninfected and HIV-1IIIB infected Jurkat T cells.  
 
Previous studies that have detected a difference in NK cell response to infected 
autologous cells have used primary isolates to infect cells from healthy individuals 
[277] or endogenously virally infected cells from viremic patients [278]. A difference 
compared to our study is the decreased expression of MHC class I molecules on these 
virally infected cells, which was not detected by us. This is probably due to the use of 
the lab adapted strain HIV-1IIIB [277]. We had anticipated that viral effects on ligands 
for activating NK cell receptors would increase NK cell recognition of HIV-1 infected 
cells [176, 278, 362]. When investigating this, an increased expression of the NKG2D 
ligands ULBP-1 and -2 was found upon in vitro infection in some but not all 
individuals investigated (Figure 12). The expression of the DNAM-1 ligands, Nectin-2 
and PVR, on the other hand was, if anything slightly decreased on HIV-1IIIB infected 
cells as compared to uninfected cells (Figure 12). Thus, we conclude that NK cells 
cannot distinguish HIV-1IIIB infected from uninfected autologous T cells due to a 
similar level of expression of inhibitory and activating NK cell ligands. One important 
factor is the in vitro activation of T cells necessary for efficient HIV-1 in vitro 
infection. We observed that the activation protocol used induced the expression of the 
NK receptor ligands ICAM-1, PVR and MHC class I (Figure 13). Future studies 
should include infection with primary viral strains. 
 
 
 
 
Figure 13: Ligands for NK cell receptors expressed on CD4+ cells ex vivo and on blasted 
cells after PHA and IL-2 stimulation. Mean fluorescent intensity (MFI) for a) PVR, b) 
ICAM-1 and c) HLA-ABC. 
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7.2.2 A KIR-binding antibody increases NK cell activity in HIV-1 
infected patients (paper I). 
The reported downregulation of HLA-A and -B but not HLA-C on HIV-1 infected cells 
[25, 201] and the increased expression of KIRs on NK cells from viremic patients 
(paper I and [371]) indicate that the interaction between HLA-C and KIRs may be 
important in preventing NK cells from killing HIV-1 infected cells. This is supported 
by the increased NK cell mediated killing of HIV-1 infected autologous T cells when 
blocking inhibitory receptors on NK cells, depleting NK cells with inhibitory receptors 
or blocking MHC class I molecules on target cells [25, 278]. The KIR specific 1-7F9 
antibody binds all KIRs that use HLA-C as a ligand, including KIR2DL1/S1 and 
KIR2DL2/L3/S2, and is therefore expected to induce “missing self” reactivity in the 
whole human population (see section 6.1) [394]. We aimed at evaluating the possible 
future use of this antibody as a treatment for HIV-1 infected patients and investigated 
the effects of 1-7F9 in vitro.
PBMC from HIV-1 infected patients and healthy individuals were incubated with the 1-
7F9 antibody and then added to autologous HIV-1 infected or uninfected T cells. This 
resulted in increased NK cell degranulation, although to a similar extent in presence of 
uninfected and HIV-1 infected autologous T cells (Figure 4 in paper I). One 
explanation for the failure of NK cells to distinguish infected and noninfected cells 
could be the IL-2 activation of the effector cells in PBMC, which could result in 
disrupted self-tolerance mechanisms [422]. In addition, NK cells were induced to 
degranulate by 1-7F9 in the absence of added target cells, which may also be explained 
by the IL-2 stimulation of PBMCs since it is possible that this could induce expression 
of activating ligands on potential target cells in the PBMC culture [423]. In the mouse 
system, cytokine stimulation of NK cells and blocking of inhibitory Ly49 receptors in
vitro resulted in killing of autologous T cell blasts [424]. However in vivo blocking did 
not result in autoreactivity on normal autologous spleen cells, but a specific effect on 
leukemic cells [424, 425]. Thus, although our in vitro study did not show any HIV-1 
specific effect of the 1-7F9 antibody, it can not be excluded that the use of 1-7F9 in 
vivo in HIV-1 infected patients could have an advantageous effect. The need for 
cytokine stimulation of both effector and target cells in vitro may conceal preferential 
activity towards virus infected cells.  
7.2.3 The KIR genotype influences the NK cell response to a KIR-
binding antibody (paper I). 
While there was no difference in effect of the 1-7F9 antibody on NK cells from HIV-1 
infected patients and healthy individuals, there was a heterogeneous response of NK 
cells from different individuals to the 1-7F9 treatment. Some showed a strong effect of 
the antibody and others showed no effect at all, and this pattern could be seen with all 
target cells used. We therefore correlated the effect of 1-7F9 on NK cell degranulation 
with frequency of KIR expressing NK cells and with KIR genotype. In healthy 
individuals and viremic patients there was a positive correlation between frequency of 
NK cells expressing the 1-7F9 bound KIRs and effect of the antibody on NK cell 
degranulation (table 3 in paper I). This indicated that treatment with 1-7F9 might have 
a strong effect on NK cells from viremic patients that have an increased expression of 
KIRs. However in the controller group this correlation was reversed, meaning that 
frequency of NK cells expressing 1-7F9 binding KIRs can not fully explain the 
heterogeneous effect of 1-7F9 treatment. We therefore explored how the KIR genotype 
might have influenced the effect (Figure 5 in paper I). Presence of at least one 
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KIR2DL2 allele resulted in stronger NK cell degranulation, as did presence of the 
activating KIR2DS2; these two KIRs are in linkage disequilibrium. Individuals with at 
least one of the activating KIRs bound by 1-7F9 (KIR2DS1 and KIR2DS2) also had a 
significantly increased NK cell activity in presence of 1-7F9. The KIR B haplotype is 
characterized by the presence of more activating KIR genes compared to the KIR A 
haplotype and NK cells from individuals possessing the B haplotype responded more to 
1-7F9 treatment. Thus presence of activating KIRs seems to influence the effect of the 
1-7F9 antibody. 
There are several potential explanations for the possible importance of activating KIRs 
on the 1-7F9 effect on NK cells. Although 1-7F9 is an IgG4 antibody with low affinity 
for Fc-receptors, it may bind the Fc receptor FcȖRI (CD64) on monocytes [394]. 
Presence of these cells in the PBMC cultures might induce cross-linking and 
subsequent activation of NK cells via activating KIRs bound by the 1-7F9 antibody. 
Blocking with sera could be used to reduce this kind of activity and this should be 
included in future experiments. It is also possible that activating KIRs could infer a 
higher responsiveness on the NK cell during the education process, similarly to what 
have been described for inhibitory receptors. However a recent publication stated that 
the activating KIR2DS1 tunes down the NK cell responsiveness in presence of its 
ligand HLA-C2 [426]. Nevertheless, NK cells with the activating KIR3DS1 gene seem 
to have an increased activity [347, 427], which will be discussed in more detail below 
(section 7.2.4). This gene is present in the KIR B haplotype and a trend towards 
increased NK cell activity in presence of 1-7F9 in individuals with the KIR3DS1 gene 
was found (data not shown).  
Due to the linkage disequilibrium between the KIR2DL2 and KIR2DS2 genes another 
possibility is that the inhibitory KIR2DL2 receptor is responsible for the increased 
effect of 1-7F9 in individuals that also posses the KIR2DS2 gene. The increased 
affinity of HLA-C for KIR2DL2 as compared to the allele KIR2DL3 [109] might 
contribute since a high affinity interaction during education between an inhibitory 
receptor and its MHC class I molecule can result in an increased functionality of that 
NK cell [45]. When this interaction is blocked by 1-7F9 an increased NK cell activity 
might be anticipated. To further delineate the effect of 1-7F9 in individuals possessing 
certain KIR genotypes the activity of NK cells with different combinations of KIRs 
could be investigated with NK cell clones or the newly described antibody 
combinations for specific KIR molecules [426]. 
7.2.4 NK cell phenotype and genotype influence NK cell mediated 
ADCC to HIV-1 infected cells (paper II). 
The NK cell mediated ADCC activity in presence of HIV-1IIIB infected Jurkat T cells 
and pooled IgG from HIV-1 infected patients (HIVIG) did, as mentioned above, not 
differ between HIV-1 infected patients and healthy individuals. However there was a 
heterogeneous response to this stimulation between individuals within the groups. We 
investigated whether expression of NK cell receptors or presence of certain receptor 
genotypes could contribute to this. An increased frequency of NK cells expressing the 
activation marker CD69 ex vivo correlated with a higher proportion of NK cells 
degranulating in response to HIVIG coated HIV-1 infected Jurkat T cells (Figure 4d in 
paper II). CD69 is usually seen as a marker for in vivo activation but it might also be 
functional in the in vitro interaction between NK cells, infected cells and antibodies. 
One of the proposed functions for CD69 is as a stimulatory receptor [428], which may 
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explain the effect found by us, although several other suggestions on CD69 function are 
equally possible [429, 430].  
The Fc receptor CD16, involved in ADCC, possesses polymorphisms that influence the 
binding of IgG antibodies [153, 154]. We genotyped all individuals included in the 
study for the polymorphism at position 158, but this did not explain the heterogeneous 
NK cell ADCC activity among donors (Figure 4e in paper II). 
7.2.4.1 KIR3DL1/S1 and HLA-B genotype influence NK cell ADCC function. 
Another genetic variable is the presence of different KIR genes, which could 
potentially influence NK cell ADCC activity [431]. We investigated the association of 
KIR3DL1/S1 and HLA-B alleles in the recorded ADCC results, since these genes have 
been associated with the rate of HIV-1 disease progression [339, 342, 345].  When 
grouping individuals according to presence or not of the HLA-B Bw4Ile80 epitope, 
which is a high affinity ligand for KIR3DL1 [110, 111], an interesting pattern 
associated with possession of KIR3DL1 or KIR3DS1 was found (Figure 14). Although 
the number of individuals with the HLA-B Bw4Ile80 allele was small, there was a 
trend towards increased NK cell ADCC activity in individuals with the activating 
KIR3DS1 allele as compared to individuals only possessing the inhibitory KIR3DL1 
allele (Figure 14a). Intriguingly individuals lacking this HLA-B epitope and instead 
possessing the HLA-B Bw4Thr80 or HLA-B Bw6 epitopes had a contrasting pattern 
with increased NK cell ADCC activity in individuals homozygous for the KIR3DL1 
allele as compared to individuals homozygous for the KIR3DS1 allele (Figure 14b).
Individuals lacking the HLA-B Bw4Ile80 epitope still can possess HLA-B Bw4 and 
HLA-A Bw4 epitopes binding KIR3DL1 [111, 115, 432]. However ADCC induced 
activity did not differ between KIR3DL1/S1 genotypes when comparing individuals 
with the HLA-Bw4 or Bw6 epitopes (data not shown), indicating that only presence of 
the HLA-B Bw4Ile80 influence the ADCC activity in our cohort.  
Figure 14: Influence of KIR3DL1/S1 and HLA-B genotype on NK cell mediated ADCC 
activity. Frequency of NK cells degranulating in presence of HIV infected Jurkat T cells and 
HIVIG (250 ȝg/ml) in individuals with different genotypes. Individuals possessing (a) or 
lacking (b) the HLA-B Bw4Ile80 epitope grouped into KIR3DL1 homozygous (L1/L1), 
KIR3DS1 homozygous (S1/S1) or KIR3DL1/S1 heterozygous (L1/S1). The horizontal line 
represents the median in each group. P-values in the figure are derived by the Kruskal-Wallis 
post-hoc test. 
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The simplest explanation for the results in Figure 14a would be that an interaction 
between KIR3DL1 and HLA-B Bw4Ile80 during the effector target interaction 
influenced NK cell ADCC activity. However, genotyping of the Jurkat T cells, used as 
target cells, indicated that these cells completely lack HLA molecules with the Bw4 
epitope, which argues against that KIR binding to HLA in the in vitro setup contributes 
to the effects recorded. Rather a difference in activation state of NK cells from these 
individuals, possibly induced during education, might be the reason. The results are 
especially interesting since they are difficult to explain using the current dogma on NK 
cell education, which states that NK cells lacking inhibitory receptors for self MHC are 
rendered hyporesponsive [42-44]. In addition, as mentioned previously, a recent 
publication suggested that activating KIRs in presence of their ligand could reduce the 
responsiveness of the NK cell [426]. One possibility is that linkage disequilibrium with 
other inhibitory receptors and HLA molecules contributes to the increased activity of 
NK cells from individuals possessing the KIR3DS1 allele together with HLA-B 
Bw4Ile80. 
Previous reports analysing NK cell degranulation in the unstimulated state or in 
response to stimulation through CD16 found an increased activity of KIR3DS1+ NK 
cells as compared to KIR3DS1- NK cells [427, 433]. In presence of HIV-1 infected 
autologous CD4+ T cells KIR3DS1+ NK cells from HLA-Bw4+ individuals 
degranulated to a higher degree as compared to NK cells from HLA-Bw6+ individuals, 
whereas KIR3DL1+ NK cells did not degranulate at all [279]. A similar effect might be 
operating in ADCC activation and could have resulted in the increased degranulation in 
KIR3DS1 positive individuals that possesses the HLA-B Bw4Ile80 epitope compared 
to individuals lacking this HLA epitope. A difference in frequency and level of 
expression of KIR3DL1 and KIR3DS1 in individuals with different HLA alleles [346, 
427, 433], which could contribute to frequency of NK cells activated is one possible 
explanation.  
From these results it seems as KIR genotype in conjunction with certain HLA alleles 
can influence NK cell ADCC activity. However, the low number of individuals positive 
for HLA-B Bw4Ile80 and/or KIR3DS1 in our study needs to be increased before any 
firm conclusions can be made. We also plan to extend the study and investigate 
differential responses in NK cell subpopulations expressing KIR3DS1 compared to 
KIR3DL1. 
7.3 NK CELL AND ANTIBODY-MEDIATED EFFECTS IN THE IN VIVO HIV-
1/MULV MOUSE MODEL 
7.3.1 NK cells are involved in the early control of HIV-1/MuLV infected 
cells in vivo (paper III) 
There are implications on a role for NK cells in protection from infection [260, 264, 
266] and during the acute HIV-1 infection [267] in humans. To further investigate the 
effects of NK cells in an in vivo model for acute HIV-1 infection, we turned to the HIV-
1/MuLV challenge model in mice. HIV-1/MuLV infected syngeneic cells were injected 
intraperitoneally into the mouse and at different timepoints thereafter the peritoneal 
cells were harvested and presence of NK cells and infected cells investigated (Figure 
6). An increased frequency of NK cells but not T cells was detected in the peritoneal 
fluid already at day one after injection of infected cells (Figure 1 in paper III). No 
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effect on the frequency of NK cells in the spleen was seen, indicating a specific 
expansion or recruitment of NK cells at the site of injection. The maturation stages of 
NK cells are known to vary in various tissues and in response to infection [62, 63, 143]. 
We therefore analyzed the maturation stages of NK cells in the peritoneum by staining 
for the markers CD27 and Mac-1 (see section 3.3.2) [62, 64]. Injection of HIV-
1/MuLV infected cells resulted in an increased proportion of more mature NK cells of 
the CD27low subset, while the less mature subsets, double negative (DN) and Mac-1low,
decreased (Figure 2 in paper III). It thus seems that there is a shift towards higher 
frequency of NK cells of a more mature phenotype at the site of injection of HIV-
1/MuLV infected cells.  
The early increase in frequency of NK cells in the peritoneum upon injection of a 
number of different virus types was previously reported by Daniels et.al. [193]. An 
increased proportion of the more mature Mac-1 positive NK cells in spleen and liver 
after systemic MCMV infection has also been reported [63, 143]. The increased 
proportion of mature NK cells upon injection of infected cells may be due to 
recruitment, proliferation or maturation of NK cells in the peritoneum and possible 
mechanisms for this are discussed below. 
Recruitment of NK cells to the peritoneum could be due to induction of chemokines 
that bind the chemokine receptors expressed by NK cells. One of these is the CCR5 
receptor that binds MIP-1Į which is involved in recruitment of NK cells to the liver 
upon MCMV infection [192]. MCMV infection induces production of type I 
interferons which are involved in recruiting MIP-1Į producing macrophages and this in 
turn results in recruitment of NK cells [191, 192]. In addition, NK cell recruitment to 
vaginal HSV-2 infection was regulated via regulatory T cells and production of the 
CCR5-binding chemokine RANTES [434]. Different NK cell subsets express different 
chemokine receptors [67], which may explain a possible preferential recruitment of 
CD27low NK cells to the site of infection. These cells express the sphingosine 1-
phosphate (S1P) receptor S1P5, that contributes to increased NK cell migration [69]. 
Also, integrins such as Mac-1 could be involved in differential recruitment [67].  
NK cells proliferate in response to multiple cytokines which are induced by infection, 
exemplified by the increased NK cell turnover in liver upon MCMV infection [194]. 
The proliferation in MCMV infection is occurring in two phases. The first phase (day 
1-2) is unspecific and involves all NK cell subsets and the later phase (day 4-6) is 
specific for mature NK cells expressing the activating receptor Ly49H [63, 194]. The 
Ly49H+ cells are stimulated by the MCMV protein m157 that binds the receptor [32, 
35]. NK cell interaction with MCMV infected cells also leads to an accelerated 
phenotypic NK cell maturation [143]. Thus phenotypic maturation during unspecific 
proliferation of the NK cells may result in the early increased frequency of CD27low NK 
cells detected by us in the HIV-1/MuLV model. However, further studies are warranted 
to determine the responsible mechanism. 
To investigate whether NK cells could have any effect on the infected cells, mice were 
depleted of NK cells with an NK1.1 specific antibody before challenge with HIV-
1/MuLV infected cells. The effect on the infected cells was measured by an HIV-1 p24 
ELISA on in vitro cultured peritoneal cells [252]. Depletion of NK1.1+ cells in mice 
resulted in an increased number of HIV-1 p24 positive cell cultures from these mice 
(Figure 4 in paper III). This indicates that NK1.1+ cells are involved in the early 
control of HIV-1/MuLV infected cells in the peritoneal cavity. A likely explanation is 
an NK cell mediated killing of the infected cells. In addition to NK cells, NK1.1+ T 
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cells are also depleted with the antibody treatment used. However CTL responses are 
not affected by anti-NK1.1 treatment [435]. When CD16 expressing cells (potentially 
NK cells, T cells and monocytes) were depleted in rhesus macaques infected 
intravenously with SIV, efficient depletion of CD16+ cells lasted for a week and in this 
early phase after infection there was a trend towards increased viral load in the CD16 
depleted macaques [436]. This effect was however lost in the later phase of the 
infection. The route of infection might have influenced the response since a mucosal 
route of infection might be more relevant for determining the contribution of NK cells 
in the early host defence. Thus, further investigations are needed to determine if NK 
cells are also important for early control of infection in non-human primates and 
patients. 
We investigated whether the HIV-1/MuLV infected cells differently expressed MHC 
class I molecules and a ligand for NKG2D as compared to uninfected cells. The ligands 
were chosen based on reported differences on HIV-1 infected human cells [359, 360, 
363]. Only slight differences in MHC class I expression and no effect on the NKG2D 
ligand Rae-1 was found (data not shown). This is in accord with our ligand stainings on 
HIV-1IIIB infected human T cells and may be explained by the use of the same HIV-1 
viral strain in the mouse system as in the above mentioned human studies (paper I and 
II). Other ligands than the ones mentioned are probably involved in the NK cell 
recognition of HIV-1/MuLV infected cells. This recognition may be directed to the 
HIV-1 virus or to the MuLV virus since the pseudovirus used consists of both these 
viruses. In the future we plan to investigate the effect of MuLV versus HIV-1 on NK 
cell recruitment and activation in the model. 
In conclusion this study shows that NK1.1+ cells are involved in the control of HIV-
1/MuLV infected cells in vivo and that these infected cells stimulate a response 
resulting in an increased frequency of NK cells with a more mature phenotype in the 
peritoneum. 
7.3.1.1 Pros and cons with the HIV-1/MuLV mouse model. 
There are some characteristics of the HIV-1/MuLV mouse model that deserves 
attention when interpreting data from these studies. The high doses of the HIV-
1/MuLV virus supernatant needed for infection of mouse cells results in a high 
frequency of dead or dying splenocytes in the infected cell cultures. When these are 
injected into the mouse it may induce immune reactivities that induce the recruitment, 
expansion or activation of NK cells, induced by apoptotic cells rather than in a virus-
specific manner. However, HIV-1 is a lytic virus which induces cell death, and 
therefore the injection of cells which are induced to die by virus may be relevant. The 
infection of cells with an uncharacterized virus consisting of a mixture of HIV-1 and 
MuLV may also affect the interpretation of these data. We have not yet investigated the 
role of MuLV itself in the data we have obtained. It is possible that the increased NK 
cell numbers we find and the mature phenotype of these cells result from MuLV as well 
as from HIV-1. Nonetheless, it is interesting to note that virus infected cells can affect 
NK cells in the peritoneum in this model.  
The data of NK cell control of virus infection in the HIV-1/MuLV model depends on 
retrieval of infected cells from the peritoneum, and thus that infected cells do not 
migrate from this site. There is no evidence for migration of cells or for the transport of 
infected cells to other organs [252]. However, if this kind of migration occurs it would 
probably not be affected by depletion of NK cells. In most mouse strains injection of 
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HIV-1/MuLV infected cells results in early clearance of the injected cells. Only a few 
mouse strains, including the HLA-A2 transgenic mouse used by us permit, persistence 
of the virus infected cells [252]. It is possible that this is due to some kind of immune 
defect or genetic difference that affects the host response to infected cells, which may 
involve NK cells. This should also be kept in mind when interpreting data from this 
model.  
Despite these considerations, studies with this model may contribute with important 
information regarding the in vivo effects of different immune cells and treatment 
modalities directed to HIV-1 infected cells during acute infection. This small scale 
model allows a great number of variables to be combined at limited space and time 
when choosing among several anti-retroviral strategies or drugs and combinations 
thereof. It may therefore be used as an in vivo advisor before embarking on larger 
animal models or clinical studies.  
7.3.2 A drug-conjugated anti-envelope antibody is effective against 
HIV-1/MuLV infected cells in vivo (paper IV). 
Despite the many unconjugated and conjugated mAbs used in human cancer therapy 
[397, 399] and the promising effects of passive immunizations in non-human primates 
[282-286], no antibody treatment has as yet had any long term effect in HIV-1 infected 
patients [292]. We investigated whether a HIV-1 specific antibody conjugated to the 
cytotoxic drug doxorubicin, used in treatment of cancer patients, is effective against 
HIV-1 infected cells in vitro and in vivo in the HIV-1/MuLV mouse model. In contrast 
to previous immunoconjugates with toxins, doxorubicin is not immunogenic. 
Conjugation of doxorubicin to cancer antigen specific mAbs is effective in mouse 
models for leukemia [437], but in a phase II clinical trial for treatment of metastatic 
breast carcinoma there was only a small number of partial regressions [438]. It is 
possible that this kind of therapy is most effective in minimal disease settings, 
exemplified by ART treated HIV-1 infected patients, and that the effect of the 
conjugate depends on the antigen targeted. We conjugated doxorubicin to a mouse 
mAb, specific for HIV-1 gp120, called P4/D10 [439]. This antibody binds to the V3 
loop and mediates both neutralization and ADCC in vitro [439]. It was proven safe in a 
phase I clinical trial for late-stage HIV-1 infected patients [440]. 
The neutralizing capacity of the conjugated antibody was tested by incubating it with 
the virus isolate HIV-1IIIB before adding the virus to Jurkat T cell cultures. The p24 
production in the cell cultures was measured by ELISA and the percent inhibition 
compared to Jurkat T cells mixed with only HIV-1IIIB was calculated. Doxorubicin-
conjugated P4/D10 neutralized HIV-1IIIB with an efficacy similar to that of the 
unconjugated P4/D10 mAb and purified IgG from HIV-1 infected patients (HIVIG) 
(Figure 1a, paper IV). The doxorubicin conjugated P4/D10 was also able to eradicate 
virus infection in already infected cell cultures and this ability was greater than that of 
unconjugated P4/D10 mAb, free doxorubicin or irrelevant doxorubicin-conjugated 
mAb (Figure 1b, paper IV). 
The possible in vivo effect of the doxorubicin-P4/D10 mAb on HIV-1 infected cells 
was investigated in the HIV-1/MuLV challenge model [252]. The conjugated or 
unconjugated antibodies were injected intraperitoneally at the same time as the mice 
were challenged with HIV-1IIIB/MuLV infected cells. Mice were completely protected 
from challenge when treated with doxorubicin-P4/D10 mAb, since no cell cultures 
from these mice became positive for HIV-1 p24 (Figure 2 paper II). Unconjugated 
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P4/D10 mAb, free doxorubicin or irrelevant doxorubicin-conjugated antibodies were 
not protective. Thus doxorubicin-P4/D10 was significantly better than all the controls 
in inhibiting HIV-1IIIB/MuLV replication in vivo, indicating that the effect of an anti-
HIV-1 antibody could be significantly enhanced by coupling it to doxorubicin. 
The effect of doxorubicin on HIV-1 infected cells could be due to induction of 
apoptosis in actively proliferating cells since it binds to topoisomerase II and hinders 
resealing of DNA breaks [441]. Repression of topoisomerase II by RNA antisense 
resulted in impaired HIV-1 replication in vitro [442], suggesting that doxorubicin may 
inhibit HIV-1 replication as well. Doxorubicin induced tumor cell death leads to an 
effective CD8+ T cell anti-tumor immune response [443]. DC uptake of apoptotic cells 
killed by doxorubicin was more effective than the DC uptake of cells killed by other 
cytostatics [443]. It is thus possible that doxorubicin-conjugated mAbs could induce an 
effective HIV-1 specific immune response at the same time as it specifically kills HIV-
1 infected cells. 
For future clinical development of this drug-conjugated mAb concept, a cocktail of 
antibodies targeting conserved regions of the HIV-1 envelope should be used to avoid 
viral escape mutations [225, 284, 292]. On top of this it may be an equally important 
strategy to couple different cytotoxic drugs to the antibodies to be able to reduce the 
dose of each single drug and thus decrease risks of toxicity (very much the same way as 
is today done with antiretroviral drugs by obtaining synergistic antiviral effects with 
reduced toxicity). Immunogenicity of mouse antibodies is problematic and human or 
humanized antibodies are preferable [397]. ART treated patients would be the target 
group to avoid problems associated with high viral load [405]. This could increase the 
chances of success by simultaneously introducing both agents that kill infected cells 
and ART, which inhibits replication. If it were possible to induce reactivation and drive 
out HIV-1 from latently infected cells in a safe way [230], simultaneous treatment with 
immunoconjugates and ART could potentially decrease the latent reservoirs [405, 407]. 
However, the feasibility to cure latent HIV-1 infection with this kind of treatment is 
questionable and needs further investigation [406]. 
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8 CONCLUDING REMARKS 
Despite the tremendous research performed to understand the HIV-1 virus and how to 
combat it, no cure or preventive measure for the disease exists today. During the last 
years the interest for the role of NK cells in HIV-1 infection has increased substantially, 
much thanks to the elucidation of the associations of certain KIR and HLA genes with a 
slower disease progression [339]. In addition, the increased activity of NK cells from 
individuals that avoid HIV-1 infection despite repeated exposures to the virus [260] 
justifies the increased interest in this field of research. In this thesis, potentially 
effective treatment modalities based on NK cells or antibodies have been examined in 
addition to studies on the involvement of NK cells in acute and chronic HIV-1 
infection. 
Our results concerning the role for NK cells in the acute HIV-1/MuLV model stresses 
the importance of considering NK cells as a component in protection from infection. 
Further knowledge on the mechanisms for this NK cell effect on infected cells are 
needed, as is understanding on what the triggers for NK cell activity in this model are. 
This type of information could contribute to development of treatments or vaccines for 
which an increased NK cell response may be advantageous.  
The interesting associations between KIR and HLA genotype and NK cell ADCC 
activity need to be extended and the phenotype of the NK cells responsible for the 
effect discerned. The possible contribution of certain KIR genes to the NK cell activity 
deserves further attention since it may affect the individuals NK cell response to HIV-1 
infection. 
The possible differences in specificity of ADCC inducing antibodies in controller 
patients may indicate that the epitopes targeted by this type of antibodies contributes to 
a slower disease progression. Further studies with increased numbers of controller 
patients are needed to confirm or refute our tentative conclusions and to in more detail 
investigate the epitopes on oligomeric envelope proteins targeted by ADCC inducing 
antibodies. Such epitopes may be good candidates for induction of protective antibodies 
with active immunization strategies. This knowledge may also be used when choosing 
which free or conjugated antibodies to use in future passive immunization trials.  
The potent effect of a drug-conjugated anti HIV-1 envelope antibody in the HIV-
1/MuLV mouse model deserves further attention and the concept should be developed 
to include conjugated-antibodies targeting different epitopes on the HIV-1 envelope 
protein.  
  59 
9 ACKNOWLEDGEMENTS 
I wish to sincerely thank everyone who in one way or another has contributed to this 
thesis. In particular, I wish to thank:  
Louise Berg my outstanding supervisor, for all great scientific discussions and your 
endless support during these years. Thank you for always believing in me and cheering 
me up during though times. Our collaboration has meant very much to me! 
Maria Johansson, for being an excellent co-supervisor with always good and sound 
scientific ideas and a careful approach. I have very much appreciated your 
encouragement and empathy in all matters. 
Britta Wahren my co-supervisor, for your generous personality and for introducing 
me to many interesting people. Thank you for taking me in to your group from the 
beginning and for guidance during the years. 
Jorma Hinkula, my all supportive co-supervisor with an amazing memory. I think you 
actually remember every single tube you have ever set your eye on and experiment that 
has been performed. 
Klas Kärre, for your enthusiasm in discussing new data and for inspiring ideas. It has 
been a great experience to work with you. 
All the co-authors that have immensely contributed to this thesis. I whish to especially 
mention; 
Hanna Brauner for your love for science and for being a great friend–especially 
appreciated during our long nightly hours by the FACS.  
Erik Rollman for your endless enthusiasm and for suggesting and arranging my visit at 
the lab in Melbourne where you did your post-doc. It was an incredible experience and 
you and Elin contributed greatly to that.  
Stephen Kent and all the other people at the lab in Melbourne for welcoming me there 
and contributing with interesting ideas.  
Rob Center for scientific suggestions and discussions regarding the HIV envelope and 
ELISA.  
Nicolai Wagtmann and David Goldenberg, for good scientific collaborations. 
Bo Hejdeman at SöS, for your invaluable help with recruiting patients and providing 
the clinical angle. 
Ronnie Ask and all the staff at Venhälsan for organizing and providing the patient 
samples.  
All the patients and healthy donors who willingly have contributed to these studies. 
Marie Arsenian-Henriksson and Mats Wahlgren for providing a good scientific 
atmosphere at the Department of Microbiology, Tumor and Cell Biology and 
Francesca Chiodi, for scientific ideas and support. 
60
Sören Andersson, Rigmor Thorstensson, Jan Albert and Annika Linde for making 
Virologen a great place to work in and the Swedish Institute for Infectious Disease 
Control for providing an excellent work place. 
The VIP group; 
Andreas Boberg, for always being willing to discuss (sometimes a bit too much ſ)
and help out. Thank you for being a great friend and for calling me up and checking 
that I’m still alive after many hours of P3 work.  
Andreas Bråve, for your sound scientific knowledge and critical reading of my thesis. 
Thank you for great company at travels and for making SMI a funnier place.  
Gunnel Engström my lab mum from the first day at SMI and onwards, for always 
being carrying and prepared to help.
Lindvi Gudmundsdotter, for sharing life at P3 and for fun times in and outside the 
lab.  
Kristian Hallermalm for nice company and critical scientific thinking, which is 
greatly missed now that you have moved on.  
David Hallengärd for sharing laughs and concerns at the office.  
Maria Isaguliants and Elizaveta Starodubova for contributing with Russian 
traditions and scientific discussions.  
Margaret Liu, for all your great advises. 
In addition, all former members of the Wahren group. Including Kalle, Lars, Paolo, 
Anne and Bartek
My “MTC group”; 
It has been a privilege to take part in the great scientific discussions at the group 
meetings and to enjoy the warm atmosphere in the corridor. Special thanks goes to 
Stina, Danika, Kanth, Jonas, Micke, Jens, Mantas, Petter H, Petter B, Björn, 
Bruno, Alexander, Marjet, Hanna S, Katja, Christina and Martha-who contributed 
with data to this thesis. 
I have had the privilege to have many nice office mates during these years.
Sara, for being my friend and for our endless discussions on life in general. You were 
the best “sällskapsdam” you could have at our trip to the West Indies ſ
Jonas Hardestam for organizing many unforgettable happenings in and outside the lab 
and for sharing my interest in games of different kinds.
Anne, Lina, Karin, Annette and Sarah for contributing to a happy and nice 
atmosphere. 
All my great colleagues at the Virology and KCB department, there is not room to 
mention all of you, but I would like to especially mention; 
Kajsa, Afsaneh and Sirka for technical support at the P3 lab.  
Maria Wahlström, Malin Karlsson, Salma, Jonas Klingström, Malin Stoltz, Ida, 
Melinda, Mattias, Helen, Anne-Marie, Andreas Mörner and Marianne for nice 
company at lunches, social activities and travels. 
Margareta Benthin, Barbro Levén, Eva Bäckman, Lisbeth Löfstrand and Anna 
Lögdberg for all your practical help.  
  61 
The animal caretakers Gunilla Marin, Reinhold Benthin, Margareta Hagelin and 
Christel Werner, for all your help with the mice.  
Birgitta Wester for help at the MTC FACS facility and Barbro Mäkitalo, Johan 
Brännström, Hans Gaines and everyone else at IVA who has helped me with the 
FACSing at SMI. 
To my friends and previous colleagues from SMI;  
Anna Ohlin for all the fun during the early years and for introducing the “Christmas 
candy” tradition,
Elisabet Gustafsson for interesting discussions and for being part of the “opera gang” 
Claudia Estrate for constantly inviting me to come to Portugal. I promise I will come 
visit you when this is over ſ.
Sofia Dahlberg for nice company by the FACS machine and at “Friskis”. 
My friends from outside the lab;  
Maria Lundqvist my dear friend, for all your great support and for always believing in 
me. I hope we will see more of each other from now on. Will be much easier now when 
you finally live on the right side of the town ſ
Ying, Johanna, Andreas Hermansson, Hanna, Annci and Monika for great parties, 
get togethers and trips, and also for sharing the ups and downs of the PhD studies.  
Annika the artist of the cover of this thesis, for all the fun we have had together since 
the start of our “Genteknik” studies.  
Therésè and Mattias for reminding me on how fun it is with music. I promise to try 
geo-catching soon ſ
Maria Wiken and Betty for the fantastic trip to Brazil. Are you going back to Itacaré 
again soon?  
My friends from “Forskarskolan” Maria Lönn for your happy contagious smile. 
Although Sydney seems a great place to live in, I hope we will soon live closer, 
because it is far, far away. Christoffer, good luck with your post-doc studies. 
Ett stort tack till alla Mina släktingar för ert stöd under dessa år och tidigare i livet. Jag 
vill särskilt tacka Mommo för alla uppmuntrande vykort och hälsningar och mina 
”Skogsböle kusiner”, för alla lov vi spenderat tillsammans och för kusinträffen i 
Bordeaux i somras. Vart ska vi åka nästa år? 
Och så klart min älskade familj; Mamma och Pappa, ni är ett otroligt stöd för mig och 
utan er uppmuntran och påhejning hade jag aldrig orkat hit, Veronica min härliga 
lillasyster och närmaste vän.  
Tobbe och Mickes familj för trevliga sammankomster. 
Micke, för att du är en underbar person och för att du gör mig så lycklig! 
62
10 REFERENCES 
[1] Medzhitov, R., Recognition of microorganisms and activation of the immune response. Nature
2007. 449: 819-826. 
[2] Kawai, T. and Akira, S., Innate immune recognition of viral infection. Nat Immunol 2006. 7:
131-137. 
[3] Caligiuri, M. A., Human natural killer cells. Blood 2008. 112: 461-469. 
[4] Lanier, L. L., NK cell recognition. Annu Rev Immunol 2005. 23: 225-274. 
[5] Rodgers, J. R. and Cook, R. G., MHC class Ib molecules bridge innate and acquired 
immunity. Nat Rev Immunol 2005. 5: 459-471. 
[6] Smith-Garvin, J. E., Koretzky, G. A. and Jordan, M. S., T cell activation. Annu Rev Immunol
2009. 27: 591-619. 
[7] Cullen, S. P. and Martin, S. J., Mechanisms of granule-dependent killing. Cell Death Differ
2008. 15: 251-262. 
[8] Schepers, K., Arens, R. and Schumacher, T. N., Dissection of cytotoxic and helper T cell 
responses. Cell Mol Life Sci 2005. 62: 2695-2710. 
[9] Bettelli, E., Korn, T., Oukka, M. and Kuchroo, V. K., Induction and effector functions of 
T(H)17 cells. Nature 2008. 453: 1051-1057. 
[10] Vignali, D. A., Collison, L. W. and Workman, C. J., How regulatory T cells work. Nat Rev 
Immunol 2008. 8: 523-532. 
[11] Godfrey, D. I., MacDonald, H. R., Kronenberg, M., Smyth, M. J. and Van Kaer, L., NKT 
cells: what's in a name? Nat Rev Immunol 2004. 4: 231-237. 
[12] Maizels, N., Immunoglobulin gene diversification. Annu Rev Genet 2005. 39: 23-46. 
[13] Huber, M. and Trkola, A., Humoral immunity to HIV-1: neutralization and beyond. J Intern 
Med 2007. 262: 5-25. 
[14] Nimmerjahn, F., Bruhns, P., Horiuchi, K. and Ravetch, J. V., FcgammaRIV: a novel FcR 
with distinct IgG subclass specificity. Immunity 2005. 23: 41-51. 
[15] Jefferis, R., Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther
2007. 7: 1401-1413. 
[16] Herberman, R. B., Nunn, M. E., Holden, H. T. and Lavrin, D. H., Natural cytotoxic 
reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization 
of effector cells. Int J Cancer 1975. 16: 230-239. 
[17] Kiessling, R., Klein, E., Pross, H. and Wigzell, H., "Natural" killer cells in the mouse. II. 
Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer 
cell. Eur J Immunol 1975. 5: 117-121. 
[18] Herberman, R. B. and Ortaldo, J. R., Natural killer cells: their roles in defenses against 
disease. Science 1981. 214: 24-30. 
[19] Bukowski, J. F., Woda, B. A., Habu, S., Okumura, K. and Welsh, R. M., Natural killer cell 
depletion enhances virus synthesis and virus-induced hepatitis in vivo. J Immunol 1983. 131:
1531-1538. 
[20] Imai, K., Matsuyama, S., Miyake, S., Suga, K. and Nakachi, K., Natural cytotoxic activity of 
peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general 
population. Lancet 2000. 356: 1795-1799. 
[21] Orange, J. S., Human natural killer cell deficiencies and susceptibility to infection. Microbes 
Infect 2002. 4: 1545-1558. 
[22] Karre, K., Ljunggren, H. G., Piontek, G. and Kiessling, R., Selective rejection of H-2-
deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986. 319:
675-678. 
[23] Kärre, K., On the immunobiology of NK cells. Karolinska Institutet 1981. 
[24] Ljunggren, H. G. and Karre, K., Host resistance directed selectively against H-2-deficient 
lymphoma variants. Analysis of the mechanism. J Exp Med 1985. 162: 1745-1759. 
[25] Bonaparte, M. I. and Barker, E., Killing of human immunodeficiency virus-infected primary 
T-cell blasts by autologous natural killer cells is dependent on the ability of the virus to alter the 
expression of major histocompatibility complex class I molecules. Blood 2004. 104: 2087-2094. 
[26] Brutkiewicz, R. R. and Welsh, R. M., Major histocompatibility complex class I antigens and 
the control of viral infections by natural killer cells. J Virol 1995. 69: 3967-3971. 
  63 
[27] Ohlen, C., Kling, G., Hoglund, P., Hansson, M., Scangos, G., Bieberich, C., Jay, G. and 
Karre, K., Prevention of allogeneic bone marrow graft rejection by H-2 transgene in donor 
mice. Science 1989. 246: 666-668. 
[28] Ljunggren, H. G. and Karre, K., In search of the 'missing self': MHC molecules and NK cell 
recognition. Immunol Today 1990. 11: 237-244. 
[29] Cerwenka, A., Baron, J. L. and Lanier, L. L., Ectopic expression of retinoic acid early 
inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-
bearing tumor in vivo. Proc Natl Acad Sci U S A 2001. 98: 11521-11526. 
[30] Groh, V., Bahram, S., Bauer, S., Herman, A., Beauchamp, M. and Spies, T., Cell stress-
regulated human major histocompatibility complex class I gene expressed in gastrointestinal 
epithelium. Proc Natl Acad Sci U S A 1996. 93: 12445-12450. 
[31] Groh, V., Rhinehart, R., Randolph-Habecker, J., Topp, M. S., Riddell, S. R. and Spies, T.,
Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-
infected cells. Nat Immunol 2001. 2: 255-260. 
[32] Arase, H., Mocarski, E. S., Campbell, A. E., Hill, A. B. and Lanier, L. L., Direct recognition 
of cytomegalovirus by activating and inhibitory NK cell receptors. Science 2002. 296: 1323-
1326. 
[33] Gazit, R., Gruda, R., Elboim, M., Arnon, T. I., Katz, G., Achdout, H., Hanna, J. et al.,
Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat
Immunol 2006. 7: 517-523. 
[34] Mandelboim, O., Lieberman, N., Lev, M., Paul, L., Arnon, T. I., Bushkin, Y., Davis, D. M.
et al., Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by 
human NK cells. Nature 2001. 409: 1055-1060. 
[35] Smith, H. R., Heusel, J. W., Mehta, I. K., Kim, S., Dorner, B. G., Naidenko, O. V., Iizuka, 
K. et al., Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc 
Natl Acad Sci U S A 2002. 99: 8826-8831. 
[36] Cooper, M. A., Fehniger, T. A. and Caligiuri, M. A., The biology of human natural killer-cell 
subsets. Trends Immunol 2001. 22: 633-640. 
[37] Freud, A. G. and Caligiuri, M. A., Human natural killer cell development. Immunol Rev 2006. 
214: 56-72. 
[38] Freud, A. G., Yokohama, A., Becknell, B., Lee, M. T., Mao, H. C., Ferketich, A. K. and 
Caligiuri, M. A., Evidence for discrete stages of human natural killer cell differentiation in 
vivo. J Exp Med 2006. 203: 1033-1043. 
[39] Huntington, N. D., Vosshenrich, C. A. and Di Santo, J. P., Developmental pathways that 
generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 2007. 7: 703-714. 
[40] Valiante, N. M., Uhrberg, M., Shilling, H. G., Lienert-Weidenbach, K., Arnett, K. L., 
D'Andrea, A., Phillips, J. H. et al., Functionally and structurally distinct NK cell receptor 
repertoires in the peripheral blood of two human donors. Immunity 1997. 7: 739-751. 
[41] Salcedo, M., Diehl, A. D., Olsson-Alheim, M. Y., Sundback, J., Van Kaer, L., Karre, K. 
and Ljunggren, H. G., Altered expression of Ly49 inhibitory receptors on natural killer cells 
from MHC class I-deficient mice. J Immunol 1997. 158: 3174-3180. 
[42] Anfossi, N., Andre, P., Guia, S., Falk, C. S., Roetynck, S., Stewart, C. A., Breso, V. et al.,
Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006. 25: 331-342. 
[43] Fernandez, N. C., Treiner, E., Vance, R. E., Jamieson, A. M., Lemieux, S. and Raulet, D. 
H., A subset of natural killer cells achieves self-tolerance without expressing inhibitory 
receptors specific for self-MHC molecules. Blood 2005. 105: 4416-4423. 
[44] Kim, S., Poursine-Laurent, J., Truscott, S. M., Lybarger, L., Song, Y. J., Yang, L., French, 
A. R. et al., Licensing of natural killer cells by host major histocompatibility complex class I 
molecules. Nature 2005. 436: 709-713. 
[45] Brodin, P., Lakshmikanth, T., Johansson, S., Karre, K. and Hoglund, P., The strength of 
inhibitory input during education quantitatively tunes the functional responsiveness of individual 
natural killer cells. Blood 2009. 113: 2434-2441. 
[46] Lanier, L. L., Le, A. M., Civin, C. I., Loken, M. R. and Phillips, J. H., The relationship of 
CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells 
and cytotoxic T lymphocytes. J Immunol 1986. 136: 4480-4486. 
[47] Arase, H., Saito, T., Phillips, J. H. and Lanier, L. L., Cutting edge: the mouse NK cell-
associated antigen recognized by DX5 monoclonal antibody is CD49b (alpha 2 integrin, very 
late antigen-2). J Immunol 2001. 167: 1141-1144. 
64
[48] Walzer, T., Blery, M., Chaix, J., Fuseri, N., Chasson, L., Robbins, S. H., Jaeger, S. et al.,
Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc 
Natl Acad Sci U S A 2007. 104: 3384-3389. 
[49] Nagler, A., Lanier, L. L., Cwirla, S. and Phillips, J. H., Comparative studies of human 
FcRIII-positive and negative natural killer cells. J Immunol 1989. 143: 3183-3191. 
[50] Cooper, M. A., Fehniger, T. A., Turner, S. C., Chen, K. S., Ghaheri, B. A., Ghayur, T., 
Carson, W. E. and Caligiuri, M. A., Human natural killer cells: a unique innate 
immunoregulatory role for the CD56(bright) subset. Blood 2001. 97: 3146-3151. 
[51] Poli, A., Michel, T., Theresine, M., Andres, E., Hentges, F. and Zimmer, J., CD56bright 
natural killer (NK) cells: an important NK cell subset. Immunology 2009. 126: 458-465. 
[52] Schepis, D., Gunnarsson, I., Eloranta, M. L., Lampa, J., Jacobson, S. H., Karre, K. and 
Berg, L., Increased proportion of CD56bright natural killer cells in active and inactive systemic 
lupus erythematosus. Immunology 2009. 126: 140-146. 
[53] Eller, M. A., Eller, L. A., Ouma, B. J., Thelian, D., Gonzalez, V. D., Guwatudde, D., 
McCutchan, F. E. et al., Elevated natural killer cell activity despite altered functional and 
phenotypic profile in Ugandans with HIV-1 clade A or clade D infection. J Acquir Immune 
Defic Syndr 2009. 51: 380-389. 
[54] Hu, P. F., Hultin, L. E., Hultin, P., Hausner, M. A., Hirji, K., Jewett, A., Bonavida, B. et al.,
Natural killer cell immunodeficiency in HIV disease is manifest by profoundly decreased 
numbers of CD16+CD56+ cells and expansion of a population of CD16dimCD56- cells with 
low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol 1995. 10: 331-340. 
[55] Fehniger, T. A., Cooper, M. A., Nuovo, G. J., Cella, M., Facchetti, F., Colonna, M. and 
Caligiuri, M. A., CD56bright natural killer cells are present in human lymph nodes and are 
activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. 
Blood 2003. 101: 3052-3057. 
[56] Chan, A., Hong, D. L., Atzberger, A., Kollnberger, S., Filer, A. D., Buckley, C. D., 
McMichael, A. et al., CD56bright human NK cells differentiate into CD56dim cells: role of 
contact with peripheral fibroblasts. J Immunol 2007. 179: 89-94. 
[57] Romagnani, C., Juelke, K., Falco, M., Morandi, B., D'Agostino, A., Costa, R., Ratto, G. et 
al., CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire 
features of CD56dim NK cells upon activation. J Immunol 2007. 178: 4947-4955. 
[58] Jacobs, R., Hintzen, G., Kemper, A., Beul, K., Kempf, S., Behrens, G., Sykora, K. W. and 
Schmidt, R. E., CD56bright cells differ in their KIR repertoire and cytotoxic features from 
CD56dim NK cells. Eur J Immunol 2001. 31: 3121-3127. 
[59] Campbell, J. J., Qin, S., Unutmaz, D., Soler, D., Murphy, K. E., Hodge, M. R., Wu, L. and 
Butcher, E. C., Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes 
identified by chemokine receptor expression repertoire. J Immunol 2001. 166: 6477-6482. 
[60] Manaster, I. and Mandelboim, O., The unique properties of human NK cells in the uterine 
mucosa. Placenta 2008. 29 Suppl A: S60-66. 
[61] Cella, M., Fuchs, A., Vermi, W., Facchetti, F., Otero, K., Lennerz, J. K., Doherty, J. M. et 
al., A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. 
Nature 2009. 457: 722-725. 
[62] Hayakawa, Y. and Smyth, M. J., CD27 dissects mature NK cells into two subsets with distinct 
responsiveness and migratory capacity. J Immunol 2006. 176: 1517-1524. 
[63] Kim, S., Iizuka, K., Kang, H. S., Dokun, A., French, A. R., Greco, S. and Yokoyama, W. 
M., In vivo developmental stages in murine natural killer cell maturation. Nat Immunol 2002. 3:
523-528. 
[64] Chiossone, L., Chaix, J., Fuseri, N., Roth, C., Vivier, E. and Walzer, T., Maturation of 
mouse NK cells is a 4-stage developmental program. Blood 2009. 113: 5488-5496. 
[65] Silva, A., Andrews, D. M., Brooks, A. G., Smyth, M. J. and Hayakawa, Y., Application of 
CD27 as a marker for distinguishing human NK cell subsets. Int Immunol 2008. 20: 625-630. 
[66] Vossen, M. T., Matmati, M., Hertoghs, K. M., Baars, P. A., Gent, M. R., Leclercq, G., 
Hamann, J. et al., CD27 defines phenotypically and functionally different human NK cell 
subsets. J Immunol 2008. 180: 3739-3745. 
[67] Gregoire, C., Chasson, L., Luci, C., Tomasello, E., Geissmann, F., Vivier, E. and Walzer, 
T., The trafficking of natural killer cells. Immunol Rev 2007. 220: 169-182. 
[68] Frey, M., Packianathan, N. B., Fehniger, T. A., Ross, M. E., Wang, W. C., Stewart, C. C., 
Caligiuri, M. A. and Evans, S. S., Differential expression and function of L-selectin on 
CD56bright and CD56dim natural killer cell subsets. J Immunol 1998. 161: 400-408. 
  65 
[69] Walzer, T., Chiossone, L., Chaix, J., Calver, A., Carozzo, C., Garrigue-Antar, L., Jacques, 
Y. et al., Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate 
receptor. Nat Immunol 2007. 8: 1337-1344. 
[70] Peters, P. J., Borst, J., Oorschot, V., Fukuda, M., Krahenbuhl, O., Tschopp, J., Slot, J. W. 
and Geuze, H. J., Cytotoxic T lymphocyte granules are secretory lysosomes, containing both 
perforin and granzymes. J Exp Med 1991. 173: 1099-1109. 
[71] Kannan, K., Stewart, R. M., Bounds, W., Carlsson, S. R., Fukuda, M., Betzing, K. W. and 
Holcombe, R. F., Lysosome-associated membrane proteins h-LAMP1 (CD107a) and h-LAMP2 
(CD107b) are activation-dependent cell surface glycoproteins in human peripheral blood 
mononuclear cells which mediate cell adhesion to vascular endothelium. Cell Immunol 1996. 
171: 10-19. 
[72] Fukuda, M., Lysosomal membrane glycoproteins. Structure, biosynthesis, and intracellular 
trafficking. J Biol Chem 1991. 266: 21327-21330. 
[73] Betts, M. R., Brenchley, J. M., Price, D. A., De Rosa, S. C., Douek, D. C., Roederer, M. and 
Koup, R. A., Sensitive and viable identification of antigen-specific CD8+ T cells by a flow 
cytometric assay for degranulation. J Immunol Methods 2003. 281: 65-78. 
[74] Alter, G., Malenfant, J. M. and Altfeld, M., CD107a as a functional marker for the 
identification of natural killer cell activity. J Immunol Methods 2004. 294: 15-22. 
[75] Screpanti, V., Wallin, R. P., Grandien, A. and Ljunggren, H. G., Impact of FASL-induced 
apoptosis in the elimination of tumor cells by NK cells. Mol Immunol 2005. 42: 495-499. 
[76] Smyth, M. J., Takeda, K., Hayakawa, Y., Peschon, J. J., van den Brink, M. R. and Yagita, 
H., Nature's TRAIL--on a path to cancer immunotherapy. Immunity 2003. 18: 1-6. 
[77] Biron, C. A., Nguyen, K. B., Pien, G. C., Cousens, L. P. and Salazar-Mather, T. P., Natural 
killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol
1999. 17: 189-220. 
[78] Loza, M. J., Zamai, L., Azzoni, L., Rosati, E. and Perussia, B., Expression of type 1 
(interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of 
natural killer cell differentiation from progenitor cells. Blood 2002. 99: 1273-1281. 
[79] Schroder, K., Hertzog, P. J., Ravasi, T. and Hume, D. A., Interferon-gamma: an overview of 
signals, mechanisms and functions. J Leukoc Biol 2004. 75: 163-189. 
[80] Martin-Fontecha, A., Thomsen, L. L., Brett, S., Gerard, C., Lipp, M., Lanzavecchia, A. 
and Sallusto, F., Induced recruitment of NK cells to lymph nodes provides IFN-gamma for 
T(H)1 priming. Nat Immunol 2004. 5: 1260-1265. 
[81] Bluman, E. M., Bartynski, K. J., Avalos, B. R. and Caligiuri, M. A., Human natural killer 
cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-
derived cytokines. J Clin Invest 1996. 97: 2722-2727. 
[82] Oliva, A., Kinter, A. L., Vaccarezza, M., Rubbert, A., Catanzaro, A., Moir, S., Monaco, J.
et al., Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an 
important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin 
Invest 1998. 102: 223-231. 
[83] Kennedy, M. K., Glaccum, M., Brown, S. N., Butz, E. A., Viney, J. L., Embers, M., 
Matsuki, N. et al., Reversible defects in natural killer and memory CD8 T cell lineages in 
interleukin 15-deficient mice. J Exp Med 2000. 191: 771-780. 
[84] Mrozek, E., Anderson, P. and Caligiuri, M. A., Role of interleukin-15 in the development of 
human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996. 87:
2632-2640. 
[85] Leonard, W. J. and Spolski, R., Interleukin-21: a modulator of lymphoid proliferation, 
apoptosis and differentiation. Nat Rev Immunol 2005. 5: 688-698. 
[86] Garcia-Sastre, A. and Biron, C. A., Type 1 interferons and the virus-host relationship: a lesson 
in detente. Science 2006. 312: 879-882. 
[87] Nguyen, K. B., Salazar-Mather, T. P., Dalod, M. Y., Van Deusen, J. B., Wei, X. Q., Liew, 
F. Y., Caligiuri, M. A. et al., Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-
15 regulation of NK cell responses to viral infection. J Immunol 2002. 169: 4279-4287. 
[88] Sato, K., Hida, S., Takayanagi, H., Yokochi, T., Kayagaki, N., Takeda, K., Yagita, H. et al.,
Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta. Eur 
J Immunol 2001. 31: 3138-3146. 
[89] Becknell, B. and Caligiuri, M. A., Interleukin-2, interleukin-15, and their roles in human 
natural killer cells. Adv Immunol 2005. 86: 209-239. 
66
[90] Orange, J. S. and Biron, C. A., An absolute and restricted requirement for IL-12 in natural 
killer cell IFN-gamma production and antiviral defense. Studies of natural killer and T cell 
responses in contrasting viral infections. J Immunol 1996. 156: 1138-1142. 
[91] Trinchieri, G., Immunobiology of interleukin-12. Immunol Res 1998. 17: 269-278. 
[92] Schmidt, K. N., Leung, B., Kwong, M., Zarember, K. A., Satyal, S., Navas, T. A., Wang, F. 
and Godowski, P. J., APC-independent activation of NK cells by the Toll-like receptor 3 
agonist double-stranded RNA. J Immunol 2004. 172: 138-143. 
[93] Sivori, S., Falco, M., Della Chiesa, M., Carlomagno, S., Vitale, M., Moretta, L. and 
Moretta, A., CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: 
induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad 
Sci U S A 2004. 101: 10116-10121. 
[94] Krzewski, K. and Strominger, J. L., The killer's kiss: the many functions of NK cell 
immunological synapses. Curr Opin Cell Biol 2008. 20: 597-605. 
[95] Long, E. O., Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev
2008. 224: 70-84. 
[96] Lanier, L. L., Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol
2008. 9: 495-502. 
[97] Colonna, M. and Samaridis, J., Cloning of immunoglobulin-superfamily members associated 
with HLA-C and HLA-B recognition by human natural killer cells. Science 1995. 268: 405-408. 
[98] Wagtmann, N., Biassoni, R., Cantoni, C., Verdiani, S., Malnati, M. S., Vitale, M., Bottino, 
C. et al., Molecular clones of the p58 NK cell receptor reveal immunoglobulin-related 
molecules with diversity in both the extra- and intracellular domains. Immunity 1995. 2: 439-
449. 
[99] Martin, M. P., Bashirova, A., Traherne, J., Trowsdale, J. and Carrington, M., Cutting 
edge: expansion of the KIR locus by unequal crossing over. J Immunol 2003. 171: 2192-2195. 
[100] Bashirova, A. A., Martin, M. P., McVicar, D. W. and Carrington, M., The killer 
immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics 
Hum Genet 2006. 7: 277-300. 
[101] Li, H., Pascal, V., Martin, M. P., Carrington, M. and Anderson, S. K., Genetic control of 
variegated KIR gene expression: polymorphisms of the bi-directional KIR3DL1 promoter are 
associated with distinct frequencies of gene expression. PLoS Genet 2008. 4: e1000254. 
[102] Gardiner, C. M., Guethlein, L. A., Shilling, H. G., Pando, M., Carr, W. H., Rajalingam, R., 
Vilches, C. and Parham, P., Different NK cell surface phenotypes defined by the DX9 
antibody are due to KIR3DL1 gene polymorphism. J Immunol 2001. 166: 2992-3001. 
[103] Gumperz, J. E., Valiante, N. M., Parham, P., Lanier, L. L. and Tyan, D., Heterogeneous 
phenotypes of expression of the NKB1 natural killer cell class I receptor among individuals of 
different human histocompatibility leukocyte antigens types appear genetically regulated, but 
not linked to major histocompatibililty complex haplotype. J Exp Med 1996. 183: 1817-1827. 
[104] Shilling, H. G., Young, N., Guethlein, L. A., Cheng, N. W., Gardiner, C. M., Tyan, D. and 
Parham, P., Genetic control of human NK cell repertoire. J Immunol 2002. 169: 239-247. 
[105] Davies, G. E., Locke, S. M., Wright, P. W., Li, H., Hanson, R. J., Miller, J. S. and 
Anderson, S. K., Identification of bidirectional promoters in the human KIR genes. Genes 
Immun 2007. 8: 245-253. 
[106] Pascal, V., Stulberg, M. J. and Anderson, S. K., Regulation of class I major 
histocompatibility complex receptor expression in natural killer cells: one promoter is not 
enough! Immunol Rev 2006. 214: 9-21. 
[107] Winter, C. C. and Long, E. O., A single amino acid in the p58 killer cell inhibitory receptor 
controls the ability of natural killer cells to discriminate between the two groups of HLA-C 
allotypes. J Immunol 1997. 158: 4026-4028. 
[108] Moesta, A. K., Norman, P. J., Yawata, M., Yawata, N., Gleimer, M. and Parham, P.,
Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a 
stronger receptor for HLA-C than KIR2DL3. J Immunol 2008. 180: 3969-3979. 
[109] Winter, C. C., Gumperz, J. E., Parham, P., Long, E. O. and Wagtmann, N., Direct binding 
and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype 
recognition. J Immunol 1998. 161: 571-577. 
[110] Cella, M., Longo, A., Ferrara, G. B., Strominger, J. L. and Colonna, M., NK3-specific 
natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J
Exp Med 1994. 180: 1235-1242. 
  67 
[111] Gumperz, J. E., Litwin, V., Phillips, J. H., Lanier, L. L. and Parham, P., The Bw4 public 
epitope of HLA-B molecules confers reactivity with natural killer cell clones that express 
NKB1, a putative HLA receptor. J Exp Med 1995. 181: 1133-1144. 
[112] Wan, A. M., Ennis, P., Parham, P. and Holmes, N., The primary structure of HLA-A32 
suggests a region involved in formation of the Bw4/Bw6 epitopes. J Immunol 1986. 137: 3671-
3674. 
[113] Luque, I., Solana, R., Galiani, M. D., Gonzalez, R., Garcia, F., Lopez de Castro, J. A. and 
Pena, J., Threonine 80 on HLA-B27 confers protection against lysis by a group of natural killer 
clones. Eur J Immunol 1996. 26: 1974-1977. 
[114] Malnati, M. S., Peruzzi, M., Parker, K. C., Biddison, W. E., Ciccone, E., Moretta, A. and 
Long, E. O., Peptide specificity in the recognition of MHC class I by natural killer cell clones. 
Science 1995. 267: 1016-1018. 
[115] Thananchai, H., Gillespie, G., Martin, M. P., Bashirova, A., Yawata, N., Yawata, M., 
Easterbrook, P. et al., Cutting Edge: Allele-specific and peptide-dependent interactions 
between KIR3DL1 and HLA-A and HLA-B. J Immunol 2007. 178: 33-37. 
[116] Hansasuta, P., Dong, T., Thananchai, H., Weekes, M., Willberg, C., Aldemir, H., Rowland-
Jones, S. and Braud, V. M., Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-
specific. Eur J Immunol 2004. 34: 1673-1679. 
[117] Rajagopalan, S. and Long, E. O., A human histocompatibility leukocyte antigen (HLA)-G-
specific receptor expressed on all natural killer cells. J Exp Med 1999. 189: 1093-1100. 
[118] Gillespie, G. M., Bashirova, A., Dong, T., McVicar, D. W., Rowland-Jones, S. L. and 
Carrington, M., Lack of KIR3DS1 binding to MHC class I Bw4 tetramers in complex with 
CD8+ T cell epitopes. AIDS Res Hum Retroviruses 2007. 23: 451-455. 
[119] Stewart, C. A., Laugier-Anfossi, F., Vely, F., Saulquin, X., Riedmuller, J., Tisserant, A., 
Gauthier, L. et al., Recognition of peptide-MHC class I complexes by activating killer 
immunoglobulin-like receptors. Proc Natl Acad Sci U S A 2005. 102: 13224-13229. 
[120] Biassoni, R., Pessino, A., Malaspina, A., Cantoni, C., Bottino, C., Sivori, S., Moretta, L. 
and Moretta, A., Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 
receptors for HLA-Cw4 molecules. Eur J Immunol 1997. 27: 3095-3099. 
[121] Katz, G., Gazit, R., Arnon, T. I., Gonen-Gross, T., Tarcic, G., Markel, G., Gruda, R. et al.,
MHC class I-independent recognition of NK-activating receptor KIR2DS4. J Immunol 2004. 
173: 1819-1825. 
[122] Kulkarni, S., Martin, M. P. and Carrington, M., The Yin and Yang of HLA and KIR in 
human disease. Semin Immunol 2008. 20: 343-352. 
[123] Lazetic, S., Chang, C., Houchins, J. P., Lanier, L. L. and Phillips, J. H., Human natural 
killer cell receptors involved in MHC class I recognition are disulfide-linked heterodimers of 
CD94 and NKG2 subunits. J Immunol 1996. 157: 4741-4745. 
[124] Lee, N., Llano, M., Carretero, M., Ishitani, A., Navarro, F., Lopez-Botet, M. and 
Geraghty, D. E., HLA-E is a major ligand for the natural killer inhibitory receptor 
CD94/NKG2A. Proc Natl Acad Sci U S A 1998. 95: 5199-5204. 
[125] Braud, V. M., Allan, D. S., O'Callaghan, C. A., Soderstrom, K., D'Andrea, A., Ogg, G. S., 
Lazetic, S. et al., HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature
1998. 391: 795-799. 
[126] Vance, R. E., Kraft, J. R., Altman, J. D., Jensen, P. E. and Raulet, D. H., Mouse 
CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility 
complex (MHC) class I molecule Qa-1(b). J Exp Med 1998. 188: 1841-1848. 
[127] Vales-Gomez, M., Reyburn, H. T., Erskine, R. A., Lopez-Botet, M. and Strominger, J. L.,
Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A 
and the activating receptor CD94/NKG2-C to HLA-E. Embo J 1999. 18: 4250-4260. 
[128] Michaelsson, J., Teixeira de Matos, C., Achour, A., Lanier, L. L., Karre, K. and 
Soderstrom, K., A signal peptide derived from hsp60 binds HLA-E and interferes with 
CD94/NKG2A recognition. J Exp Med 2002. 196: 1403-1414. 
[129] Lanier, L. L., Corliss, B., Wu, J. and Phillips, J. H., Association of DAP12 with activating 
CD94/NKG2C NK cell receptors. Immunity 1998. 8: 693-701. 
[130] Guma, M., Angulo, A., Vilches, C., Gomez-Lozano, N., Malats, N. and Lopez-Botet, M.,
Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. Blood 2004. 
104: 3664-3671. 
[131] Koo, G. C., Dumont, F. J., Tutt, M., Hackett, J., Jr. and Kumar, V., The NK-1.1(-) mouse: a 
model to study differentiation of murine NK cells. J Immunol 1986. 137: 3742-3747. 
68
[132] Arase, N., Arase, H., Park, S. Y., Ohno, H., Ra, C. and Saito, T., Association with 
FcRgamma is essential for activation signal through NKR-P1 (CD161) in natural killer (NK) 
cells and NK1.1+ T cells. J Exp Med 1997. 186: 1957-1963. 
[133] Bennett, I. M., Zatsepina, O., Zamai, L., Azzoni, L., Mikheeva, T. and Perussia, B.,
Definition of a natural killer NKR-P1A+/CD56-/CD16- functionally immature human NK cell 
subset that differentiates in vitro in the presence of interleukin 12. J Exp Med 1996. 184: 1845-
1856. 
[134] Aldemir, H., Prod'homme, V., Dumaurier, M. J., Retiere, C., Poupon, G., Cazareth, J., 
Bihl, F. and Braud, V. M., Cutting Edge: Lectin-Like Transcript 1 Is a Ligand for the CD161 
Receptor. J Immunol 2005. 175: 7791-7795. 
[135] Rosen, D. B., Bettadapura, J., Alsharifi, M., Mathew, P. A., Warren, H. S. and Lanier, L. 
L., Cutting Edge: Lectin-Like Transcript-1 Is a Ligand for the Inhibitory Human NKR-P1A 
Receptor. J Immunol 2005. 175: 7796-7799. 
[136] Cosman, D., Fanger, N., Borges, L., Kubin, M., Chin, W., Peterson, L. and Hsu, M. L., A 
novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. 
Immunity 1997. 7: 273-282. 
[137] Chapman, T. L., Heikeman, A. P. and Bjorkman, P. J., The inhibitory receptor LIR-1 uses a 
common binding interaction to recognize class I MHC molecules and the viral homolog UL18. 
Immunity 1999. 11: 603-613. 
[138] Berg, L., Riise, G. C., Cosman, D., Bergstrom, T., Olofsson, S., Karre, K. and Carbone, E.,
LIR-1 expression on lymphocytes, and cytomegalovirus disease in lung-transplant recipients. 
Lancet 2003. 361: 1099-1101. 
[139] Prod'homme, V., Griffin, C., Aicheler, R. J., Wang, E. C., McSharry, B. P., Rickards, C. 
R., Stanton, R. J. et al., The human cytomegalovirus MHC class I homolog UL18 inhibits LIR-
1+ but activates LIR-1- NK cells. J Immunol 2007. 178: 4473-4481. 
[140] Ito, M., Maruyama, T., Saito, N., Koganei, S., Yamamoto, K. and Matsumoto, N., Killer 
cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK 
cell cytotoxicity. J Exp Med 2006. 203: 289-295. 
[141] Grundemann, C., Bauer, M., Schweier, O., von Oppen, N., Lassing, U., Saudan, P., 
Becker, K. F. et al., Cutting edge: identification of E-cadherin as a ligand for the murine killer 
cell lectin-like receptor G1. J Immunol 2006. 176: 1311-1315. 
[142] Huntington, N. D., Tabarias, H., Fairfax, K., Brady, J., Hayakawa, Y., Degli-Esposti, M. 
A., Smyth, M. J. et al., NK cell maturation and peripheral homeostasis is associated with 
KLRG1 up-regulation. J Immunol 2007. 178: 4764-4770. 
[143] Robbins, S. H., Tessmer, M. S., Mikayama, T. and Brossay, L., Expansion and contraction 
of the NK cell compartment in response to murine cytomegalovirus infection. J Immunol 2004. 
173: 259-266. 
[144] Takai, T., Li, M., Sylvestre, D., Clynes, R. and Ravetch, J. V., FcR gamma chain deletion 
results in pleiotrophic effector cell defects. Cell 1994. 76: 519-529. 
[145] Perussia, B., Acuto, O., Terhorst, C., Faust, J., Lazarus, R., Fanning, V. and Trinchieri, 
G., Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor 
functions. II. Studies of B73.1 antibody-antigen interaction on the lymphocyte membrane. J
Immunol 1983. 130: 2142-2148. 
[146] Hibbs, M. L., Selvaraj, P., Carpen, O., Springer, T. A., Kuster, H., Jouvin, M. H. and 
Kinet, J. P., Mechanisms for regulating expression of membrane isoforms of Fc gamma RIII 
(CD16). Science 1989. 246: 1608-1611. 
[147] Kurosaki, T. and Ravetch, J. V., A single amino acid in the glycosyl phosphatidylinositol 
attachment domain determines the membrane topology of Fc gamma RIII. Nature 1989. 342:
805-807. 
[148] Lanier, L. L., Yu, G. and Phillips, J. H., Co-association of CD3 zeta with a receptor (CD16) 
for IgG Fc on human natural killer cells. Nature 1989. 342: 803-805. 
[149] Warren, H. S. and Kinnear, B. F., Quantitative analysis of the effect of CD16 ligation on 
human NK cell proliferation. J Immunol 1999. 162: 735-742. 
[150] Anegon, I., Cuturi, M. C., Trinchieri, G. and Perussia, B., Interaction of Fc receptor (CD16) 
ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and 
expression of their products in human natural killer cells. J Exp Med 1988. 167: 452-472. 
[151] Bryceson, Y. T., March, M. E., Ljunggren, H. G. and Long, E. O., Activation, coactivation, 
and costimulation of resting human natural killer cells. Immunol Rev 2006. 214: 73-91. 
  69 
[152] Vance, B. A., Huizinga, T. W., Wardwell, K. and Guyre, P. M., Binding of monomeric 
human IgG defines an expression polymorphism of Fc gamma RIII on large granular 
lymphocyte/natural killer cells. J Immunol 1993. 151: 6429-6439. 
[153] Koene, H. R., Kleijer, M., Algra, J., Roos, D., von dem Borne, A. E. and de Haas, M., Fc 
gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc 
gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997. 90: 1109-
1114. 
[154] Wu, J., Edberg, J. C., Redecha, P. B., Bansal, V., Guyre, P. M., Coleman, K., Salmon, J. E. 
and Kimberly, R. P., A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function 
and predisposes to autoimmune disease. J Clin Invest 1997. 100: 1059-1070. 
[155] Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P. and 
Watier, H., Therapeutic activity of humanized anti-CD20 monoclonal antibody and 
polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002. 99: 754-758. 
[156] Hatjiharissi, E., Xu, L., Santos, D. D., Hunter, Z. R., Ciccarelli, B. T., Verselis, S., Modica, 
M. et al., Increased natural killer cell expression of CD16, augmented binding and ADCC 
activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F 
polymorphism. Blood 2007. 110: 2561-2564. 
[157] Pende, D., Parolini, S., Pessino, A., Sivori, S., Augugliaro, R., Morelli, L., Marcenaro, E. et 
al., Identification and molecular characterization of NKp30, a novel triggering receptor involved 
in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999. 190: 1505-1516. 
[158] Sivori, S., Vitale, M., Morelli, L., Sanseverino, L., Augugliaro, R., Bottino, C., Moretta, L. 
and Moretta, A., p46, a novel natural killer cell-specific surface molecule that mediates cell 
activation. J Exp Med 1997. 186: 1129-1136. 
[159] Vitale, M., Bottino, C., Sivori, S., Sanseverino, L., Castriconi, R., Marcenaro, E., 
Augugliaro, R. et al., NKp44, a novel triggering surface molecule specifically expressed by 
activated natural killer cells, is involved in non-major histocompatibility complex-restricted 
tumor cell lysis. J Exp Med 1998. 187: 2065-2072. 
[160] Arnon, T. I., Lev, M., Katz, G., Chernobrov, Y., Porgador, A. and Mandelboim, O.,
Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 2001. 31:
2680-2689. 
[161] Hecht, M. L., Rosental, B., Horlacher, T., Hershkovitz, O., De Paz, J. L., Noti, C., Schauer, 
S. et al., Natural cytotoxicity receptors NKp30, NKp44 and NKp46 bind to different heparan 
sulfate/heparin sequences. J Proteome Res 2009. 8: 712-720. 
[162] Bloushtain, N., Qimron, U., Bar-Ilan, A., Hershkovitz, O., Gazit, R., Fima, E., Korc, M. et 
al., Membrane-associated heparan sulfate proteoglycans are involved in the recognition of 
cellular targets by NKp30 and NKp46. J Immunol 2004. 173: 2392-2401. 
[163] Ferlazzo, G., Tsang, M. L., Moretta, L., Melioli, G., Steinman, R. M. and Munz, C., Human 
dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 
receptor by activated NK cells. J Exp Med 2002. 195: 343-351. 
[164] Pogge von Strandmann, E., Simhadri, V. R., von Tresckow, B., Sasse, S., Reiners, K. S., 
Hansen, H. P., Rothe, A. et al., Human leukocyte antigen-B-associated transcript 3 is released 
from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity 2007. 27:
965-974. 
[165] Arnon, T. I., Achdout, H., Levi, O., Markel, G., Saleh, N., Katz, G., Gazit, R. et al.,
Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol
2005. 6: 515-523. 
[166] Vieillard, V., Strominger, J. L. and Debre, P., NK cytotoxicity against CD4+ T cells during 
HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc Natl Acad Sci 
U S A 2005. 102: 10981-10986. 
[167] Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L. and Spies, T.,
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science
1999. 285: 727-729. 
[168] Cosman, D., Mullberg, J., Sutherland, C. L., Chin, W., Armitage, R., Fanslow, W., Kubin, 
M. and Chalupny, N. J., ULBPs, novel MHC class I-related molecules, bind to CMV 
glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity
2001. 14: 123-133. 
[169] Jan Chalupny, N., Sutherland, C. L., Lawrence, W. A., Rein-Weston, A. and Cosman, D.,
ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun 2003. 305: 129-
135. 
70
[170] Cerwenka, A., Bakker, A. B., McClanahan, T., Wagner, J., Wu, J., Phillips, J. H. and 
Lanier, L. L., Retinoic acid early inducible genes define a ligand family for the activating 
NKG2D receptor in mice. Immunity 2000. 12: 721-727. 
[171] Diefenbach, A., Jamieson, A. M., Liu, S. D., Shastri, N. and Raulet, D. H., Ligands for the 
murine NKG2D receptor: expression by tumor cells and activation of NK cells and 
macrophages. Nat Immunol 2000. 1: 119-126. 
[172] Carayannopoulos, L. N., Naidenko, O. V., Fremont, D. H. and Yokoyama, W. M., Cutting 
edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a 
high-affinity ligand for murine NKG2D. J Immunol 2002. 169: 4079-4083. 
[173] Gonzalez, S., Lopez-Soto, A., Suarez-Alvarez, B., Lopez-Vazquez, A. and Lopez-Larrea, 
C., NKG2D ligands: key targets of the immune response. Trends Immunol 2008. 29: 397-403. 
[174] Wu, J., Song, Y., Bakker, A. B., Bauer, S., Spies, T., Lanier, L. L. and Phillips, J. H., An 
activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999. 285: 730-
732. 
[175] Jonjic, S., Polic, B. and Krmpotic, A., Viral inhibitors of NKG2D ligands: friends or foes of 
immune surveillance? Eur J Immunol 2008. 38: 2952-2956. 
[176] Cerboni, C., Neri, F., Casartelli, N., Zingoni, A., Cosman, D., Rossi, P., Santoni, A. and 
Doria, M., Human immunodeficiency virus 1 Nef protein downmodulates the ligands of the 
activating receptor NKG2D and inhibits natural killer cell-mediated cytotoxicity. J Gen Virol
2007. 88: 242-250. 
[177] Shibuya, A., Campbell, D., Hannum, C., Yssel, H., Franz-Bacon, K., McClanahan, T., 
Kitamura, T. et al., DNAM-1, a novel adhesion molecule involved in the cytolytic function of 
T lymphocytes. Immunity 1996. 4: 573-581. 
[178] Bottino, C., Castriconi, R., Pende, D., Rivera, P., Nanni, M., Carnemolla, B., Cantoni, C. et 
al., Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human 
DNAM-1 (CD226) activating molecule. J Exp Med 2003. 198: 557-567. 
[179] Mavilio, D., Lombardo, G., Kinter, A., Fogli, M., La Sala, A., Ortolano, S., Farschi, A. et 
al., Characterization of the defective interaction between a subset of natural killer cells and 
dendritic cells in HIV-1 infection. J Exp Med 2006. 203: 2339-2350. 
[180] Seth, S., Georgoudaki, A. M., Chambers, B. J., Qiu, Q., Kremmer, E., Maier, M. K., 
Czeloth, N. et al., Heterogeneous expression of the adhesion receptor CD226 on murine NK 
and T cells and its function in NK-mediated killing of immature dendritic cells. J Leukoc Biol
2009. 86: 91-101. 
[181] Shibuya, K., Lanier, L. L., Phillips, J. H., Ochs, H. D., Shimizu, K., Nakayama, E., 
Nakauchi, H. and Shibuya, A., Physical and functional association of LFA-1 with DNAM-1 
adhesion molecule. Immunity 1999. 11: 615-623. 
[182] Tomasec, P., Wang, E. C., Davison, A. J., Vojtesek, B., Armstrong, M., Griffin, C., 
McSharry, B. P. et al., Downregulation of natural killer cell-activating ligand CD155 by human 
cytomegalovirus UL141. Nat Immunol 2005. 6: 181-188. 
[183] Andoniou, C. E., Coudert, J. D. and Degli-Esposti, M. A., Killers and beyond: NK-cell-
mediated control of immune responses. Eur J Immunol 2008. 38: 2938-2942. 
[184] Moretta, L., Ferlazzo, G., Bottino, C., Vitale, M., Pende, D., Mingari, M. C. and Moretta, 
A., Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev
2006. 214: 219-228. 
[185] Carbone, E., Terrazzano, G., Ruggiero, G., Zanzi, D., Ottaiano, A., Manzo, C., Karre, K. 
and Zappacosta, S., Recognition of autologous dendritic cells by human NK cells. Eur J 
Immunol 1999. 29: 4022-4029. 
[186] Wilson, J. L., Heffler, L. C., Charo, J., Scheynius, A., Bejarano, M. T. and Ljunggren, H. 
G., Targeting of human dendritic cells by autologous NK cells. J Immunol 1999. 163: 6365-
6370. 
[187] Hayakawa, Y., Screpanti, V., Yagita, H., Grandien, A., Ljunggren, H. G., Smyth, M. J. 
and Chambers, B. J., NK cell TRAIL eliminates immature dendritic cells in vivo and limits 
dendritic cell vaccination efficacy. J Immunol 2004. 172: 123-129. 
[188] Vitale, M., Della Chiesa, M., Carlomagno, S., Pende, D., Arico, M., Moretta, L. and 
Moretta, A., NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released 
upon engagement of the NKp30 triggering receptor. Blood 2005. 106: 566-571. 
[189] Lee, S. H., Miyagi, T. and Biron, C. A., Keeping NK cells in highly regulated antiviral 
warfare. Trends Immunol 2007. 28: 252-259. 
[190] Lanier, L. L., Evolutionary struggles between NK cells and viruses. Nat Rev Immunol 2008. 8:
259-268. 
  71 
[191] Salazar-Mather, T. P., Lewis, C. A. and Biron, C. A., Type I interferons regulate 
inflammatory cell trafficking and macrophage inflammatory protein 1alpha delivery to the liver. 
J Clin Invest 2002. 110: 321-330. 
[192] Salazar-Mather, T. P., Orange, J. S. and Biron, C. A., Early murine cytomegalovirus 
(MCMV) infection induces liver natural killer (NK) cell inflammation and protection through 
macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways. J Exp Med 1998. 
187: 1-14. 
[193] Daniels, K. A., Devora, G., Lai, W. C., O'Donnell, C. L., Bennett, M. and Welsh, R. M.,
Murine cytomegalovirus is regulated by a discrete subset of natural killer cells reactive with 
monoclonal antibody to Ly49H. J Exp Med 2001. 194: 29-44. 
[194] Dokun, A. O., Kim, S., Smith, H. R., Kang, H. S., Chu, D. T. and Yokoyama, W. M.,
Specific and nonspecific NK cell activation during virus infection. Nat Immunol 2001. 2: 951-
956. 
[195] Loh, J., Chu, D. T., O'Guin, A. K., Yokoyama, W. M. and Virgin, H. W. t., Natural killer 
cells utilize both perforin and gamma interferon to regulate murine cytomegalovirus infection in 
the spleen and liver. J Virol 2005. 79: 661-667. 
[196] Sun, J. C., Beilke, J. N. and Lanier, L. L., Adaptive immune features of natural killer cells. 
Nature 2009. 457: 557-561. 
[197] Cooper, M. A., Elliott, J. M., Keyel, P. A., Yang, L., Carrero, J. A. and Yokoyama, W. M.,
Cytokine-induced memory-like natural killer cells. Proc Natl Acad Sci U S A 2009. 106: 1915-
1919. 
[198] O'Leary, J. G., Goodarzi, M., Drayton, D. L. and von Andrian, U. H., T cell- and B cell-
independent adaptive immunity mediated by natural killer cells. Nat Immunol 2006. 7: 507-516. 
[199] Orange, J. S., Human natural killer cell deficiencies. Curr Opin Allergy Clin Immunol 2006. 6:
399-409. 
[200] Gascoyne, D. M., Long, E., Veiga-Fernandes, H., de Boer, J., Williams, O., Seddon, B., 
Coles, M. et al., The basic leucine zipper transcription factor E4BP4 is essential for natural 
killer cell development. Nat Immunol 2009. 10: 1118-1124. 
[201] Cohen, G. B., Gandhi, R. T., Davis, D. M., Mandelboim, O., Chen, B. K., Strominger, J. L. 
and Baltimore, D., The selective downregulation of class I major histocompatibility complex 
proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999. 10: 661-671. 
[202] Gottlieb, M. S., Schroff, R., Schanker, H. M., Weisman, J. D., Fan, P. T., Wolf, R. A. and 
Saxon, A., Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy 
homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981. 
305: 1425-1431. 
[203] Siegal, F. P., Lopez, C., Hammer, G. S., Brown, A. E., Kornfeld, S. J., Gold, J., Hassett, J.
et al., Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal 
ulcerative herpes simplex lesions. N Engl J Med 1981. 305: 1439-1444. 
[204] Barre-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., Gruest, J., 
Dauguet, C. et al., Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired 
immune deficiency syndrome (AIDS). Science 1983. 220: 868-871. 
[205] Popovic, M., Sarngadharan, M. G., Read, E. and Gallo, R. C., Detection, isolation, and 
continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-
AIDS. Science 1984. 224: 497-500. 
[206] WHO/UNAIDS, AIDS epidemic update 2009. UNAIDS/09.36E/JC1700E 2009. 
[207] Freed, A. D. and Martin, M. A., HIVs and their replication, 4 Edn. Lippincott Williams & 
Wilkins, Philadelphia: 2001. 
[208] Gao, F., Bailes, E., Robertson, D. L., Chen, Y., Rodenburg, C. M., Michael, S. F., 
Cummins, L. B. et al., Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature
1999. 397: 436-441. 
[209] Hirsch, V. M., Olmsted, R. A., Murphey-Corb, M., Purcell, R. H. and Johnson, P. R., An 
African primate lentivirus (SIVsm) closely related to HIV-2. Nature 1989. 339: 389-392. 
[210] Worobey, M., Gemmel, M., Teuwen, D. E., Haselkorn, T., Kunstman, K., Bunce, M., 
Muyembe, J. J. et al., Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. 
Nature 2008. 455: 661-664. 
[211] Zhu, T., Korber, B. T., Nahmias, A. J., Hooper, E., Sharp, P. M. and Ho, D. D., An African 
HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature 1998. 391:
594-597. 
72
[212] Boily, M. C., Baggaley, R. F., Wang, L., Masse, B., White, R. G., Hayes, R. J. and Alary, 
M., Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of 
observational studies. Lancet Infect Dis 2009. 9: 118-129. 
[213] de Jong, M. A. and Geijtenbeek, T. B., Human immunodeficiency virus-1 acquisition in 
genital mucosa: Langerhans cells as key-players. J Intern Med 2009. 265: 18-28. 
[214] Geijtenbeek, T. B., Kwon, D. S., Torensma, R., van Vliet, S. J., van Duijnhoven, G. C., 
Middel, J., Cornelissen, I. L. et al., DC-SIGN, a dendritic cell-specific HIV-1-binding protein 
that enhances trans-infection of T cells. Cell 2000. 100: 587-597. 
[215] Guadalupe, M., Reay, E., Sankaran, S., Prindiville, T., Flamm, J., McNeil, A. and 
Dandekar, S., Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human 
immunodeficiency virus type 1 infection and substantial delay in restoration following highly 
active antiretroviral therapy. J Virol 2003. 77: 11708-11717. 
[216] Mellors, J. W., Rinaldo, C. R., Jr., Gupta, P., White, R. M., Todd, J. A. and Kingsley, L. 
A., Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996. 
272: 1167-1170. 
[217] Brenchley, J. M., Price, D. A., Schacker, T. W., Asher, T. E., Silvestri, G., Rao, S., Kazzaz, 
Z. et al., Microbial translocation is a cause of systemic immune activation in chronic HIV 
infection. Nat Med 2006. 12: 1365-1371. 
[218] Berger, E. A., Murphy, P. M. and Farber, J. M., Chemokine receptors as HIV-1 coreceptors: 
roles in viral entry, tropism, and disease. Annu Rev Immunol 1999. 17: 657-700. 
[219] Roux, K. H. and Taylor, K. A., AIDS virus envelope spike structure. Curr Opin Struct Biol
2007. 17: 244-252. 
[220] Sierra, S., Kupfer, B. and Kaiser, R., Basics of the virology of HIV-1 and its replication. J
Clin Virol 2005. 34: 233-244. 
[221] Schroder, A. R., Shinn, P., Chen, H., Berry, C., Ecker, J. R. and Bushman, F., HIV-1 
integration in the human genome favors active genes and local hotspots. Cell 2002. 110: 521-
529. 
[222] Williams, S. A. and Greene, W. C., Regulation of HIV-1 latency by T-cell activation. Cytokine
2007. 39: 63-74. 
[223] Frankel, A. D. and Young, J. A., HIV-1: fifteen proteins and an RNA. Annu Rev Biochem
1998. 67: 1-25. 
[224] Jolly, C., Kashefi, K., Hollinshead, M. and Sattentau, Q. J., HIV-1 cell to cell transfer across 
an Env-induced, actin-dependent synapse. J Exp Med 2004. 199: 283-293. 
[225] Pantophlet, R. and Burton, D. R., GP120: target for neutralizing HIV-1 antibodies. Annu Rev 
Immunol 2006. 24: 739-769. 
[226] Huang, C. C., Tang, M., Zhang, M. Y., Majeed, S., Montabana, E., Stanfield, R. L., 
Dimitrov, D. S. et al., Structure of a V3-containing HIV-1 gp120 core. Science 2005. 310:
1025-1028. 
[227] Hartley, O., Klasse, P. J., Sattentau, Q. J. and Moore, J. P., V3: HIV's switch-hitter. AIDS 
Res Hum Retroviruses 2005. 21: 171-189. 
[228] Perno, C. F., Moyle, G., Tsoukas, C., Ratanasuwan, W., Gatell, J. and Schechter, M.,
Overcoming resistance to existing therapies in HIV-infected patients: the role of new 
antiretroviral drugs. J Med Virol 2008. 80: 565-576. 
[229] Siliciano, J. D., Kajdas, J., Finzi, D., Quinn, T. C., Chadwick, K., Margolick, J. B., Kovacs, 
C. et al., Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in 
resting CD4+ T cells. Nat Med 2003. 9: 727-728. 
[230] Richman, D. D., Margolis, D. M., Delaney, M., Greene, W. C., Hazuda, D. and Pomerantz, 
R. J., The challenge of finding a cure for HIV infection. Science 2009. 323: 1304-1307. 
[231] WHO/UNAIDS, 2008 UNAIDS annual report, towards universal access. UNAIDS/09.25E/ 
JC1736E 2008. 
[232] Foss, A. M., Watts, C. H., Vickerman, P. and Heise, L., Condoms and prevention of HIV. 
Bmj 2004. 329: 185-186. 
[233] Doyle, S. M., Kahn, J. G., Hosang, N. and Carroll, P. R., The Impact of Male Circumcision 
on HIV Transmission. J Urol 2009. 
[234] Patterson, B. K., Landay, A., Siegel, J. N., Flener, Z., Pessis, D., Chaviano, A. and Bailey, 
R. C., Susceptibility to human immunodeficiency virus-1 infection of human foreskin and 
cervical tissue grown in explant culture. Am J Pathol 2002. 161: 867-873. 
[235] Lederman, M. M., Veazey, R. S., Offord, R., Mosier, D. E., Dufour, J., Mefford, M., 
Piatak, M., Jr. et al., Prevention of vaginal SHIV transmission in rhesus macaques through 
inhibition of CCR5. Science 2004. 306: 485-487. 
  73 
[236] Paintsil, E. and Andiman, W. A., Update on successes and challenges regarding mother-to-
child transmission of HIV. Curr Opin Pediatr 2009. 21: 94-101. 
[237] Rutjens, E., Balla-Jhagjhoorsingh, S., Verschoor, E., Bogers, W., Koopman, G. and 
Heeney, J., Lentivirus infections and mechanisms of disease resistance in chimpanzees. Front 
Biosci 2003. 8: d1134-1145. 
[238] Gardner, M. B., SIV infection of macaques: a model for AIDS vaccine development. Dev Biol 
Stand 1990. 72: 259-266. 
[239] Li, J., Lord, C. I., Haseltine, W., Letvin, N. L. and Sodroski, J., Infection of cynomolgus 
monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope 
glycoproteins. J Acquir Immune Defic Syndr 1992. 5: 639-646. 
[240] Liovat, A. S., Jacquelin, B., Ploquin, M. J., Barre-Sinoussi, F. and Muller-Trutwin, M. C.,
African non human primates infected by SIV - why don't they get sick? Lessons from studies on 
the early phase of non-pathogenic SIV infection. Curr HIV Res 2009. 7: 39-50. 
[241] Bieniasz, P. D., Grdina, T. A., Bogerd, H. P. and Cullen, B. R., Recruitment of a protein 
complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. 
Embo J 1998. 17: 7056-7065. 
[242] Goff, S. P., Retrovirus restriction factors. Mol Cell 2004. 16: 849-859. 
[243] Boberg, A., Brave, A., Johansson, S., Wahren, B., Hinkula, J. and Rollman, E., Murine 
models for HIV vaccination and challenge. Expert Rev Vaccines 2008. 7: 117-130. 
[244] Bonyhadi, M. L. and Kaneshima, H., The SCID-hu mouse: an in vivo model for HIV-1 
infection in humans. Mol Med Today 1997. 3: 246-253. 
[245] Baenziger, S., Tussiwand, R., Schlaepfer, E., Mazzucchelli, L., Heikenwalder, M., Kurrer, 
M. O., Behnke, S. et al., Disseminated and sustained HIV infection in CD34+ cord blood cell-
transplanted Rag2-/-gamma c-/- mice. Proc Natl Acad Sci U S A 2006. 103: 15951-15956. 
[246] Traggiai, E., Chicha, L., Mazzucchelli, L., Bronz, L., Piffaretti, J. C., Lanzavecchia, A. and 
Manz, M. G., Development of a human adaptive immune system in cord blood cell-
transplanted mice. Science 2004. 304: 104-107. 
[247] Kavanaugh, M. P., Miller, D. G., Zhang, W., Law, W., Kozak, S. L., Kabat, D. and Miller, 
A. D., Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus 
are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci U S A 1994. 91:
7071-7075. 
[248] Hartley, J. W. and Rowe, W. P., Naturally occurring murine leukemia viruses in wild mice: 
characterization of a new "amphotropic" class. J Virol 1976. 19: 19-25. 
[249] Rasheed, S., Gardner, M. B. and Chan, E., Amphotropic host range of naturally occuring 
wild mouse leukemia viruses. J Virol 1976. 19: 13-18. 
[250] Spector, D. H., Wade, E., Wright, D. A., Koval, V., Clark, C., Jaquish, D. and Spector, S. 
A., Human immunodeficiency virus pseudotypes with expanded cellular and species tropism. J
Virol 1990. 64: 2298-2308. 
[251] Andang, M., Hinkula, J., Hotchkiss, G., Larsson, S., Britton, S., Wong-Staal, F., Wahren, 
B. and Ahrlund-Richter, L., Dose-response resistance to HIV-1/MuLV pseudotype virus ex 
vivo in a hairpin ribozyme transgenic mouse model. Proc Natl Acad Sci U S A 1999. 96: 12749-
12753. 
[252] Hinkula, J., Rollman, E., Lundholm, P., Benthin, R., Okuda, K. and Wahren, B., Genetic 
immunization with multiple HIV-1 genes provides protection against HIV-1/MuLV pseudovirus 
challenge in vivo. Cells Tissues Organs 2004. 177: 169-184. 
[253] Potash, M. J., Chao, W., Bentsman, G., Paris, N., Saini, M., Nitkiewicz, J., Belem, P. et al.,
A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and 
neuroinvasiveness. Proc Natl Acad Sci U S A 2005. 102: 3760-3765. 
[254] Rollman, E., Mathy, N., Brave, A., Boberg, A., Kjerrstrom, A., van Wely, C., Engstrom, G.
et al., Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein 
vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype 
challenge model. Vaccine 2007. 25: 2145-2154. 
[255] Buchbinder, S. P., Katz, M. H., Hessol, N. A., O'Malley, P. M. and Holmberg, S. D., Long-
term HIV-1 infection without immunologic progression. Aids 1994. 8: 1123-1128. 
[256] Okulicz, J. F., Marconi, V. C., Landrum, M. L., Wegner, S., Weintrob, A., Ganesan, A., 
Hale, B. et al., Clinical outcomes of elite controllers, viremic controllers, and long-term 
nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 2009. 
200: 1714-1723. 
[257] Miyazawa, M., Lopalco, L., Mazzotta, F., Lo Caputo, S., Veas, F. and Clerici, M., The 
'immunologic advantage' of HIV-exposed seronegative individuals. Aids 2009. 23: 161-175. 
74
[258] Devito, C., Hinkula, J., Kaul, R., Lopalco, L., Bwayo, J. J., Plummer, F., Clerici, M. and 
Broliden, K., Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a 
primary HIV-1 isolate. Aids 2000. 14: 1917-1920. 
[259] Rowland-Jones, S. L., Nixon, D. F., Aldhous, M. C., Gotch, F., Ariyoshi, K., Hallam, N., 
Kroll, J. S. et al., HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected 
infant. Lancet 1993. 341: 860-861. 
[260] Scott-Algara, D., Truong, L. X., Versmisse, P., David, A., Luong, T. T., Nguyen, N. V., 
Theodorou, I. et al., Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected 
Vietnamese intravascular drug users. J Immunol 2003. 171: 5663-5667. 
[261] Blankson, J. N., Effector mechanisms in HIV-1 infected elite controllers: Highly active 
immune responses? Antiviral Res 2009. 
[262] Bochud, P. Y., Hersberger, M., Taffe, P., Bochud, M., Stein, C. M., Rodrigues, S. D., 
Calandra, T. et al., Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-
1 infection. Aids 2007. 21: 441-446. 
[263] Soumelis, V., Scott, I., Gheyas, F., Bouhour, D., Cozon, G., Cotte, L., Huang, L. et al.,
Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS 
patients. Blood 2001. 98: 906-912. 
[264] Montoya, C. J., Velilla, P. A., Chougnet, C., Landay, A. L. and Rugeles, M. T., Increased 
IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but 
uninfected individuals. Clin Immunol 2006. 120: 138-146. 
[265] Piacentini, L., Biasin, M., Fenizia, C. and Clerici, M., Genetic correlates of protection against 
HIV infection: the ally within. J Intern Med 2009. 265: 110-124. 
[266] Ravet, S., Scott-Algara, D., Bonnet, E., Tran, H. K., Tran, T., Nguyen, N., Truong, L. X. et 
al., Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in 
HIV-exposed uninfected individuals. Blood 2007. 109: 4296-4305. 
[267] Alter, G., Teigen, N., Ahern, R., Streeck, H., Meier, A., Rosenberg, E. S. and Altfeld, M.,
Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect 
Dis 2007. 195: 1452-1460. 
[268] Alter, G., Teigen, N., Davis, B. T., Addo, M. M., Suscovich, T. J., Waring, M. T., Streeck, 
H. et al., Sequential deregulation of NK cell subset distribution and function starting in acute 
HIV-1 infection. Blood 2005. 106: 3366-3369. 
[269] Titanji, K., Sammicheli, S., De Milito, A., Mantegani, P., Fortis, C., Berg, L., Karre, K. et 
al., Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in 
primary and chronic human immunodeficiency virus-1 infection. Immunology 2008. 123: 164-
170. 
[270] Giavedoni, L. D., Velasquillo, M. C., Parodi, L. M., Hubbard, G. B. and Hodara, V. L.,
Cytokine expression, natural killer cell activation, and phenotypic changes in lymphoid cells 
from rhesus macaques during acute infection with pathogenic simian immunodeficiency virus. J
Virol 2000. 74: 1648-1657. 
[271] LaBonte, M. L., McKay, P. F. and Letvin, N. L., Evidence of NK cell dysfunction in SIV-
infected rhesus monkeys: impairment of cytokine secretion and NKG2C/C2 expression. Eur J 
Immunol 2006. 36: 2424-2433. 
[272] Nuvor, S. V., van der Sande, M., Rowland-Jones, S., Whittle, H. and Jaye, A., Natural killer 
cell function is well preserved in asymptomatic human immunodeficiency virus type 2 (HIV-2) 
infection but similar to that of HIV-1 infection when CD4 T-cell counts fall. J Virol 2006. 80:
2529-2538. 
[273] Barker, E., Martinson, J., Brooks, C., Landay, A. and Deeks, S., Dysfunctional natural killer 
cells, in vivo, are governed by HIV viremia regardless of whether the infected individual is on 
antiretroviral therapy. Aids 2007. 21: 2363-2365. 
[274] O'Connor, G. M., Holmes, A., Mulcahy, F. and Gardiner, C. M., Natural Killer cells from 
long-term non-progressor HIV patients are characterized by altered phenotype and function. 
Clin Immunol 2007. 124: 277-283. 
[275] Bandyopadhyay, S., Ziegner, U., Campbell, D. E., Miller, D. S., Hoxie, J. A. and Starr, S. 
E., Natural killer cell-mediated lysis of T cell lines chronically infected with HIV-1. Clin Exp 
Immunol 1990. 79: 430-435. 
[276] Bonaparte, M. I. and Barker, E., Inability of natural killer cells to destroy autologous HIV-
infected T lymphocytes. Aids 2003. 17: 487-494. 
[277] Tomescu, C., Chehimi, J., Maino, V. C. and Montaner, L. J., NK cell lysis of HIV-1-
infected autologous CD4 primary T cells: requirement for IFN-mediated NK activation by 
plasmacytoid dendritic cells. J Immunol 2007. 179: 2097-2104. 
  75 
[278] Fogli, M., Mavilio, D., Brunetta, E., Varchetta, S., Ata, K., Roby, G., Kovacs, C. et al.,
Lysis of endogenously infected CD4+ T cell blasts by rIL-2 activated autologous natural killer 
cells from HIV-infected viremic individuals. PLoS Pathog 2008. 4: e1000101. 
[279] Alter, G., Martin, M. P., Teigen, N., Carr, W. H., Suscovich, T. J., Schneidewind, A., 
Streeck, H. et al., Differential natural killer cell-mediated inhibition of HIV-1 replication based 
on distinct KIR/HLA subtypes. J Exp Med 2007. 204: 3027-3036. 
[280] Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C. and Lusso, P.,
Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors 
produced by CD8+ T cells. Science 1995. 270: 1811-1815. 
[281] Ward, J. P., Bonaparte, M. I. and Barker, E., HLA-C and HLA-E reduce antibody-dependent 
natural killer cell-mediated cytotoxicity of HIV-infected primary T cell blasts. Aids 2004. 18:
1769-1779. 
[282] Emini, E. A., Schleif, W. A., Nunberg, J. H., Conley, A. J., Eda, Y., Tokiyoshi, S., Putney, 
S. D. et al., Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific 
monoclonal antibody. Nature 1992. 355: 728-730. 
[283] Mascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, D., Louder, 
M. K. et al., Protection of Macaques against pathogenic simian/human immunodeficiency virus 
89.6PD by passive transfer of neutralizing antibodies. J Virol 1999. 73: 4009-4018. 
[284] Ferrantelli, F., Rasmussen, R. A., Buckley, K. A., Li, P. L., Wang, T., Montefiori, D. C., 
Katinger, H. et al., Complete protection of neonatal rhesus macaques against oral exposure to 
pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. 
J Infect Dis 2004. 189: 2167-2173. 
[285] Conley, A. J., Kessler, J. A., II, Boots, L. J., McKenna, P. M., Schleif, W. A., Emini, E. A., 
Mark, G. E., III et al., The consequence of passive administration of an anti-human 
immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of 
chimpanzees with a primary virus isolate. J Virol 1996. 70: 6751-6758. 
[286] Yamamoto, H., Kawada, M., Takeda, A., Igarashi, H. and Matano, T., Post-infection 
immunodeficiency virus control by neutralizing antibodies. PLoS One 2007. 2: e540. 
[287] Miller, C. J., Genesca, M., Abel, K., Montefiori, D., Forthal, D., Bost, K., Li, J. et al.,
Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J
Virol 2007. 81: 5024-5035. 
[288] Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E., Beurskens, F. J., Bakker, J. 
M., Lanigan, C. M. et al., Fc receptor but not complement binding is important in antibody 
protection against HIV. Nature 2007. 449: 101-104. 
[289] Hessell, A. J., Poignard, P., Hunter, M., Hangartner, L., Tehrani, D. M., Bleeker, W. K., 
Parren, P. W. et al., Effective, low-titer antibody protection against low-dose repeated mucosal 
SHIV challenge in macaques. Nat Med 2009. 15: 951-954. 
[290] Forthal, D. N., Landucci, G., Cole, K. S., Marthas, M., Becerra, J. C. and Van Rompay, 
K., Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency 
virus in the presence of human or autologous rhesus effector cells. J Virol 2006. 80: 9217-9225. 
[291] Van Rompay, K. K., Berardi, C. J., Dillard-Telm, S., Tarara, R. P., Canfield, D. R., 
Valverde, C. R., Montefiori, D. C. et al., Passive immunization of newborn rhesus macaques 
prevents oral simian immunodeficiency virus infection. J Infect Dis 1998. 177: 1247-1259. 
[292] Trkola, A., Kuster, H., Rusert, P., Joos, B., Fischer, M., Leemann, C., Manrique, A. et al.,
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of 
human neutralizing antibodies. Nat Med 2005. 11: 615-622. 
[293] Parren, P. W., Burton, D. R. and Sattentau, Q. J., HIV-1 antibody--debris or virion? Nat
Med 1997. 3: 366-367. 
[294] Johnson, W. E. and Desrosiers, R. C., Viral persistance: HIV's strategies of immune system 
evasion. Annu Rev Med 2002. 53: 499-518. 
[295] Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F. et 
al., Antibody neutralization and escape by HIV-1. Nature 2003. 422: 307-312. 
[296] Moog, C., Fleury, H. J., Pellegrin, I., Kirn, A. and Aubertin, A. M., Autologous and 
heterologous neutralizing antibody responses following initial seroconversion in human 
immunodeficiency virus type 1-infected individuals. J Virol 1997. 71: 3734-3741. 
[297] Pilgrim, A. K., Pantaleo, G., Cohen, O. J., Fink, L. M., Zhou, J. Y., Zhou, J. T., Bolognesi, 
D. P. et al., Neutralizing antibody responses to human immunodeficiency virus type 1 in 
primary infection and long-term-nonprogressive infection. J Infect Dis 1997. 176: 924-932. 
[298] Koup, R. A., Safrit, J. T., Cao, Y., Andrews, C. A., McLeod, G., Borkowsky, W., Farthing, 
C. and Ho, D. D., Temporal association of cellular immune responses with the initial control of 
76
viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994. 68: 4650-
4655. 
[299] Albert, J., Abrahamsson, B., Nagy, K., Aurelius, E., Gaines, H., Nystrom, G. and Fenyo, E. 
M., Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection 
and consequent emergence of virus variants which resist neutralization by autologous sera. Aids
1990. 4: 107-112. 
[300] Cecilia, D., Kleeberger, C., Munoz, A., Giorgi, J. V. and Zolla-Pazner, S., A longitudinal 
study of neutralizing antibodies and disease progression in HIV-1-infected subjects. J Infect Dis
1999. 179: 1365-1374. 
[301] Harrer, T., Harrer, E., Kalams, S. A., Elbeik, T., Staprans, S. I., Feinberg, M. B., Cao, Y.
et al., Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons 
with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses 1996. 12: 585-
592. 
[302] Lambotte, O., Ferrari, G., Moog, C., Yates, N. L., Liao, H. X., Parks, R. J., Hicks, C. B. et 
al., Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in 
HIV-1 elite controllers. Aids 2009. 23: 897-906. 
[303] Pereyra, F., Addo, M. M., Kaufmann, D. E., Liu, Y., Miura, T., Rathod, A., Baker, B. et 
al., Genetic and immunologic heterogeneity among persons who control HIV infection in the 
absence of therapy. J Infect Dis 2008. 197: 563-571. 
[304] Stamatatos, L., Morris, L., Burton, D. R. and Mascola, J. R., Neutralizing antibodies 
generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med 2009. 15:
866-870. 
[305] Mazzoli, S., Trabattoni, D., Lo Caputo, S., Piconi, S., Ble, C., Meacci, F., Ruzzante, S. et 
al., HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-
seropositive individuals. Nat Med 1997. 3: 1250-1257. 
[306] Hildreth, J. E., Hampton, R. and Halsey, N. A., Antibody-dependent cell-mediated 
cytotoxicity can protect PBMC from infection by cell-associated HIV-1. Clin Immunol 1999. 
90: 203-212. 
[307] Connick, E., Marr, D. G., Zhang, X. Q., Clark, S. J., Saag, M. S., Schooley, R. T. and 
Curiel, T. J., HIV-specific cellular and humoral immune responses in primary HIV infection. 
AIDS Res Hum Retroviruses 1996. 12: 1129-1140. 
[308] Forthal, D. N., Landucci, G. and Daar, E. S., Antibody from patients with acute human 
immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence 
of natural-killer effector cells. J Virol 2001. 75: 6953-6961. 
[309] Sawyer, L. A., Katzenstein, D. A., Hendry, R. M., Boone, E. J., Vujcic, L. K., Williams, C. 
C., Zeger, S. L. et al., Possible beneficial effects of neutralizing antibodies and antibody-
dependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res 
Hum Retroviruses 1990. 6: 341-356. 
[310] Koup, R. A., Pikora, C. A., Mazzara, G., Panicali, D. and Sullivan, J. L., Broadly reactive 
antibody-dependent cellular cytotoxic response to HIV-1 envelope glycoproteins precedes broad 
neutralizing response in human infection. Viral Immunol 1991. 4: 215-223. 
[311] Broliden, K., Sievers, E., Tovo, P. A., Moschese, V., Scarlatti, G., Broliden, P. A., Fundaro, 
C. and Rossi, P., Antibody-dependent cellular cytotoxicity and neutralizing activity in sera of 
HIV-1-infected mothers and their children. Clin Exp Immunol 1993. 93: 56-64. 
[312] Baum, L. L., Cassutt, K. J., Knigge, K., Khattri, R., Margolick, J., Rinaldo, C., 
Kleeberger, C. A. et al., HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity 
correlates with rate of disease progression. J Immunol 1996. 157: 2168-2173. 
[313] Rook, A. H., Lane, H. C., Folks, T., McCoy, S., Alter, H. and Fauci, A. S., Sera from HTLV-
III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against 
HTLV-III/LAV-infected T cells. J Immunol 1987. 138: 1064-1067. 
[314] Nag, P., Kim, J., Sapiega, V., Landay, A. L., Bremer, J. W., Mestecky, J., Reichelderfer, P.
et al., Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower 
genital HIV-1 RNA loads. J Infect Dis 2004. 190: 1970-1978. 
[315] Chuenchitra, T., Wasi, C., Louisirirojchanakul, S., Nitayaphan, S., Sutthent, R., Cox, J. 
H., De Souza, M. S. et al., Longitudinal study of humoral immune responses in HIV type 1 
subtype CRF01_AE (E)-infected Thai patients with different rates of disease progression. AIDS 
Res Hum Retroviruses 2003. 19: 293-305. 
[316] Dalgleish, A., Sinclair, A., Steel, M., Beatson, D., Ludlam, C. and Habeshaw, J., Failure of 
ADCC to predict HIV-associated disease progression or outcome in a haemophiliac cohort. Clin 
Exp Immunol 1990. 81: 5-10. 
  77 
[317] Huber, M., Fischer, M., Misselwitz, B., Manrique, A., Kuster, H., Niederost, B., Weber, R.
et al., Complement lysis activity in autologous plasma is associated with lower viral loads 
during the acute phase of HIV-1 infection. PLoS Med 2006. 3: e441. 
[318] Walker, B. D., Chakrabarti, S., Moss, B., Paradis, T. J., Flynn, T., Durno, A. G., 
Blumberg, R. S. et al., HIV-specific cytotoxic T lymphocytes in seropositive individuals. 
Nature 1987. 328: 345-348. 
[319] Borrow, P., Lewicki, H., Hahn, B. H., Shaw, G. M. and Oldstone, M. B., Virus-specific 
CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human 
immunodeficiency virus type 1 infection. J Virol 1994. 68: 6103-6110. 
[320] Schmitz, J. E., Kuroda, M. J., Santra, S., Sasseville, V. G., Simon, M. A., Lifton, M. A., 
Racz, P. et al., Control of viremia in simian immunodeficiency virus infection by CD8+ 
lymphocytes. Science 1999. 283: 857-860. 
[321] Phillips, R. E., Rowland-Jones, S., Nixon, D. F., Gotch, F. M., Edwards, J. P., Ogunlesi, A. 
O., Elvin, J. G. et al., Human immunodeficiency virus genetic variation that can escape 
cytotoxic T cell recognition. Nature 1991. 354: 453-459. 
[322] Betts, M. R., Nason, M. C., West, S. M., De Rosa, S. C., Migueles, S. A., Abraham, J., 
Lederman, M. M. et al., HIV nonprogressors preferentially maintain highly functional HIV-
specific CD8+ T cells. Blood 2006. 107: 4781-4789. 
[323] Kiepiela, P., Ngumbela, K., Thobakgale, C., Ramduth, D., Honeyborne, I., Moodley, E., 
Reddy, S. et al., CD8+ T-cell responses to different HIV proteins have discordant associations 
with viral load. Nat Med 2007. 13: 46-53. 
[324] Emu, B., Sinclair, E., Hatano, H., Ferre, A., Shacklett, B., Martin, J. N., McCune, J. M. 
and Deeks, S. G., HLA class I-restricted T-cell responses may contribute to the control of 
human immunodeficiency virus infection, but such responses are not always necessary for long-
term virus control. J Virol 2008. 82: 5398-5407. 
[325] Saez-Cirion, A., Sinet, M., Shin, S. Y., Urrutia, A., Versmisse, P., Lacabaratz, C., 
Boufassa, F. et al., Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: 
association with Gag-specific CD8 T cell responses. J Immunol 2009. 182: 7828-7837. 
[326] Saez-Cirion, A., Lacabaratz, C., Lambotte, O., Versmisse, P., Urrutia, A., Boufassa, F., 
Barre-Sinoussi, F. et al., HIV controllers exhibit potent CD8 T cell capacity to suppress HIV 
infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci 
U S A 2007. 104: 6776-6781. 
[327] Kaul, R., Rowland-Jones, S. L., Kimani, J., Dong, T., Yang, H. B., Kiama, P., Rostron, T.
et al., Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific 
CD8+ responses. J Clin Invest 2001. 107: 341-349. 
[328] Kalams, S. A., Buchbinder, S. P., Rosenberg, E. S., Billingsley, J. M., Colbert, D. S., Jones, 
N. G., Shea, A. K. et al., Association between virus-specific cytotoxic T-lymphocyte and helper 
responses in human immunodeficiency virus type 1 infection. J Virol 1999. 73: 6715-6720. 
[329] Rosenberg, E. S., Billingsley, J. M., Caliendo, A. M., Boswell, S. L., Sax, P. E., Kalams, S. 
A. and Walker, B. D., Vigorous HIV-1-specific CD4+ T cell responses associated with control 
of viremia. Science 1997. 278: 1447-1450. 
[330] Boaz, M. J., Waters, A., Murad, S., Easterbrook, P. J. and Vyakarnam, A., Presence of 
HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated 
with nonprogression in HIV-1 infection. J Immunol 2002. 169: 6376-6385. 
[331] Clerici, M., Giorgi, J. V., Chou, C. C., Gudeman, V. K., Zack, J. A., Gupta, P., Ho, H. N. et 
al., Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in 
seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992. 165:
1012-1019. 
[332] Furci, L., Scarlatti, G., Burastero, S., Tambussi, G., Colognesi, C., Quillent, C., Longhi, R.
et al., Antigen-driven C-C chemokine-mediated HIV-1 suppression by CD4(+) T cells from 
exposed uninfected individuals expressing the wild-type CCR-5 allele. J Exp Med 1997. 186:
455-460. 
[333] Carrington, M., Dean, M., Martin, M. P. and O'Brien, S. J., Genetics of HIV-1 infection: 
chemokine receptor CCR5 polymorphism and its consequences. Hum Mol Genet 1999. 8: 1939-
1945. 
[334] Bratt, G., Leandersson, A. C., Albert, J., Sandstrom, E. and Wahren, B., MT-2 tropism and 
CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals. Aids
1998. 12: 729-736. 
78
[335] Carrington, M., Nelson, G. W., Martin, M. P., Kissner, T., Vlahov, D., Goedert, J. J., 
Kaslow, R. et al., HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. 
Science 1999. 283: 1748-1752. 
[336] Flores-Villanueva, P. O., Yunis, E. J., Delgado, J. C., Vittinghoff, E., Buchbinder, S., 
Leung, J. Y., Uglialoro, A. M. et al., Control of HIV-1 viremia and protection from AIDS are 
associated with HLA-Bw4 homozygosity. Proc Natl Acad Sci U S A 2001. 98: 5140-5145. 
[337] Migueles, S. A., Sabbaghian, M. S., Shupert, W. L., Bettinotti, M. P., Marincola, F. M., 
Martino, L., Hallahan, C. W. et al., HLA B*5701 is highly associated with restriction of virus 
replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A
2000. 97: 2709-2714. 
[338] Miura, T., Brockman, M. A., Schneidewind, A., Lobritz, M., Pereyra, F., Rathod, A., 
Block, B. L. et al., HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers 
select for rare gag variants associated with reduced viral replication capacity and strong 
cytotoxic T-lymphocyte [corrected] recognition. J Virol 2009. 83: 2743-2755. 
[339] Carrington, M., Martin, M. P. and van Bergen, J., KIR-HLA intercourse in HIV disease. 
Trends Microbiol 2008. 16: 620-627. 
[340] Fellay, J., Shianna, K. V., Ge, D., Colombo, S., Ledergerber, B., Weale, M., Zhang, K. et 
al., A whole-genome association study of major determinants for host control of HIV-1. Science
2007. 317: 944-947. 
[341] Catano, G., Kulkarni, H., He, W., Marconi, V. C., Agan, B. K., Landrum, M., Anderson, 
S. et al., HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles 
are attributable mainly to either HLA-A10 or HLA-B*57 alleles. PLoS One 2008. 3: e3636. 
[342] Martin, M. P., Gao, X., Lee, J. H., Nelson, G. W., Detels, R., Goedert, J. J., Buchbinder, S.
et al., Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat 
Genet 2002. 31: 429-434. 
[343] Qi, Y., Martin, M. P., Gao, X., Jacobson, L., Goedert, J. J., Buchbinder, S., Kirk, G. D. et 
al., KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS 
Pathog 2006. 2: e79. 
[344] Barbour, J. D., Sriram, U., Caillier, S. J., Levy, J. A., Hecht, F. M. and Oksenberg, J. R.,
Synergy or independence? Deciphering the interaction of HLA Class I and NK cell KIR alleles 
in early HIV-1 disease progression. PLoS Pathog 2007. 3: e43. 
[345] Gaudieri, S., Desantis, D., McKinnon, E., Moore, C., Nolan, D., Witt, C. S., Mallal, S. A. 
and Christiansen, F. T., Killer immunoglobulin-like receptors and HLA act both independently 
and synergistically to modify HIV disease progression. Genes Immun 2005. 
[346] Alter, G., Rihn, S., Walter, K., Nolting, A., Martin, M., Rosenberg, E. S., Miller, J. S. et al.,
HLA class I subtype-dependent expansion of KIR3DS1+ and KIR3DL1+ NK cells during acute 
human immunodeficiency virus type 1 infection. J Virol 2009. 83: 6798-6805. 
[347] Long, B. R., Ndhlovu, L. C., Oksenberg, J. R., Lanier, L. L., Hecht, F. M., Nixon, D. F. and 
Barbour, J. D., Conferral of enhanced natural killer cell function by KIR3DS1 in early human 
immunodeficiency virus type 1 infection. J Virol 2008. 82: 4785-4792. 
[348] Martin, M. P., Qi, Y., Gao, X., Yamada, E., Martin, J. N., Pereyra, F., Colombo, S. et al.,
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007. 39: 733-
740. 
[349] Boulet, S., Sharafi, S., Simic, N., Bruneau, J., Routy, J. P., Tsoukas, C. M. and Bernard, N. 
F., Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. Aids
2008. 22: 595-599. 
[350] Boulet, S., Kleyman, M., Kim, J. Y., Kamya, P., Sharafi, S., Simic, N., Bruneau, J. et al., A 
combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a 
reduced risk of HIV infection. Aids 2008. 22: 1487-1491. 
[351] Jennes, W., Verheyden, S., Demanet, C., Adje-Toure, C. A., Vuylsteke, B., Nkengasong, J. 
N. and Kestens, L., Cutting edge: resistance to HIV-1 infection among African female sex 
workers is associated with inhibitory KIR in the absence of their HLA ligands. J Immunol 2006. 
177: 6588-6592. 
[352] Choudhary, S. K., Vrisekoop, N., Jansen, C. A., Otto, S. A., Schuitemaker, H., Miedema, 
F. and Camerini, D., Low immune activation despite high levels of pathogenic human 
immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol 2007. 81:
8838-8842. 
[353] Leligdowicz, A. and Rowland-Jones, S., Tenets of protection from progression to AIDS: 
lessons from the immune responses to HIV-2 infection. Expert Rev Vaccines 2008. 7: 319-331. 
  79 
[354] Iannello, A., Debbeche, O., Samarani, S. and Ahmad, A., Antiviral NK cell responses in HIV 
infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination. J
Leukoc Biol 2008. 84: 27-49. 
[355] Li, D. and Xu, X. N., NKT cells in HIV-1 infection. Cell Res 2008. 18: 817-822. 
[356] Piguet, V. and Steinman, R. M., The interaction of HIV with dendritic cells: outcomes and 
pathways. Trends Immunol 2007. 28: 503-510. 
[357] Moir, S. and Fauci, A. S., B cells in HIV infection and disease. Nat Rev Immunol 2009. 9: 235-
245. 
[358] El-Far, M., Halwani, R., Said, E., Trautmann, L., Doroudchi, M., Janbazian, L., Fonseca, 
S. et al., T-cell exhaustion in HIV infection. Curr HIV/AIDS Rep 2008. 5: 13-19. 
[359] Scheppler, J. A., Nicholson, J. K., Swan, D. C., Ahmed-Ansari, A. and McDougal, J. S.,
Down-modulation of MHC-I in a CD4+ T cell line, CEM-E5, after HIV-1 infection. J Immunol
1989. 143: 2858-2866. 
[360] Schwartz, O., Marechal, V., Le Gall, S., Lemonnier, F. and Heard, J. M., Endocytosis of 
major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat
Med 1996. 2: 338-342. 
[361] Matucci, A., Rossolillo, P., Baroni, M., Siccardi, A. G., Beretta, A. and Zipeto, D., HLA-C 
increases HIV-1 infectivity and is associated with gp120. Retrovirology 2008. 5: 68. 
[362] Ward, J., Bonaparte, M., Sacks, J., Guterman, J., Fogli, M., Mavilio, D. and Barker, E.,
HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic 
responses on infected primary T-cell blasts. Blood 2007. 110: 1207-1214. 
[363] Ward, J., Davis, Z., DeHart, J., Zimmerman, E., Bosque, A., Brunetta, E., Mavilio, D. et 
al., HIV-1 Vpr triggers natural killer cell-mediated lysis of infected cells through activation of 
the ATR-mediated DNA damage response. PLoS Pathog 2009. 5: e1000613. 
[364] Fausther-Bovendo, H., Sol-Foulon, N., Candotti, D., Agut, H., Schwartz, O., Debre, P. and 
Vieillard, V., HIV escape from natural killer cytotoxicity: nef inhibits NKp44L expression on 
CD4+ T cells. Aids 2009. 23: 1077-1087. 
[365] Vieillard, V., Le Grand, R., Dausset, J. and Debre, P., A vaccine strategy against AIDS: an 
HIV gp41 peptide immunization prevents NKp44L expression and CD4+ T cell depletion in 
SHIV-infected macaques. Proc Natl Acad Sci U S A 2008. 105: 2100-2104. 
[366] Valentin, A., Rosati, M., Patenaude, D. J., Hatzakis, A., Kostrikis, L. G., Lazanas, M., 
Wyvill, K. M. et al., Persistent HIV-1 infection of natural killer cells in patients receiving 
highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2002. 99: 7015-7020. 
[367] Alter, G., Malenfant, J. M., Delabre, R. M., Burgett, N. C., Yu, X. G., Lichterfeld, M., 
Zaunders, J. and Altfeld, M., Increased natural killer cell activity in viremic HIV-1 infection. J
Immunol 2004. 173: 5305-5311. 
[368] Azzoni, L., Papasavvas, E., Chehimi, J., Kostman, J. R., Mounzer, K., Ondercin, J., 
Perussia, B. and Montaner, L. J., Sustained impairment of IFN-gamma secretion in 
suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective 
reconstitution of innate immunity. J Immunol 2002. 168: 5764-5770. 
[369] Mela, C. M., Steel, A., Lindsay, J., Gazzard, B. G., Gotch, F. M. and Goodier, M. R.,
Depletion of natural killer cells in the colonic lamina propria of viraemic HIV-1-infected 
individuals. Aids 2007. 21: 2177-2182. 
[370] Tarazona, R., Casado, J. G., Delarosa, O., Torre-Cisneros, J., Villanueva, J. L., Sanchez, 
B., Galiani, M. D. et al., Selective depletion of CD56(dim) NK cell subsets and maintenance of 
CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 2002. 
22: 176-183. 
[371] Mavilio, D., Benjamin, J., Daucher, M., Lombardo, G., Kottilil, S., Planta, M. A., 
Marcenaro, E. et al., Natural killer cells in HIV-1 infection: dichotomous effects of viremia on 
inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A
2003. 100: 15011-15016. 
[372] Mavilio, D., Lombardo, G., Benjamin, J., Kim, D., Follman, D., Marcenaro, E., O'Shea, M. 
A. et al., Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK 
subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A 2005. 102:
2886-2891. 
[373] Kottilil, S., Shin, K., Planta, M., McLaughlin, M., Hallahan, C. W., Ghany, M., Chun, T. 
W. et al., Expression of chemokine and inhibitory receptors on natural killer cells: effect of 
immune activation and HIV viremia. J Infect Dis 2004. 189: 1193-1198. 
[374] De Maria, A., Fogli, M., Costa, P., Murdaca, G., Puppo, F., Mavilio, D., Moretta, A. and 
Moretta, L., The impaired NK cell cytolytic function in viremic HIV-1 infection is associated 
80
with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and 
NKp44). Eur J Immunol 2003. 33: 2410-2418. 
[375] Guma, M., Angulo, A. and Lopez-Botet, M., NK cell receptors involved in the response to 
human cytomegalovirus infection. Curr Top Microbiol Immunol 2006. 298: 207-223. 
[376] Mela, C. M., Burton, C. T., Imami, N., Nelson, M., Steel, A., Gazzard, B. G., Gotch, F. M. 
and Goodier, M. R., Switch from inhibitory to activating NKG2 receptor expression in HIV-1 
infection: lack of reversion with highly active antiretroviral therapy. Aids 2005. 19: 1761-1769. 
[377] Guma, M., Cabrera, C., Erkizia, I., Bofill, M., Clotet, B., Ruiz, L. and Lopez-Botet, M.,
Human cytomegalovirus infection is associated with increased proportions of NK cells that 
express the CD94/NKG2C receptor in aviremic HIV-1-positive patients. J Infect Dis 2006. 194:
38-41. 
[378] Scott-Algara, D., Vuillier, F., Cayota, A. and Dighiero, G., Natural killer (NK) cell activity 
during HIV infection: a decrease in NK activity is observed at the clonal level and is not 
restored after in vitro long-term culture of NK cells. Clin Exp Immunol 1992. 90: 181-187. 
[379] Liu, Q., Sun, Y., Rihn, S., Nolting, A., Tsoukas, P. N., Jost, S., Cohen, K. et al., Matrix 
metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular 
cytotoxicity in human immunodeficiency virus type 1 infection. J Virol 2009. 83: 8705-8712. 
[380] Geertsma, M. F., Stevenhagen, A., van Dam, E. M. and Nibbering, P. H., Expression of zeta 
molecules is decreased in NK cells from HIV-infected patients. FEMS Immunol Med Microbiol
1999. 26: 249-257. 
[381] Goodier, M. R., Imami, N., Moyle, G., Gazzard, B. and Gotch, F., Loss of the CD56hiCD16- 
NK cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-
1: partial recovery by human growth hormone. Clin Exp Immunol 2003. 134: 470-476. 
[382] Meier, U. C., Owen, R. E., Taylor, E., Worth, A., Naoumov, N., Willberg, C., Tang, K. et 
al., Shared alterations in NK cell frequency, phenotype, and function in chronic human 
immunodeficiency virus and hepatitis C virus infections. J Virol 2005. 79: 12365-12374. 
[383] Kottilil, S., Chun, T. W., Moir, S., Liu, S., McLaughlin, M., Hallahan, C. W., Maldarelli, F.
et al., Innate immunity in human immunodeficiency virus infection: effect of viremia on natural 
killer cell function. J Infect Dis 2003. 187: 1038-1045. 
[384] Tasca, S., Tambussi, G., Nozza, S., Capiluppi, B., Zocchi, M. R., Soldini, L., Veglia, F. et 
al., Escape of monocyte-derived dendritic cells of HIV-1 infected individuals from natural killer 
cell-mediated lysis. Aids 2003. 17: 2291-2298. 
[385] Scott-Algara, D., Arnold, V., Didier, C., Kattan, T., Pirozzi, G., Barre-Sinoussi, F. and 
Pancino, G., The CD85j+ NK cell subset potently controls HIV-1 replication in autologous 
dendritic cells. PLoS One 2008. 3: e1975. 
[386] Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N. and Zitvogel, L., Natural killer cell-
directed therapies: moving from unexpected results to successful strategies. Nat Immunol 2008. 
9: 486-494. 
[387] Woo, C. Y., Clay, T. M., Lyerly, H. K., Morse, M. A. and Osada, T., Role of natural killer 
cell function in dendritic cell-based vaccines. Expert Rev Vaccines 2006. 5: 55-65. 
[388] Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S.
et al., Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic 
transplants. Science 2002. 295: 2097-2100. 
[389] Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., 
Shlomchik, M. J. and Emerson, S. G., Prevention of graft versus host disease by inactivation 
of host antigen-presenting cells. Science 1999. 285: 412-415. 
[390] Malmberg, K. J., Schaffer, M., Ringden, O., Remberger, M. and Ljunggren, H. G., KIR-
ligand mismatch in allogeneic hematopoietic stem cell transplantation. Mol Immunol 2005. 42:
531-534. 
[391] Gill, S., Olson, J. A. and Negrin, R. S., Natural killer cells in allogeneic transplantation: effect 
on engraftment, graft- versus-tumor, and graft-versus-host responses. Biol Blood Marrow 
Transplant 2009. 15: 765-776. 
[392] Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., 
Fautsch, S. K., McKenna, D. et al., Successful adoptive transfer and in vivo expansion of 
human haploidentical NK cells in patients with cancer. Blood 2005. 105: 3051-3057. 
[393] Koh, C. Y., Blazar, B. R., George, T., Welniak, L. A., Capitini, C. M., Raziuddin, A., 
Murphy, W. J. and Bennett, M., Augmentation of antitumor effects by NK cell inhibitory 
receptor blockade in vitro and in vivo. Blood 2001. 97: 3132-3137. 
  81 
[394] Romagne, F., Andre, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M. et al.,
Pre-clinical characterization of 1-7F9, a novel human anti-KIR therapeutic antibody that 
augments NK-mediated killing of tumor cells. Blood 2009. Jun 24. [Epub ahead of print].
[395] Keller, M. A. and Stiehm, E. R., Passive immunity in prevention and treatment of infectious 
diseases. Clin Microbiol Rev 2000. 13: 602-614. 
[396] Kohler, G. and Milstein, C., Continuous cultures of fused cells secreting antibody of 
predefined specificity. Nature 1975. 256: 495-497. 
[397] Chames, P., Van Regenmortel, M., Weiss, E. and Baty, D., Therapeutic antibodies: 
successes, limitations and hopes for the future. Br J Pharmacol 2009. 157: 220-233. 
[398] McLaughlin, P., Grillo-Lopez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. 
E., Heyman, M. R. et al., Rituximab chimeric anti-CD20 monoclonal antibody therapy for 
relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin 
Oncol 1998. 16: 2825-2833. 
[399] Brumlik, M. J., Daniel, B. J., Waehler, R., Curiel, D. T., Giles, F. J. and Curiel, T. J.,
Trends in immunoconjugate and ligand-receptor based targeting development for cancer 
therapy. Expert Opin Drug Deliv 2008. 5: 87-103. 
[400] Davey, R. T., Jr., Boenning, C. M., Herpin, B. R., Batts, D. H., Metcalf, J. A., Wathen, L., 
Cox, S. R. et al., Use of recombinant soluble CD4 Pseudomonas exotoxin, a novel 
immunotoxin, for treatment of persons infected with human immunodeficiency virus. J Infect 
Dis 1994. 170: 1180-1188. 
[401] Ramachandran, R. V., Katzenstein, D. A., Wood, R., Batts, D. H. and Merigan, T. C.,
Failure of short-term CD4-PE40 infusions to reduce virus load in human immunodeficiency 
virus-infected persons. J Infect Dis 1994. 170: 1009-1013. 
[402] Saavedra-Lozano, J., Cao, Y., Callison, J., Sarode, R., Sodora, D., Edgar, J., Hatfield, J. et 
al., An anti-CD45RO immunotoxin kills HIV-latently infected cells from individuals on 
HAART with little effect on CD8 memory. Proc Natl Acad Sci U S A 2004. 101: 2494-2499. 
[403] Till, M. A., Zolla-Pazner, S., Gorny, M. K., Patton, J. S., Uhr, J. W. and Vitetta, E. S.,
Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal 
human anti-gp41 antibodies coupled to ricin A chain. Proc Natl Acad Sci U S A 1989. 86: 1987-
1991. 
[404] Dadachova, E., Patel, M. C., Toussi, S., Apostolidis, C., Morgenstern, A., Brechbiel, M. W., 
Gorny, M. K. et al., Targeted killing of virally infected cells by radiolabeled antibodies to viral 
proteins. PLoS Med 2006. 3: e427. 
[405] Berger, E. A., Moss, B. and Pastan, I., Reconsidering targeted toxins to eliminate HIV 
infection: you gotta have HAART. Proc Natl Acad Sci U S A 1998. 95: 11511-11513. 
[406] Chun, T. W. and Fauci, A. S., Latent reservoirs of HIV: obstacles to the eradication of virus. 
Proc Natl Acad Sci U S A 1999. 96: 10958-10961. 
[407] Brooks, D. G., Hamer, D. H., Arlen, P. A., Gao, L., Bristol, G., Kitchen, C. M., Berger, E. 
A. and Zack, J. A., Molecular characterization, reactivation, and depletion of latent HIV. 
Immunity 2003. 19: 413-423. 
[408] Geeraert, L., Kraus, G. and Pomerantz, R. J., Hide-and-seek: the challenge of viral 
persistence in HIV-1 infection. Annu Rev Med 2008. 59: 487-501. 
[409] Lehrman, G., Hogue, I. B., Palmer, S., Jennings, C., Spina, C. A., Wiegand, A., Landay, A. 
L. et al., Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005. 
366: 549-555. 
[410] Gilbert, P. B., Peterson, M. L., Follmann, D., Hudgens, M. G., Francis, D. P., Gurwith, M., 
Heyward, W. L. et al., Correlation between immunologic responses to a recombinant 
glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive 
vaccine trial. J Infect Dis 2005. 191: 666-677. 
[411] Buchbinder, S. P., Mehrotra, D. V., Duerr, A., Fitzgerald, D. W., Mogg, R., Li, D., Gilbert, 
P. B. et al., Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a 
double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008. 372: 1881-
1893. 
[412] Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., 
Premsri, N. et al., Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in 
Thailand. N Engl J Med 2009. 
[413] Cohen, J., HIV/AIDS research. Beyond Thailand: making sense of a qualified AIDS vaccine 
"success". Science 2009. 326: 652-653. 
[414] Sandstrom, E., Nilsson, C., Hejdeman, B., Brave, A., Bratt, G., Robb, M., Cox, J. et al.,
Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with 
82
heterologous HIV-1 recombinant modified vaccinia virus Ankara. J Infect Dis 2008. 198: 1482-
1490. 
[415] Chung, A. W., Rollman, E., Center, R. J., Kent, S. J. and Stratov, I., Rapid degranulation of 
NK cells following activation by HIV-specific antibodies. J Immunol 2009. 182: 1202-1210. 
[416] Ahmad, R., Sindhu, S. T., Toma, E., Morisset, R., Vincelette, J., Menezes, J. and Ahmad, 
A., Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-
HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol 2001. 21: 227-
233. 
[417] Stratov, I., Chung, A. and Kent, S. J., Robust NK cell-mediated human immunodeficiency 
virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 2008. 82:
5450-5459. 
[418] Sandstrom, E. and Wahren, B., Therapeutic immunisation with recombinant gp160 in HIV-1 
infection: a randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. 
Lancet 1999. 353: 1735-1742. 
[419] Alsmadi, O., Herz, R., Murphy, E., Pinter, A. and Tilley, S. A., A novel antibody-dependent 
cellular cytotoxicity epitope in gp120 is identified by two monoclonal antibodies isolated from a 
long-term survivor of human immunodeficiency virus type 1 infection. J Virol 1997. 71: 925-
933. 
[420] Ljunggren, K., Karlson, A., Fenyo, E. M. and Jondal, M., Natural and antibody-dependent 
cytotoxicity in different clinical stages of human immunodeficiency virus type 1 infection. Clin 
Exp Immunol 1989. 75: 184-189. 
[421] Hultstrom, A. L., Hejdeman, B., Leandersson, A. C., Bratt, G., Carbone, E. and Wahren, 
B., Human natural killer cells in asymptomatic human immunodeficiency virus-1 infection. 
Intervirology 2000. 43: 294-301. 
[422] Salcedo, M., Andersson, M., Lemieux, S., Van Kaer, L., Chambers, B. J. and Ljunggren, 
H. G., Fine tuning of natural killer cell specificity and maintenance of self tolerance in MHC 
class I-deficient mice. Eur J Immunol 1998. 28: 1315-1321. 
[423] Kloss, M., Decker, P., Baltz, K. M., Baessler, T., Jung, G., Rammensee, H. G., Steinle, A. et 
al., Interaction of monocytes with NK cells upon Toll-like receptor-induced expression of the 
NKG2D ligand MICA. J Immunol 2008. 181: 6711-6719. 
[424] Vahlne, G., Lindholm, K., Meier, A., Wickström, S., Lakshmikanth, T., Brennan, F., 
Wilken, M. et al., In vivo tumour cell rejection induced by NK cell inhibitory receptor 
blockade: Maintained tolerance to normal cells even in the presence of IL-2. Eur J Immunol
2009. In press.
[425] Sola, C., Andre, P., Lemmers, C., Fuseri, N., Bonnafous, C., Blery, M., Wagtmann, N. R. et 
al., Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition 
in vivo. Proc Natl Acad Sci U S A 2009. 106: 12879-12884. 
[426] Fauriat, C., Ivarsson, M. A., Ljunggren, H. G., Malmberg, K. J. and Michaelsson, J.,
Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. 
Blood 2009. 
[427] Pascal, V., Yamada, E., Martin, M. P., Alter, G., Altfeld, M., Metcalf, J. A., Baseler, M. W.
et al., Detection of KIR3DS1 on the cell surface of peripheral blood NK cells facilitates 
identification of a novel null allele and assessment of KIR3DS1 expression during HIV-1 
infection. J Immunol 2007. 179: 1625-1633. 
[428] Borrego, F., Robertson, M. J., Ritz, J., Pena, J. and Solana, R., CD69 is a stimulatory 
receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. 
Immunology 1999. 97: 159-165. 
[429] Sancho, D., Gomez, M. and Sanchez-Madrid, F., CD69 is an immunoregulatory molecule 
induced following activation. Trends Immunol 2005. 26: 136-140. 
[430] Shiow, L. R., Rosen, D. B., Brdickova, N., Xu, Y., An, J., Lanier, L. L., Cyster, J. G. and 
Matloubian, M., CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and 
lymphocyte egress from lymphoid organs. Nature 2006. 440: 540-544. 
[431] Binyamin, L., Alpaugh, R. K., Hughes, T. L., Lutz, C. T., Campbell, K. S. and Weiner, L. 
M., Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular 
cytotoxicity in a model of anti-lymphoma therapy. J Immunol 2008. 180: 6392-6401. 
[432] Foley, B. A., De Santis, D., Van Beelen, E., Lathbury, L. J., Christiansen, F. T. and Witt, 
C. S., The reactivity of Bw4+ HLA-B and HLA-A alleles with KIR3DL1: implications for 
patient and donor suitability for haploidentical stem cell transplantations. Blood 2008. 112: 435-
443. 
  83 
[433] Morvan, M., Willem, C., Gagne, K., Kerdudou, N., David, G., Sebille, V., Follea, G. et al.,
Phenotypic and functional analyses of KIR3DL1+ and KIR3DS1+ NK cell subsets demonstrate 
differential regulation by Bw4 molecules and induced KIR3DS1 expression on stimulated NK 
cells. J Immunol 2009. 182: 6727-6735. 
[434] Lund, J. M., Hsing, L., Pham, T. T. and Rudensky, A. Y., Coordination of early protective 
immunity to viral infection by regulatory T cells. Science 2008. 320: 1220-1224. 
[435] Seaman, W. E., Sleisenger, M., Eriksson, E. and Koo, G. C., Depletion of natural killer cells 
in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy 
without loss of cellular or humoral immunity. J Immunol 1987. 138: 4539-4544. 
[436] Choi, E. I., Reimann, K. A. and Letvin, N. L., In vivo natural killer cell depletion during 
primary simian immunodeficiency virus infection in rhesus monkeys. J Virol 2008. 82: 6758-
6761. 
[437] Griffiths, G. L., Mattes, M. J., Stein, R., Govindan, S. V., Horak, I. D., Hansen, H. J. and 
Goldenberg, D. M., Cure of SCID mice bearing human B-lymphoma xenografts by an anti-
CD74 antibody-anthracycline drug conjugate. Clin Cancer Res 2003. 9: 6567-6571. 
[438] Tolcher, A. W., Sugarman, S., Gelmon, K. A., Cohen, R., Saleh, M., Isaacs, C., Young, L.
et al., Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic 
breast cancer. J Clin Oncol 1999. 17: 478-484. 
[439] Broliden, P. A., Ljunggren, K., Hinkula, J., Norrby, E., Akerblom, L. and Wahren, B., A 
monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular 
cytotoxicity and neutralization. J Virol 1990. 64: 936-940. 
[440] Hinkula, J., Bratt, G., Gilljam, G., Nordlund, S., Broliden, P. A., Holmberg, V., Olausson-
Hansson, E. et al., Immunological and virological interactions in patients receiving passive 
immunotherapy with HIV-1 neutralizing monoclonal antibodies. J Acquir Immune Defic Syndr
1994. 7: 940-951. 
[441] Binaschi, M., Bigioni, M., Cipollone, A., Rossi, C., Goso, C., Maggi, C. A., Capranico, G. 
and Animati, F., Anthracyclines: selected new developments. Curr Med Chem Anti-Canc 
Agents 2001. 1: 113-130. 
[442] Bouille, P., Subra, F., Mouscadet, J. F. and Auclair, C., Antisense-mediated repression of 
DNA topoisomerase II expression leads to an impairment of HIV-1 replicative cycle. J Mol Biol
1999. 285: 945-954. 
[443] Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., 
Schmitt, E. et al., Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. 
J Exp Med 2005. 202: 1691-1701. 

